# www.lupin.com

> Lupin is a global pharmaceutical company from India, advancing healthcare through innovation, research and accessible medicines globally.

## Home

[Leading Global Pharmaceutical Company in India - Lupin](https://www.lupin.com/): Lupin is a global pharmaceutical company from India, advancing healthcare through innovation, research and accessible medicines globally.

## About us

[Quality in Action | Compliance and Safety Standards - Lupin](https://www.lupin.com/about-us/quality-in-action/): Learn how Lupin ensures patient safety through quality systems, compliance frameworks and continuous improvement across global operations.
[Compliance, Ethics and Governance - Lupin](https://www.lupin.com/about-us/compliance-ethics-governance/): Our policies and processes ensure accountability to all stakeholders and help us remain steadfast in maintaining the highest governance standards.
[Core Values and Principles - Lupin](https://www.lupin.com/about-us/our-values/): At Lupin, we pride ourselves on our promise of caring for our customers, our commitment to our employees’ growth and welfare.
[Purpose, Mission and Vision - Lupin](https://www.lupin.com/about-us/our-purpose/): A purpose-driven journey of over five decades - improving lives, building sustainability, and delivering long-term value to our stakeholders.
[Global Presence | Worldwide Operations and Reach - Lupin](https://www.lupin.com/about-us/global-presence/): We have operations in 11 countries across six continents, allowing for safe and reliable delivery of medicines to our patients across 100+ countries.
[Global Technical Operations - Lupin](https://www.lupin.com/about-us/global-technical-operations): Lupin’s Global Technical Operations drive world-class manufacturing, quality assurance and supply excellence across international markets.
[Alfonso Zulueta - Independent Director | Lupin Leadership](https://www.lupin.com/about-us/leadership/alfonso-zulueta/): Learn about Alfonso Zulueta, Independent Director, their background, education, and role at Lupin Limited.
[About Us - Lupin](https://www.lupin.com/about-us/): Learn about Lupin, our purpose, values, leadership and global journey as a trusted pharmaceutical company committed to innovation and patient care.
[Dr. Abdelaziz Toumi - CEO – Lupin Manufacturing Solutions | Lupin Leadership](https://www.lupin.com/about-us/leadership/dr-abdelaziz-toumi/): Learn about Dr. Abdelaziz Toumi, CEO – Lupin Manufacturing Solutions, their background, education, and role at Lupin Limited.
[Pharmaceutical Research and Digital Transformation - Lupin](https://www.lupin.com/about-us/our-science/): Discover Lupin’s scientific expertise using R & D, digital transformation, and more to drive advanced healthcare solutions worldwide.
[Jeffrey Kindler - Independent Director | Lupin Leadership](https://www.lupin.com/about-us/leadership/jeffrey-kindler/): Learn about Jeffrey Kindler, Independent Director, their background, education, and role at Lupin Limited.
[Leaders - Lupin | Our Leadership Team](https://www.lupin.com/about-us/leadership/): Meet the leadership team at Lupin, driving innovation and excellence in the pharmaceutical industry.
[Manju D Gupta - Chairperson (Non-Executive) | Lupin Leadership](https://www.lupin.com/about-us/leadership/manju-gupta/): Learn about Manju D Gupta, Chairperson (Non-Executive), their background, education, and role at Lupin Limited.
[Claus Jepsen - President – Global Specialty | Lupin Leadership](https://www.lupin.com/about-us/leadership/claus-jepsen/): Learn about Claus Jepsen, President – Global Specialty, their background, education, and role at Lupin Limited.
[Punita Lal - Independent Director | Lupin Leadership](https://www.lupin.com/about-us/leadership/punita-lal/): Learn about Punita Lal, Independent Director, their background, education, and role at Lupin Limited.
[Mark D. McDade - Independent Director | Lupin Leadership](https://www.lupin.com/about-us/leadership/mark-d-mcdade/): Learn about Mark D. McDade, Independent Director, their background, education, and role at Lupin Limited.
[K B S Anand - Independent Director | Lupin Leadership](https://www.lupin.com/about-us/leadership/kbs-anand/): Learn about K B S Anand, Independent Director, their background, education, and role at Lupin Limited.
[Christoph Funke - Chief Technical Operations Officer | Lupin Leadership](https://www.lupin.com/about-us/leadership/christoph-funke/): Learn about Christoph Funke, Chief Technical Operations Officer, their background, education, and role at Lupin Limited.
[Ramesh Swaminathan - Executive Director, Global CFO, Head of IT and API Plus SBU | Lupin Leadership](https://www.lupin.com/about-us/leadership/ramesh-swaminathan/): Learn about Ramesh Swaminathan, Executive Director, Global CFO, Head of IT and API Plus SBU, their background, education, and role at Lupin Limited.
[Nilesh D Gupta - Managing Director | Lupin Leadership](https://www.lupin.com/about-us/leadership/nilesh-gupta/): Learn about Nilesh D Gupta, Managing Director, their background, education, and role at Lupin Limited.
[Dr. Cyrus Karkaria - President – Biotech Businesses | Lupin Leadership](https://www.lupin.com/about-us/leadership/cyrus-karkaria/): Learn about Dr. Cyrus Karkaria, President – Biotech Businesses, their background, education, and role at Lupin Limited.
[Vinita Gupta - Chief Executive Officer | Lupin Leadership](https://www.lupin.com/about-us/leadership/vinita-gupta/): Learn about Vinita Gupta, Chief Executive Officer, their background, education, and role at Lupin Limited.
[Dr. Fabrice Egros - President – Corporate Development | Lupin Leadership](https://www.lupin.com/about-us/leadership/dr-fabrice-egros/): Learn about Dr. Fabrice Egros, President – Corporate Development, their background, education, and role at Lupin Limited.
[Dr. Ranjana Pathak - President - Chief Quality Officer | Lupin Leadership](https://www.lupin.com/about-us/leadership/dr-ranjana-pathak/): Learn about Dr. Ranjana Pathak, President - Chief Quality Officer, their background, education, and role at Lupin Limited.
[Leader | Lupin Leadership](https://www.lupin.com/about-us/leadership/rajender-kamboj/): Learn about Leader, their background, education, and role at Lupin Limited.
[Rajeev Sibal - President – India Region Formulations | Lupin Leadership](https://www.lupin.com/about-us/leadership/rajeev-sibal/): Learn about Rajeev Sibal, President – India Region Formulations, their background, education, and role at Lupin Limited.
[Spiro Gavaris - President – U.S. Generics | Lupin Leadership](https://www.lupin.com/about-us/leadership/spiro-gavaris/): Learn about Spiro Gavaris, President – U.S. Generics, their background, education, and role at Lupin Limited.
[Dr. Sofia Mumtaz - President – Legal and Compliance, Canada, ANZ, and NEA business | Lupin Leadership](https://www.lupin.com/about-us/leadership/sofia-mumtaz/): Learn about Dr. Sofia Mumtaz, President – Legal and Compliance, Canada, ANZ, and NEA business, their background, education, and role at Lupin Limited.
[Dr. Shahin Fesharaki - Chief Scientific Officer | Lupin Leadership](https://www.lupin.com/about-us/leadership/shahin-fesharaki/): Learn about Dr. Shahin Fesharaki, Chief Scientific Officer, their background, education, and role at Lupin Limited.
[Thierry Volle - President – EMEA and Emerging Markets | Lupin Leadership](https://www.lupin.com/about-us/leadership/thierry-volle/): Learn about Thierry Volle, President – EMEA and Emerging Markets, their background, education, and role at Lupin Limited.
[Yashwant Mahadik - President – Global Human Resources | Lupin Leadership](https://www.lupin.com/about-us/leadership/yashwant-mahadik/): Learn about Yashwant Mahadik, President – Global Human Resources, their background, education, and role at Lupin Limited.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/about-us/our-manufacturing-sites/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Awards and Recognition - Lupin](https://www.lupin.com/about-us/awards-and-recognition/): Our actions and our products are the hallmark of our commitment to our patients, the healthcare ecosystem and the communities who we serve.
[Global Technical Operations - Lupin](https://www.lupin.com/about-us/global-technical-operations/): Lupin’s Global Technical Operations drive world-class manufacturing, quality assurance and supply excellence across international markets.

## Our business

[Healthcare Solutions in Emerging Markets - Lupin](https://www.lupin.com/our-business/emerging-markets/): Lupin delivers affordable, accessible, high-quality healthcare solutions tailored to the evolving needs of patients across emerging markets.
[Patient Support and Disease Management Programs - Lupin](https://www.lupin.com/our-business/india/patient-support-programs/): Lupin’s patient support programs focus on awareness, early diagnosis, and long-term disease management across therapies in India.
[Global Pharmaceutical Business - Lupin](https://www.lupin.com/our-business/): Explore Lupin’s global pharmaceutical business delivering affordable, sustainable, high-quality healthcare across developed and emerging markets.
[Pharmaceutical Company in India - Lupin](https://www.lupin.com/our-business/india/): Lupin is a leading pharmaceutical company in India with a diverse portfolio across major key therapeutic areas.
[Global Generics Pharmaceutical Company - Lupin](https://www.lupin.com/our-business/global-generics/): Lupin is a leading global generics pharmaceutical company delivering affordable, and accessible high-quality medicines across major healthcare markets.
[Biosimilars Research and Manufacturing - Lupin](https://www.lupin.com/our-business/biosimilars/): Lupin’s biosimilars focus on expanding access to high-quality biologics through advanced research and manufacturing excellence.
[Pharmaceuticals Specialty and Innovation - Lupin](https://www.lupin.com/our-business/specialty/): Lupin’s specialty business is driven by science-led innovation across complex pharmaceutical platforms and technologies.
[Lupin’s Business Adjacencies, Strategic Arms - Lupin](https://www.lupin.com/our-business/our-adjacencies/): Lupin’s patient-centric initiatives support holistic healthcare by extending care beyond medicines and treatment.

## Investors

[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Code of Conduct - Lupin](https://www.lupin.com/investors/code-of-conduct/): Read Lupin's Code of Conduct, understand ethical standards, compliance principles, & practices that guide our corporate governance & business integrity.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/disclosure-under-regulation-46-of-sebi-regulations-2015/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/dividend/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/analyst-coverage/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Committees of the Board - Lupin](https://www.lupin.com/investors/committees-of-the-board/): Explore Lupin's board of committees, see governance roles, committee functions, and leadership driving strategic oversight and corporate accountability.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/investor-faqs/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Shareholding Pattern and Ownership Data - Lupin](https://www.lupin.com/investors/shareholding-pattern/): Explore Lupin’s shareholding pattern to view the detailed investor mix, promoter holdings, and institutional ownership, and understand market participation.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/policies/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/unclaimed-dividend/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/financials/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/iepf-saksham-niveshak/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/subsidiaries/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/transfer-of-physical-shares-re-lodgement/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/notices/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/employee-stock-option-schemes/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/tips-for-shareholders/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Press Releases and Official News - Lupin](https://www.lupin.com/investors/news-events/): Read Lupin’s latest press releases and official news covering company updates, business announcements, research milestones, and global initiatives.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/reports-filings/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.
[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/investors/other-statutory-information/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.

## Sustainability

[Sustainability and ESG in Healthcare - Lupin](https://www.lupin.com/sustainability/): Lupin integrates sustainability into operations through responsible manufacturing, environmental care, and ethical governance.

## Media

[Lupin Media Kit - Press Assets and Corporate Info](https://www.lupin.com/media/media-kit/): Download Lupin’s media kit, access corporate presentations and official logos to support press, stories and brand coverage.
[A diagnosis doesn’t have to take your breath away - Lupin | Perspective](https://www.lupin.com/media/perspectives/a-diagnosis-doesnt-have-to-take-your-breath-away/): “I Can’t Breathe” became a slogan in 2020 for a different kind of civil unrest but for 339 million people living with asthma, this is an everyday concern. While the former is a call to action to bring about…
[A Call to Action: Bridging Mental Health Gaps in India Inclusively - Lupin | Perspective](https://www.lupin.com/media/perspectives/a-call-to-action-bridging-mental-health-gaps-in-india-inclusively/): In the kaleidoscope of India’s myriad challenges, mental health emerges as a poignant concern demanding our collective attention. The rising disease burden of mental health is now a public health juggernaut affecting diverse demographics. Specifically, among the youth the…
[A Healthy India - Lupin | Perspective](https://www.lupin.com/media/perspectives/a-healthy-india/): Health is not valued till sickness comes. And Covid-19 has shown us that for India to be truly a world class economy, its healthcare system has to be robust STHANA BALA – is a Sanskrit phrase, which translates poorly…
[Lupin News Coverage | Media Highlights and Mentions](https://www.lupin.com/media/media-coverage/): Get all the latest Lupin information, News, Videos and updates here.
[Accelerating Action for Women’s Health - Lupin | Perspective](https://www.lupin.com/media/perspectives/accelerating-action-for-womens-health/): 1. What are the distinctive health-related challenges and influences that shape the life journey of young women in today’s generation? The health of young women in India today is shaped by a complex interplay of socioeconomic, cultural, health-related, and…
[Perspectives: Industry Insights and Expert Views - Lupin](https://www.lupin.com/media/perspectives/): Explore Lupin’s expert insights, thought leadership and commentary on pharma trends, innovation, AI, sustainability and industry direction.
[AI is Aiding in Faster and Better-Decision Making - Lupin | Perspective](https://www.lupin.com/media/perspectives/ai-is-aiding-in-faster-and-better-decision-making/): Global pharma major Lupin is accelerating its digital transformation to streamline operations, hasten drug discovery, and champion patient-centricity. From automating supply chain processes to leveraging big data analytics for improved decision-making, Lupin is streamlining operations and accelerating drug discovery and development…
[Analysing the top 3 factors contributing to Diabetes in India and how to address them - Lupin | Perspective](https://www.lupin.com/media/perspectives/analysing-the-top-3-factors-contributing-to-diabetes-in-india-and-how-to-address-them/): Although China recently overtook India as the ‘Diabetes Capital of the World’, there are two startling statistics about India’s relationship with diabetes which are worrisome: 57% of adults with type 2 diabetes don’t know they have it, and over…
[A Scorecard for the Pharmacy for the World - Lupin | Perspective](https://www.lupin.com/media/perspectives/a-score-card-for-the-pharmacy-for-the-world/): Jonas Salk, the inventor of the polio vaccine, asked the question “Are we being good ancestors?” This long-term measure of success recognizes that anything valuable takes time to create, and current difficulties while painful are less important for the…
[We are well-aligned to capitalize on the CDMO opportunity - Lupin | Perspective](https://www.lupin.com/media/perspectives/abdelaziz-ceo-lupin-manufacturing-solutions-interview-pharma-cdmo-express-healthcare/): Dr Abdelaziz Toumi, CEO, Lupin Manufacturing Solutions (LMS), in an interview with Viveka Roychowdhury, Express Pharma In light of the BioSecure Act and the PILLS Act, aimed at reducing dependencies on other countries and incentivising manufacturing of pharma…
[Integration of AI and ML to play a critical role in reshaping pharma manufacturing operations - Lupin | Perspective](https://www.lupin.com/media/perspectives/abdelaziz-toumi-interview-biovoice-news-jan-2025-issue-integration-of-ai-and-ml-to-play-a-critical-role-in-reshaping-pharma-manufacturing-operations/): How does Lupin Manufacturing Solutions (LMS) ensure the highest standards of quality and reliability across its manufacturing processes? Any recent technological advancements adopted by you? LMS upholds the highest standards of quality and reliability in its manufacturing processes by…
[Asthma Care – Delivering on People’s Right to Breathe - Lupin | Perspective](https://www.lupin.com/media/perspectives/asthma-care-delivering-on-peoples-right-to-breathe/): As the world continues to battle the respiratory pandemic, it is important to remember that long before the COVID-19 pandemic began, millions of people around the world have been struggling with chronic respiratory diseases, such as asthma. Breathing is…
[Lupin Media Hub - News, Insights and Resources](https://www.lupin.com/media/): Here you will get all the latest Lupin information, News, Videos, Press Releases and updates.
[Asthma education in India, a call for action - Lupin | Perspective](https://www.lupin.com/media/perspectives/asthma-education-in-india-a-call-for-action/): We are no strangers to witnessing the detrimental impact of irritants present in the air on humans. The presence of these irritants often leads to wheezing, coughing, and shortness of breath, which significantly affects the quality of life. This…
[Asthma myths that take your breath away! - Lupin | Perspective](https://www.lupin.com/media/perspectives/asthma-myths-that-take-your-breath-away/): Chronic Respiratory conditions are on an exponential rise, now more than ever, with drastic decrease in the quality of air we breathe, unfortunately shadowed by pandemic infections like COVID-19, which continue to dominate the health discourse in the media….
[Beyond the pills: How remote cardiac rehab transforms post-hospital recovery - Lupin | Perspective](https://www.lupin.com/media/perspectives/beyond-the-pills-how-remote-cardiac-rehab-transforms-post-hospital-recovery/): Remote cardiac rehabilitation offers a structured, medically guided digital program delivered via a patient’s phone, ensuring continuous, expert-backed recovery at home after a heart scare When someone you know—whether a friend, relative, or colleague—returns home after a heart scare,…
[Cardiac Care in Post COVID-19 Era - Lupin | Perspective](https://www.lupin.com/media/perspectives/cardiac-care-in-post-covid-19-era/): According to the World Health Organisation (WHO), cardiovascular diseases take the lives of 17.9 million people every year, which is 31% of all the global deaths¹. The WHO also states that India accounts for one-fifth of the total deaths…
[Cardiologist Dr. Purabi Koch talks about cardiovascular diseases in women - Lupin | Perspective](https://www.lupin.com/media/perspectives/cardiologist-dr-purabi-koch-on-heart-diseases-and-women/): Join #LupinIndia​ with Dr. Purabi Koch and hear what she has to say about Women and Heart Diseases. It is time we take a step towards preventing this preventable disease by busting myths and increasing awareness. #NovelStartToLife​ #HealthyHeart​…
[Breaking Down Barriers To Build A Brighter Future For Pharma - Lupin | Perspective](https://www.lupin.com/media/perspectives/breaking-down-barriers-to-build-a-brighter-future-for-pharma/): In the dynamic landscape of global healthcare, the Indian pharmaceutical industry stands tall as a testament to groundbreaking medical advancements and innovation. Ranking third in the world by volume and 14th by value, the Indian pharma sector, aptly…
[Building a Resilient Future for India’s Lungs - Lupin | Perspective](https://www.lupin.com/media/perspectives/building-a-resilient-future-for-indias-lungs/): Rajeev Sibal, President, India Region Formulations, Lupin Limited Breathing is the simplest and most essential act of life. Yet for millions of Indians, it is no longer effortless. Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), tuberculosis,…
[Comprehensive Women’s Health: A Holistic Approach to Wellness - Lupin | Perspective](https://www.lupin.com/media/perspectives/comprehensive-womens-health-a-holistic-approach-to-wellness/): More concerning is cardiovascular disease, one of the leading causes of death among women worldwide, which often goes unrecognized. While women do receive cardiac care, they face a 20per cent higher risk of complications than men, with their symptoms…
[Climate change is affecting occupational safety, too - Lupin | Perspective](https://www.lupin.com/media/perspectives/climate-change-is-affecting-occupational-safety-too/): As the world grapples with the multifaceted challenges posed by climate change, industries across the globe are awakening to its profound impact on every aspect of our lives. At the forefront of this discourse stands the issue of occupational…
[Digital Innovation: The Key to Affordable, Patient-First Healthcare - Lupin | Perspective](https://www.lupin.com/media/perspectives/digital-innovation-the-key-to-affordable-patient-first-healthcare/): Every breakthrough starts with a spark of innovation – a shift in perspective that redefines possibilities. Today, digital healthcare is that spark, igniting a transformation in how we deliver care, enhance outcomes, and empower patients across India. For…
[Building a tech-driven operations ecosystem to adapt to global shifts - Lupin | Perspective](https://www.lupin.com/media/perspectives/christoph-funke-interview-et-pharma-building-a-tech-driven-operations-eco-systems-to-adapt-to-global-shifts-25-02-2025/): As Lupin’s first Chief Technical Operations Officer, what are your key priorities in integrating manufacturing, supply chain, and procurement? How do you see this role evolving amid the rapidly changing dynamics of global pharmaceutical operations? We’ve strategically integrated manufacturing,…
[Digital Intelligence Accelerates Drug Discovery - Lupin | Perspective](https://www.lupin.com/media/perspectives/digital-intelligence-accelerates-drug-discovery/): Embedding digital intelligence into research, manufacturing, quality, and commercial functions has accelerated drug discovery and streamlined processes, says Rakesh Bhardwaj, Global CIO at Lupin Pharma major Lupin reaped the benefits of its digital-first strategy in FY25, clocking ₹435…
[Digital Therapeutics: Digital Revolution in Healthcare - Lupin | Perspective](https://www.lupin.com/media/perspectives/digital-therapeutics-digital-revolution-in-healthcare/): Ever since Rekha’s mother opted for a connected wearable activity tracker to monitor her activity, sleep and fitness, her vitals have stabilised and there have been no more emergency trips to the hospital. Her healthcare provider (HCP) can now…
[Digital Therapeutics Revolutionizing Women’s Cardiac Health - Lupin | Perspective](https://www.lupin.com/media/perspectives/digital-therapeutics-revolutionizing-womens-cardiac-health/): Every year, we celebrate International Women’s Day, honoring the achievements and contributions of women worldwide. Yet amidst the festivities, an often over-looked aspect is the silent danger lurking for women: their heart health. Despite advancements in various fields, women’s…
[Emotional Sustainability: The Next Frontier In Workplace Wellbeing - Lupin | Perspective](https://www.lupin.com/media/perspectives/emotional-sustainability-the-next-frontier-in-workplace-wellbeing/): As India’s pharma industry advances globally, emotional sustainability emerges as a vital pillar for innovation and workforce resilience A scientist in a sterile lab. A manufacturing supervisor overseeing a critical batch. Seemingly so small, yet the microcosm of everyday…
[Driving Sustainability and Innovation - Lupin | Perspective](https://www.lupin.com/media/perspectives/driving-sustainability-and-innovation/): What strategies has the company adopted to minimise waste and hazards? Lupin is advancing the adoption of green chemistry to minimise hazardous substance generation by leveraging metrics like atom economy and e-factor. Our objectives align with the 12…
[Empowering Women’s Heart Health: Breaking Barriers and Building a Healthier Future - Lupin | Perspective](https://www.lupin.com/media/perspectives/empowering-womens-heart-health-breaking-barriers-and-building-a-healthier-future/): It’s been over a century since the celebration of the first International Women’s Day, and yet, the imperative for inclusive empowerment persists. Today, as we commemorate the strides made towards gender equality, there’s an urgent call to prioritise women’s…
[Employees are at the front line of cyber attacks - Lupin | Perspective](https://www.lupin.com/media/perspectives/employees-are-at-the-front-line-of-cyber-attacks/): Employees equipped with the ability to make the right decisions today, can help build a safer tomorrow for their firms With the pandemic ushering in disruptive changes across the business landscape, a cure for virus has been in the…
[Enabling Employee Safety in Pharmaceutical Manufacturing - Lupin | Perspective](https://www.lupin.com/media/perspectives/enabling-employee-safety-in-pharmaceutical-manufacturing/): When we think of Employees in the healthcare industry, our mind often goes to doctors, nurses, and other hospital workers. But what about those that work behind the scenes, manufacturing the medicines that keep us healthy and disease-free! India’s…
[Evolution of the Diagnostics Industry: New Trends, Models Transforming Healthcare Industry - Lupin | Perspective](https://www.lupin.com/media/perspectives/evolution-of-the-diagnostics-industry-new-trends-models-transforming-healthcare-industry/): In the vast tapestry of India’s healthcare landscape, the diagnostics industry emerges as a dynamic force, weaving together technological advancements, changing patient expectations, and an ever-expanding vision for a healthier nation. Indian diagnostics sector itself is projecting INR 1,360…
[From risk to resilience: Tackling cardiovascular challenges - Lupin | Perspective](https://www.lupin.com/media/perspectives/from-risk-to-resilience-tackling-cardiovascular-challenges/): Do you know what is the leading cause of death among Indians? It indeed is ischaemic heart disease, the most common form of cardiovascular disease (CVD) and a condition in which the heart does not get sufficient oxygen owing…
[From the Power of the Present to the Hope of the Future - Lupin | Perspective](https://www.lupin.com/media/perspectives/from-the-power-of-the-present-to-the-hope-of-the-future/): “You cannot predict the future, but you can create it” said Drucker in his famous book. For the healthcare and pharmaceutical industry, this is more relevant today than ever. It took 300 years for germ theory to translate into…
[Head and Neck Cancer Awareness Month – why a patient-centric approach is crucial - Lupin | Perspective](https://www.lupin.com/media/perspectives/head-and-neck-cancer-awareness-month-why-a-patient-centric-approach-is-crucial/): Cancer is a multifaceted illness that remains a persistent threat to humanity and is one of the leading causes of death globally. While discussions around cervical, breast, and lung cancers are a mainstay, it is imperative to recognize the…
[How can we work towards better mental health as a society? - Lupin | Perspective](https://www.lupin.com/media/perspectives/how-can-we-work-towards-better-mental-health-as-a-society/): Proximity bias, psychological safety, toxic positivity – these terms were not commonly known by the average Indian a few years ago. Thanks to social media and an increased discourse around mental wellbeing during the pandemic, more individuals today recognise…
[How Indian Pharma is Building a Sustainability Framework for a Greener Future - Lupin | Perspective](https://www.lupin.com/media/perspectives/how-indian-pharma-is-building-a-sustainability-framework-for-a-greener-future/): The Indian pharmaceutical industry remains a cornerstone of India’s economy, with a projected growth of 12.2% CAGR (2024-2032) and a projected market value of $ 156.25 billion by 2032. As the industry evolves to tackle complex global challenges, organisations…
[How technology is causing a shift towards preventive health care - Lupin | Perspective](https://www.lupin.com/media/perspectives/how-technology-is-causing-a-shift-towards-preventive-health-care/): The doctor of the future will give no medicine, but will instruct his patient in the care of the human frame, in diet, and the cause and prevention of disease” – Thomas A. Edison A prediction made about 120…
[How to Address Gender Disparities in Diagnosis and Treatment - Lupin | Perspective](https://www.lupin.com/media/perspectives/how-to-address-gender-disparities-in-diagnosis-and-treatment/): Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death globally, claimed 3.5 million lives in 2021, approximately 5% of all global deaths 1 with a growing and disproportionate impact on women. COPD 2 is no longer a…
[India’s Diabetes Crisis: Comprehensive Strategies for Prevention and Early Intervention - Lupin | Perspective](https://www.lupin.com/media/perspectives/indias-diabetes-crisis-comprehensive-strategies-for-prevention-and-early-intervention/): In the fight against diabetes, early detection is crucial. Too often, the diagnosis happens only after the disease has taken hold. To change this, we must pivot from a reactive approach to a proactive one that is focused on…
[India’s tuberculosis endemic in the COVID-19 era - Lupin | Perspective](https://www.lupin.com/media/perspectives/indias-tuberculosis-endemic-in-the-covid-19-era-2/): Like during the pandemic, we must work together to improve awareness and outcomes in diagnosis, prevention, treatment, and eventual elimination of TB from the country Nearly a year ago, India entered into a nationwide lockdown to arrest the spread…
[Lupin banks on complex generics, speciality products to sustain growth in FY26–27 - Lupin | Perspective](https://www.lupin.com/media/perspectives/lupin-banks-on-complex-generics-speciality-products-to-sustain-growth-in-fy26-27/): Ramesh Swaminathan in an interview with Business Today The United States market remains the company’s strongest growth driver, contributing 40% of total sales and rising 47% year-on-year to ₹2,762 crore. After delivering one of its strongest quarters ever, pharmaceutical…
[Integrated healthcare solutions that puts patients first - Lupin | Perspective](https://www.lupin.com/media/perspectives/integrated-healthcare-solutions-that-puts-patients-first/): India has surpassed the population of China this year, mainly as a result of younger population, higher fertility rate, and increased life expectancy. Life expectancy in India in the 1950s was about 32 years1 primarily due to limited access…
[International Day of Action for Women’s Health: Why investing in women’s health is important - Lupin | Perspective](https://www.lupin.com/media/perspectives/international-day-of-action-for-womens-health-why-investing-in-womens-health-is-important/): More than 450 million menopausal women globally may have increased risk of long-term conditions like cardiovascular disease, diabetes, neurological disorders and osteoporosis, when symptoms are not managed timely, observes Lupin’s Rajeev Sibal. The nation’s strength lies not only…
[Lupin hosts Hon. Ambassador of India to the USA, Taranjit Singh Sandhu - Lupin | Perspective](https://www.lupin.com/media/perspectives/lupin-hosts-hon-ambassador-of-india-to-the-usa-taranjit-singh-sandhu/): The Lupin Pharmaceuticals team at Baltimore was really pleased to host Ambassador Sandhu and his senior staff. It was an engaging dialogue with the Ambassador and senior staff from Commerce and Science & Technology. He was impressed with the…
[Lupin’s going beyond the pill to grow its digital therapeutics arm - Lupin | Perspective](https://www.lupin.com/media/perspectives/lupins-going-beyond-the-pill-to-grow-its-digital-therapeutics-arm/): By Sidharth Srinivasan, CEO, Lupin Digital Health Limited Introduced in FY2023, Lupin Digital Health marked the company’s foray into the fast-growing digital therapeutics space. Its Lyfe platform focuses on real-time monitoring of patients and offers interventions for cardiac…
[Navigating the Future: Trends and Innovations in Diagnostics - Lupin | Perspective](https://www.lupin.com/media/perspectives/navigating-the-future-trends-and-innovations-in-diagnostics/): As we stand on the cusp of 2024, the healthcare industry is poised for transformative changes in the diagnostics sector. The Indian diagnostics sector itself is projecting a INR 1,360 Bn market with a CAGR of 14%, comprising 60%…
[Mr. Ravindra Kumar, Vice President and Head Lupin Diagnostics in an interview with Shardul Nautiyal, Financial Express - Lupin | Perspective](https://www.lupin.com/media/perspectives/mr-ravindra-kumar-vice-president-and-head-lupin-diagnostics-in-an-interview-with-shardul-nautiyal-financial-express/): Lupin Diagnostics looks for franchise partners in Maharashtra, West Bengal, Bihar, Jharkhand, North-East as part of expansion During the launch period, Lupin diagnostic services will be available in multiple cities in West India like Mumbai, Pune, Nagpur, Nashik, and…
[Digital transformation in Indian pharma industry is building tomorrow’s care today - Lupin | Perspective](https://www.lupin.com/media/perspectives/nilesh-gupta-business-today-digital-transformation-in-indian-pharma-industry-is-building-tomorrow-january-2025/): By Nilesh Gupta The Indian pharma industry is at a juncture where digital transformation is sweeping the healthcare landscape. One of the founders of the Indian pharma industry, my father D.B. Gupta, started Lupin over 55 years ago with…
[Patent expiry of significant number of biologics by 2030 presents huge opportunities for biosimilars players - Lupin | Perspective](https://www.lupin.com/media/perspectives/patent-expiry-of-significant-number-of-biologics-by-2030-presents-huge-opportunities-for-biosimilars-players/): Dr Cyrus Karkaria leads Lupin’s biotechnology division and is responsible for developing the company’s global biosimilars portfolio. With over three decades of experience at Celldex Therapeutics, CuraGen and Biogen, Cyrus has a proven track record in managing biologic…
[Patient Awareness and Empowerment, The Key to Liver Health - Lupin | Perspective](https://www.lupin.com/media/perspectives/patient-awareness-and-empowerment-the-key-to-liver-health/): The liver, frequently undervalued due to its complexity in the human body, is crucial in upholding overall health and well-being. As the body’s largest internal organ, the liver is a veritable powerhouse, silently performing over five hundred essential functions,…
[Lupin’s Legacy: Building a Better Tomorrow - Lupin | Perspective](https://www.lupin.com/media/perspectives/lupins-legacy-building-a-better-tomorrow/): Success is not just defined by sales and profits but also by the impact one can make on the world and the people around them. To transform these thoughts into actions, Dr Desh Bandhu Gupta established the Lupin Human…
[Pharma needs a dose of Sustainability - Lupin | Perspective](https://www.lupin.com/media/perspectives/pharma-needs-a-dose-of-sustainability/): Did you know industrial water usage accounts for up to 22% of global water consumption? This staggering statistic underscores the critical role of water as an essential input for day-to-day operations across industries. Among these, the pharmaceutical sector stands…
[Patient centricity must drive the pharma sector - Lupin | Perspective](https://www.lupin.com/media/perspectives/patient-centricity-must-drive-the-pharma-sector/): “You treat a disease: you win, you lose. You treat a person, I guarantee you you’ll win, no matter what the outcome.” These words by Hunter Doherty “Patch” Adams, the doctor-comedian-author, truly underline the patient-centric approach that is bringing in a…
[Pharma’s Next Frontier: Legacy Systems to Life-Changing Innovations - Lupin | Perspective](https://www.lupin.com/media/perspectives/pharmas-next-frontier-legacy-systems-to-life-changing-innovations/): The pharmaceutical and healthcare industries are at the epicentre of a sweeping digital revolution, that is altering the delivery of healthcare services and outcomes. Innovations such as Artificial Intelligence (AI)-driven drug discovery, the emergence of personalized medicine and other…
[Predictions 2022: Diagnostics to be centrestage of healthcare - Lupin | Perspective](https://www.lupin.com/media/perspectives/predictions-2022-diagnostics-to-be-centrestage-of-healthcare/): Healthcare facilities were forced outside hospital boundaries in the pandemic, leading to a rise in home diagnostics, but there is a need of a more analytical approach in managing, gathering data. A timely and accurate diagnosis is vital to…
[Redefining the Pharmaceutical Industry’s Role in Combating Climate Change - Lupin | Perspective](https://www.lupin.com/media/perspectives/redefining-the-pharmaceutical-industrys-role-in-combating-climate-change/): Climate change has emerged as one of the most critical challenges of our era, affecting all sectors, particularly the pharmaceutical industry. The industry is considered a significant contributor to greenhouse gas emissions, necessitating urgent action. A silver lining, however,…
[Revolutionizing Cancer Care: A Call for Accessibility and Affordability in India - Lupin | Perspective](https://www.lupin.com/media/perspectives/revolutionizing-cancer-care-a-call-for-accessibility-and-affordability-in-india/): The looming threat of cancer continues to cast a dark shadow over India’s health landscape, impacting millions of lives. According to the Global Cancer Observatory, India has seen a staggering 2.08 million new cancer cases in 2023, placing the…
[Recalibrating Strategy - Lupin | Perspective](https://www.lupin.com/media/perspectives/recalibrating-strategy/): Budget 2022: Challenges govt needs to address this year The Eye of the World – touted as the successor to the wildly successful TV series and streaming phenomenon Game of Thrones – is the story of a quest led…
[Rethinking and reinventing corporate India - Lupin | Perspective](https://www.lupin.com/media/perspectives/rethinking-and-reinventing-corporate-india/): With ESG reporting, companies can redefine identity, brand and purpose ‘There are no passengers on Spaceship Earth,’ said Marshall McLuhan, communications and media theorist, ‘we are all crew.’ As India’s largest companies get ready to take on the now-mandatory…
[Scalability: The Key for Biosimilar Manufacturing - Lupin | Perspective](https://www.lupin.com/media/perspectives/scalability-the-key-for-biosimilar-manufacturing/): When we think of medical breakthroughs, we often picture scientists in labs, complex molecules under microscopes, and the relentless pursuit of cures. Yet, behind every vial of biologic therapy lies another kind of breakthrough — one that happens…
[Shift in Customer Dynamics Fueling Future-Forward Business Growth - Lupin | Perspective](https://www.lupin.com/media/perspectives/shift-in-customer-dynamics-fueling-future-forward-business-growth/): Considering India’s ‘Pharmacy of the World’ stature, what are the primary drivers propelling its pharmaceutical industry, and how has Lupin specifically contributed to this global prominence? India’s stature as the ‘Pharmacy of the World’ is driven by its unmatched…
[Small steps towards better heart health, how can India’s young avoid heart ailments - Lupin | Perspective](https://www.lupin.com/media/perspectives/small-steps-towards-better-heart-health-how-can-indias-young-avoid-heart-ailments/): Globally, India stands at an enviable position as one of the fastest growing economies, and this is only slated to grow further. Why? Because as the rest of the world’s strongest economies age, half of our population of 1.3…
[Spotlight on Indian Pharma’s resilience during pandemic times - Lupin | Perspective](https://www.lupin.com/media/perspectives/spotlight-on-indian-pharmas-resilience-during-pandemic-times/): “Promise me you’ll always remember that you are braver than you believe, stronger than you seem and smarter than you think…”. This quote from the beloved Winnie the Pooh wasn’t quite the words but were exactly the sentiment that…
[Lupin’s Sourabh Agrawal believes that creativity thrives beyond big budgets - Lupin | Perspective](https://www.lupin.com/media/perspectives/sourabh-agrawal-interview-campaign-india-jan-2025-featured-in-the-cmos-column-22-01-2025/): Sourabh Agrawal, Executive Vice President – Sales and Marketing, Lupin What are the biggest marketing challenges and opportunities, respectively, for your brand currently? Healthcare’s regulated nature presents specific marketing challenges like raising awareness about therapies, ensuring access to underserved…
[Start them young: The importance of mental health awareness among adolescents - Lupin | Perspective](https://www.lupin.com/media/perspectives/start-them-young-the-importance-of-mental-health-awareness-among-adolescents/): ”I know that the most joy in my life has come to me from my violin,” said one of the world’s most celebrated Nobel Prize winner Physicist. One might have expected him to have spoken about the Theory of…
[The 3Cs to solve the TB Conundrum - Lupin | Perspective](https://www.lupin.com/media/perspectives/the-3cs-to-solve-the-tb-conundrum/): Breathe in and breathe out, then repeat. But what if you can’t? Tuberculosis, a serious infectious bacterial disease that mainly affects the lungs, affects an estimated 10 million people globally. Till 2019, it held its undisputed position as the…
[Strong Financial Planning Key for Making Healthcare Accessible: Roadmap for 2024 - Lupin | Perspective](https://www.lupin.com/media/perspectives/strong-financial-planning-key-for-making-healthcare-accessible-roadmap-for-2024/): In India, where only 34% of the population has access to essential healthcare within a 5-km radius, the need for a comprehensive financial strategy is even more pressing than ever. With nearly two-thirds of health spending driven by out-of-pocket…
[The ₹40-crore AI payoff: How Lupin is building a data-first, AI-ready pharma enterprise - Lupin | Perspective](https://www.lupin.com/media/perspectives/the-40-crore-ai-payoff-how-lupin-is-building-a-data-first-ai-ready-pharma-enterprise/): Pharma giant Lupin started its digital transformation journey in 2021. Four years later, AI is now embedded across the company’s $2.5 billion global operations. From the company’s labs to shop floors to its supply chains, it’s strategically woven…
[The battle against TB needs to be stepped up - Lupin | Perspective](https://www.lupin.com/media/perspectives/the-battle-against-tb-needs-to-be-stepped-up/): Tuberculosis, colloquially known as the ‘white death,’ has plagued humanity for centuries, persistently claiming lives and leaving a trail of devastation. Despite remarkable progress in healthcare, TB remains a formidable threat, surpassing smallpox, plague, cholera and influenza combined in…
[The Diabetes Epidemic in India: Embracing a Healthier Future - Lupin | Perspective](https://www.lupin.com/media/perspectives/the-diabetes-epidemic-in-india-embracing-a-healthier-future/): India finds itself at a crucial healthcare crossroads. While nearly 77 million Indians suffer from diabetes, the numbers are expected to rise to over 124 million by 2045. This relentless rise presents a formidable healthcare challenge and shows a…
[Step up for NASH: LivAlert to Confront the silent threat of Liver Diseases - Lupin | Perspective](https://www.lupin.com/media/perspectives/step-up-for-nash-livalert-to-confront-the-silent-threat-of-liver-diseases/): Indians are today grappling with lifestyle-related disorders, and the number of people experiencing the challenges of liver diseases has been growing significantly. The liver, a remarkable organ known for its diversemetabolic functions and resilience, bears the brunt of unhealthy…
[The Rising Threat of Liver Diseases: Why Screening Matters - Lupin | Perspective](https://www.lupin.com/media/perspectives/the-rising-threat-of-liver-diseases-why-screening-matters/): Amidst the backdrop of India’s burgeoning health landscape, a concerning trend is emerging: the rise of lifestyle-related diseases, particularly those affecting the liver. With unhealthy habits taking a toll, fatty liver diseases, including Non-Alcoholic Fatty Liver Disease (NAFLD) and…
[The Evolving Landscape of Head and Neck Cancer Care in India - Lupin | Perspective](https://www.lupin.com/media/perspectives/the-evolving-landscape-of-head-and-neck-cancer-care-in-india/): Each year, more than 5.5 lakh patients are diagnosed with Head and Neck Cancers (HNC), representing 27.5% of all cancer cases in India. The disease burden in India is in sharp contrast to a mere 4% of cases reported…
[The Role of Emerging Technologies in Scaling Healthcare through Digital Therapeutics - Lupin | Perspective](https://www.lupin.com/media/perspectives/the-role-of-emerging-technologies-in-scaling-healthcare-through-digital-therapeutics/): In today’s interconnected world, technology has now become an integral part of our personal and professional lives. It’s hard to imagine how we communicated, worked, or even relaxed before the era of smartphones, social media, and virtual assistants. With…
[Uniting Against Head & Neck Cancer - Lupin | Perspective](https://www.lupin.com/media/perspectives/uniting-against-head-neck-cancer/): Head and Neck Cancer (HNC) is a formidable global health challenge, representing a spectrum of malignancies affecting the mouth, throat, larynx, sinuses, and salivary glands. With an estimated 650,000 new cases and 330,000 deaths annually worldwide, the disease burden…
[Understanding and Managing Hypertension - Lupin | Perspective](https://www.lupin.com/media/perspectives/understanding-and-managing-hypertension/): Within the dynamic landscape of public health in India, an alarming reality unfolds – statistics indicate that at least one in every four individuals is grappling with hypertension1. Hypertension, commonly known as uncontrolled blood pressure, is a paramount risk…
[The Silent Killer Meets Its Match: Digital Therapeutics In Hypertension Management - Lupin | Perspective](https://www.lupin.com/media/perspectives/the-silent-killer-meets-its-match-digital-therapeutics-in-hypertension-management/): Every morning, Mr. Sharma, a 62-year-old retired teacher from Pune, sits at his dining table with a cup of tea and his trusted blood pressure monitor. He diligently records his readings in a worn-out notebook, a ritual he’s…
[The Silent Crisis: Young Adults Battling Heart Disease - Lupin | Perspective](https://www.lupin.com/media/perspectives/the-silent-crisis-young-adults-battling-heart-disease/): In the aftermath of a global pandemic, a deeply concerning trend is quietly taking root, largely unnoticed. Young adults in their 30s and 40s grapple with severe cardiovascular diseases (CVDs) and the associated complications. This silent crisis affects even…
[Towards a Cleaner Future: Bringing Renewable Energy and Green Chemistry into Mainstream Pharma - Lupin | Perspective](https://www.lupin.com/media/perspectives/towards-a-cleaner-future-bringing-renewable-energy-and-green-chemistry-into-mainstream-pharma/): The future of healthcare will be influenced not solely by the medicines we develop, but also by the methods employed in their production. Climate change is emerging as one of the biggest health threats of our time, with the…
[Trends 2025: Redefining the Pharma Supply Chain - Lupin | Perspective](https://www.lupin.com/media/perspectives/trends-2025-redefining-the-pharma-supply-chain/): AI integration, digitization, and sustainability that are shaping a future-ready supply chain Supply chain management used to be simple—or at least it seemed that way. You produced goods, stored them, and shipped them out, hoping everything stayed on track….
[Towards a TB-free India - Lupin | Perspective](https://www.lupin.com/media/perspectives/towards-a-tb-free-india-2/): Till 2019, tuberculosis held its undisputed position as the most common cause of death from a single infectious pathogen, dislodged only by Covid-19 in 2020. It is now back to the ignominious first spot Margaret J Wheatley aptly stated…
[The Urgency of Addressing Respiratory Diseases’ Disproportionate Impact on Global Health - Lupin | Perspective](https://www.lupin.com/media/perspectives/the-urgency-of-addressing-respiratory-diseases-disproportionate-impact-on-global-health/): Healthy lungs are essential to life. The lungs provide life-giving oxygen to each cell of our body1. However, the escalating crisis of lung health disparities globally is looming large, demanding an urgent call to action for health advocates. Despite…
[Transforming Heart Health in India: Leveraging Integrated & Affordable Care - Lupin | Perspective](https://www.lupin.com/media/perspectives/transforming-heart-health-in-india-leveraging-integrated-affordable-care/): India is grappling with a silent cardiovascular epidemic, as evidenced by the alarming 14.23 per cent rise in heart attack cases in 2022. The epidemic is often described as ‘silent’ because many forms of cardiovascular disease (CVD) can develop without…
[We are planning to expand our therapeutic footprint in high-demand disease areas - Lupin | Perspective](https://www.lupin.com/media/perspectives/we-are-planning-to-expand-our-therapeutic-footprint-in-high-demand-disease-areas/): 1. What is the status of the CDMO market landscape in India? How Lupin is planning to use this trend as a growth opportunity? India’s CDMO market is at an inflection point, projected to grow significantly, driven by shifts…
[Why Gender-Specific Approaches to Cardiac Disease are Vital - Lupin | Perspective](https://www.lupin.com/media/perspectives/why-gender-specific-approaches-to-cardiac-disease-are-vital/): A month ago, Priya (name changed), a devoted mother in her early 40s, experienced a life-altering event. While attending to her family’s needs, she dismissed the unusual tightness in her chest and shortness of breath as mere fatigue, attributing…
[We are expanding our CDMO capabilities to meet the next wave of complex therapies starting with oncology - Lupin | Perspective](https://www.lupin.com/media/perspectives/we-are-expanding-our-cdmo-capabilities-to-meet-the-next-wave-of-complex-therapies-starting-with-oncology/): Lupin Manufacturing Solutions has been gaining visibility lately. For those who might not be familiar, how would you describe LMS and its vision within the Lupin Group? Lupin Manufacturing Solutions (LMS) represents Lupin’s commitment to extending its scientific excellence…
[World Lung Day 2023 | How to Break Down Barriers to Healthy Lungs - Lupin | Perspective](https://www.lupin.com/media/perspectives/world-lung-day-2023-how-to-break-down-barriers-to-healthy-lungs/): Imagine a world where each breath is a source of vitality and strength, where our lungs quietly conduct the orchestra of life. Unlike other parts of our body, our lungs have a reserve capacity that helps us in tough…
[Women’s Heart Health in India: A Growing Concern - Lupin | Perspective](https://www.lupin.com/media/perspectives/womens-heart-health-in-india-a-growing-concern/): What is the prevalence of heart disease among women in India? The increasing prevalence of heart disease among women in India is a pressing public health issue that demands urgent attention. More than 40 per cent of all deaths…
[4QFY20 and FY20 Earnings Conference call on 29 May 2020 - Lupin | Press Release](https://www.lupin.com/media/press-releases/4qfy20-and-fy20-earnings-conference-call-on-29-may-2020/): Read the latest press releases and corporate communications from Lupin Limited.
[6 Years of Sustained Growth Lupin Net Profit up by 27% in FY 2010-11 - Lupin | Press Release](https://www.lupin.com/media/press-releases/6-years-of-sustained-growth-lupin-net-profit-up-by-27-in-fy-2010-11/): Read the latest press releases and corporate communications from Lupin Limited.
[Alliance to commercialize generic equivalent of FOSRENOL® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/alliance-to-commercialize-generic-equivalent-of-fosrenol-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[World Environment Day: Why a collective action needed to navigate the environmental impact - Lupin | Perspective](https://www.lupin.com/media/perspectives/world-environment-day-why-a-collective-action-needed-to-navigate-the-environmental-impact/): Nanotechnology, genetic modification and advanced chemical processes have the potential to mitigate plastic pollution. These advancements can lead to the development of natural substitutes and the production of more biodegradable plastics India generates over 3.4 million tonnes of…
[Astellas and Lupin’s subsidiary Kyowa enter into an Agreement - Lupin | Press Release](https://www.lupin.com/media/press-releases/astellas-and-lupins-subsidiary-kyowa-enter-into-an-agreement/): Kyowa to exclusively market Quetiapine Fumarate Extended-Release tablets in Japan Osaka (Japan): Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co., Ltd. (Head Office: Osaka, Japan; President & Representative Director: Ray Tsunoda; hereafter referred…
[American Academy of Ophthalmology and Lupin Collaborate to Enhance Continuing Ophthalmic Medical Education in India - Lupin | Press Release](https://www.lupin.com/media/press-releases/american-academy-of-ophthalmology-and-lupin-collaborate-to-enhance-continuing-ophthalmic-medical-education-in-india/): Agreement expands reach of physician-developed, industry-leading clinical training programs San Francisco and Mumbai: The American Academy of Ophthalmology and Pharma major Lupin Limited (Lupin) today announced an agreement that would seek to expand and enhance continuing ophthalmic education in India. The…
[Dr. Kamal K. Sharma to join Lupin as Managing Director - Lupin | Press Release](https://www.lupin.com/media/press-releases/dr-kamal-k-sharma-to-join-lupin-as-managing-director/): Read the latest press releases and corporate communications from Lupin Limited.
[Co-authored article by Dr. Cyrus Karkaria, President – Biotech Business, and Sanjay Tiwari, Vice President – R&D (Biotech), on ‘Biotech industry propels research, innovation & ethical solutions to overcome challenges in drug development’ published on Pharmabiz portal on November 8, 2025 - Lupin | Press Release](https://www.lupin.com/media/press-releases/co-authored-article-by-dr-cyrus-karkaria-president-biotech-business-and-sanjay-tiwari-vice-president-rd-biotech-on-biotech-industry-propels-research-innovation-ethical-solutio/): Read the latest press releases and corporate communications from Lupin Limited.
[Consistent Growth, Net Sales up 17% India and Japan Drive Growth - Lupin | Press Release](https://www.lupin.com/media/press-releases/consistent-growth-net-sales-up-17-india-and-japan-drive-growth/): Read the latest press releases and corporate communications from Lupin Limited.
[Consistent Growth, Robust Profits Quarter II Results, FY 2013-14 Net Sales up 18%; EBITDA up 42%; Net profit up 40% - Lupin | Press Release](https://www.lupin.com/media/press-releases/consistent-growth-robust-profits-quarter-ii-results-fy-2013-14-net-sales-up-18-ebitda-up-42-net-profit-up-40/): Read the latest press releases and corporate communications from Lupin Limited.
[Dr. Desh Bandhu Gupta, Founder and Chairman of Lupin passes away - Lupin | Press Release](https://www.lupin.com/media/press-releases/dr-desh-bandhu-gupta-founder-and-chairman-of-lupin-passes-away/): Mumbai, India: Dr. Desh Bandhu Gupta, Founder and Chairman of Lupin Limited (Lupin), passed away early this morning in Mumbai. He was 79 years old. He will be remembered as a visionary, path-breaker and a nationalist who created a…
[Dr. Desh Bandhu Gupta AAiPS Award 2019 Conferred on Dr. Umesh Gupta - Lupin | Press Release](https://www.lupin.com/media/press-releases/dr-desh-bandhu-gupta-aaips-award-2019-conferred-on-dr-umesh-gupta/): Mumbai, San Antonio: American Association of Indian Pharmaceutical Scientists (AAiPS) in collaboration with the Indian Pharmaceutical Association (IPA), announced Dr. Umesh Gupta, Assistant Professor, Central University of Rajasthan, as the recipient of the Dr. Desh Bandhu Gupta AAiPS…
[Boehringer Ingelheim India and Lupin expand collaboration for co-marketing of two oral anti-diabetic drugs - Lupin | Press Release](https://www.lupin.com/media/press-releases/boehringer-ingelheim-india-and-lupin-expand-collaboration-for-co-marketing-of-two-oral-anti-diabetic-drugs/): Expanded partnership will help co-market two oral anti—diabetic drugs Gibtulio Met® (Empagliflozin + Metformin) and Ajaduo® (Empagliflozin + Linagliptin ) Gibtulio Met® has potential for addressing CVD risk along with effective blood sugar control in adult Indian patients…
[DSM Anti-Infectives India And Lupin Enter Into A Strategic Cooperation For Cephalosporins - Lupin | Press Release](https://www.lupin.com/media/press-releases/dsm-anti-infectives-india-and-lupin-enter-into-a-strategic-cooperation-for-cephalosporins/): Read the latest press releases and corporate communications from Lupin Limited.
[Dr. Vijay Kelkar and Mr. R A Shah join Lupin Board - Lupin | Press Release](https://www.lupin.com/media/press-releases/dr-vijay-kelkar-and-mr-r-a-shah-join-lupin-board/): Read the latest press releases and corporate communications from Lupin Limited.
[DST and Lupin join hands over Migraine and Psoriasis - Lupin | Press Release](https://www.lupin.com/media/press-releases/dst-and-lupin-join-hands-over-migraine-and-psoriasis-2/): Read the latest press releases and corporate communications from Lupin Limited.
[DST and Lupin join hands over Migraine and Psoriasis - Lupin | Press Release](https://www.lupin.com/media/press-releases/dst-and-lupin-join-hands-over-migraine-and-psoriasis/): Read the latest press releases and corporate communications from Lupin Limited.
[EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Lupin for Commercialization of BINOSTO® in Vietnam & Philippines - Lupin | Press Release](https://www.lupin.com/media/press-releases/effrx-pharmaceuticals-signs-exclusive-licensing-and-distribution-agreement-with-lupin-for-commercialization-of-binosto-in-vietnam-philippines/): Freienbach, February 6, 2024 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced that it has signed an exclusive licensing and distribution agreement for Binosto® in…
[Eli Lilly India and Lupin announce strategic collaboration to help fight the battle against diabetes - Lupin | Press Release](https://www.lupin.com/media/press-releases/eli-lilly-india-and-lupin-announce-strategic-collaboration-to-help-fight-the-battle-against-diabetes/): Read the latest press releases and corporate communications from Lupin Limited.
[Ernst & Young announces Lupin Pharmaceuticals Inc., CEO Vinita Gupta as Entrepreneur of the Year, Maryland – 060712 - Lupin | Press Release](https://www.lupin.com/media/press-releases/ernst-young-announces-lupin-pharmaceuticals-inc-ceo-vinita-gupta-as-entrepreneur-of-the-year-maryland-060712/): Read the latest press releases and corporate communications from Lupin Limited.
[Press Releases and Official News - Lupin](https://www.lupin.com/media/press-releases/): Read Lupin’s latest press releases and official news covering company updates, business announcements, research milestones, and global initiatives.
[France’s ANSM completes inspection at Lupin’s Mandideep facility (Unit-1) - Lupin | Press Release](https://www.lupin.com/media/press-releases/frances-ansm-completes-inspection-at-lupins-mandideep-facility-unit-1/): Mumbai: Pharma major Lupin Limited (Lupin) today announced the completion of the Good Manufacturing Practices (GMP) Inspection of its finished product manufacturing facility (Unit-1) at Mandideep, by the French National Agency for Medicines and Health Products Safety (ANSM)….
[Governor Murphy and Local Leaders Attend Ribbon-Cutting Ceremony, Marking the Inauguration of Lupin’s New Corporate Offices in Bridgewater - Lupin | Press Release](https://www.lupin.com/media/press-releases/governor-murphy-and-local-leaders-attend-ribbon-cutting-ceremony-marking-the-inauguration-of-lupins-new-corporate-offices-in-bridgewater/): The new space expands Lupin’s footprint in New Jersey, underscoring its strong commitment to advancing pharmaceutical innovation and contributing to the state’s economy, while actively supporting the broader U.S. healthcare system Media Contact: Elise Titan, Director, U.S. Communications, Pharma…
[HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer - Lupin | Press Release](https://www.lupin.com/media/press-releases/hdma-honors-lupin-with-diana-award-for-best-overall-generic-manufacturer/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives IND approval for anti-migraine molecule - Lupin | Press Release](https://www.lupin.com/media/press-releases/intimation-sent-to-the-bse-nse-in-connection-with-change-in-the-partnership-interest-of-the-company-in-abcd-technologies-llp/): Lupin Ltd said today that its Investigational New Drug Application (INDA) for the prophylactic treatment of migraine has been approved by the IND Sub-committee of the Indian Council of Medical Research (ICMR); the Sub-committee is headed by the ICMR…
[Fiscal year 2019 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/fiscal-year-2019-results/): Board recommends dividend of 250% Mumbai: Pharma major Lupin Limited reported its financial performance for the fourth quarter and fiscal year ending March 31st, 2019. These audited results were taken on record by the Board of Directors at a…
[Intimation to the Stock Exchange on LPI Gavis settlement - Lupin | Press Release](https://www.lupin.com/media/press-releases/intimation-to-the-stock-exchange-on-lpi-gavis-settlement-2/): Read the latest press releases and corporate communications from Lupin Limited.
[Intimation to the Stock Exchange on LPI Gavis settlement - Lupin | Press Release](https://www.lupin.com/media/press-releases/intimation-to-the-stock-exchange-on-lpi-gavis-settlement/): Read the latest press releases and corporate communications from Lupin Limited.
[Japan’s PMDA issues GMP Certificate to Lupin’s Unit II Mandideep facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/japans-pmda-issues-gmp-certificate-to-lupins-unit-ii-mandideep-facility/): Mumbai: Pharma major Lupin today announced the receipt of GMP (Good Manufacturing Practice) Certificate from the Pharmaceutical and Medical Devices Agency (PMDA), Japan for its Mandideep API facility (Unit II). The GMP Certificate was issued following an inspection conducted…
[Japan’s PMDA completes inspection of Lupin’s Mandideep facility (Unit-2) - Lupin | Press Release](https://www.lupin.com/media/press-releases/japans-pmda-completes-inspection-of-lupins-mandideep-facility-unit-2/): Mumbai: Pharma major Lupin today announced the completion of the Good Manufacturing Practices (GMP) inspection of its Mandideep facility (Unit-2), by the Pharmaceutical and Medical Devices Agency (PMDA), Japan. The inspection was conducted between May 14, 2019 and May…
[Jeffrey Kindler and Alfonso Zulueta Join Lupin Board as Independent Directors - Lupin | Press Release](https://www.lupin.com/media/press-releases/jeffrey-kindler-and-alfonso-zulueta-join-lupin-board-as-independent-directors/): Mumbai, Naples, May 09, 2024: Pharma major Lupin Limited (Lupin) announced the appointment of Mr. Jeffrey Kindler and Mr. Alfonso “Chito” Zulueta as Independent Directors to its Board. Mr. Kindler is an experienced healthcare executive, investor and advisor. He…
[Letter to the Exchange on Intimation on IT security - Lupin | Press Release](https://www.lupin.com/media/press-releases/letter-to-the-exchange-on-intimation-on-it-security-2/): Read the latest press releases and corporate communications from Lupin Limited.
[Letter to the Exchange on Intimation on IT security - Lupin | Press Release](https://www.lupin.com/media/press-releases/letter-to-the-exchange-on-intimation-on-it-security/): Read the latest press releases and corporate communications from Lupin Limited.
[Luforbec® 200/6 (beclometasone 200mcg / formoterol 6mcg) a certified carbon neutral inhaler is launched in the UK for the treatment of adult asthma1,2,3 - Lupin | Press Release](https://www.lupin.com/media/press-releases/luforbec-200-6-beclometasone-200mcg-formoterol-6mcg-a-certified-carbon-neutral-inhaler-is-launched-in-the-uk-for-the-treatment-of-adult-asthma123/): This higher dose option complements the Luforbec 100/6 pMDI providing a costeffective asthma treatment range4,5,6 Slough, UK, November 14, 2022: Lupin Healthcare, the UK-based wholly owned subsidiary of Lupin Limited (Lupin) today announced the UK launch of Luforbec 200/6…
[Lupin Achieves GMP Certification from TGA Australia for Dabhasa API Facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-achieves-gmp-certification-from-tga-australia-for-dabhasa-api-facility/): Mumbai, Melbourne, July 17, 2025:: Global pharma major Lupin Limited (Lupin) today announced that the API manufacturing facility of its wholly owned subsidiary, Lupin Manufacturing Solutions (LMS), in Dabhasa, Gujarat, has received the Good Manufacturing Practice (GMP) certification…
[Lupin Achieves Significant Milestone with ISO 14001 and ISO 45001 Certification Across All its Indian Manufacturing Sites, R&D Center and Corporate Office - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-achieves-significant-milestone-with-iso-14001-and-iso-45001-certification-across-all-its-indian-manufacturing-sites-rd-center-and-corporate-office/): Mumbai, May 15, 2024: Global pharma major Lupin Limited (Lupin) today announced that all 12 of its manufacturing sites, its R&D Center and corporate office in India have successfully completed rigorous audits and been certified by DNV for ISO…
[Lupin Acquires 3 Trademarks from Boehringer Ingelheim to Strengthen Diabetes Portfolio - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-3-trademarks-from-boehringer-ingelheim-to-strengthen-diabetes-portfolio/): GIBTULIO®, GIBTULIO MET® and AJADUO® are key components for Diabetes Treatment Mumbai, December 13, 2024: Global pharma major Lupin Limited (Lupin) announced today the acquisition of anti-diabetes trademarks GIBTULIO®, GIBTULIO MET® and AJADUO® from Boehringer Ingelheim International GmbH…
[Lupin Acquires Biocom in Russia - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-biocom-in-russia/): Mumbai: Pharma Major Lupin Limited today announced the acquisition of 100% equity stake in ZAO “Biocom” in Russia subject to certain closing conditions. The acquisition marks Lupin’s foray into the Russian pharmaceutical market which recorded RUB 765 billion in…
[Lupin Acquires Brands ONDERO® and ONDERO MET® to expand Diabetes Portfolio in India - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-brands-ondero-and-ondero-met-to-expand-diabetes-portfolio-in-india/): Mumbai, August 18, 2023: Global pharma major Lupin Limited (Lupin) announced today the acquisition of diabetes brands ONDERO® and ONDERO MET®, from Boehringer Ingelheim International GmbH (Boehringer Ingelheim), including the trademark rights associated with these brands. Lupin has been…
[Lupin Acquires Branded Product Portfolio from Shionogi in Japan - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-branded-product-portfolio-from-shionogi-in-japan/): Mumbai, India and Osaka, Japan: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co., Ltd. (Head Office: Osaka, Japan; President & Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase…
[Lupin Acquires Five Brands from Menarini - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-five-brands-from-menarini/): Strengthens its Position and Key Therapy Portfolio in India Mumbai, September 22, 2023: Global pharma major Lupin Limited (Lupin) announced today that it has signed an agreement to acquire five legacy brands in strategic therapy areas – Gastroenterology,…
[Lupin Acquires GAVIS to Expand US Generic Business - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-gavis-to-expand-us-generic-business/): Mumbai: Pharma Major Lupin Limited (Lupin) has entered into a definitive agreement to acquire privately held GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS), subject to certain closing conditions, in a transaction valued at USD 880 million, cash free…
[Lupin Acquires Huminsulin from Lilly to Enhance Diabetes Portfolio - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-huminsulin-from-lilly-to-enhance-diabetes-portfolio/): Mumbai, December 30, 2024: Global pharma major Lupin Limited (Lupin) announced today the acquisition of Huminsulin® in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin range of products…
[Lupin acquires in Japan - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-in-japan/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Acquires I’rom Pharmaceuticals through its Japanese Subsidiary - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-irom-pharmaceuticals-through-its-japanese-subsidiary/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Acquires Laboratorios Grin S.A. De C.V., Mexico; Specialty Ophthalmic Company; Enters the Latin American Market. - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-laboratorios-grin-s-a-de-c-v-mexico-specialty-ophthalmic-company-enters-the-latin-american-market/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin acquires majority stake in Multicare Pharmaceuticals Philippines, Inc. - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-majority-stake-in-multicare-pharmaceuticals-philippines-inc/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Acquires Nine Brands of Medical Nutritional Institute in South Africa - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-nine-brands-of-medical-nutritional-institute-in-south-africa/): Mumbai, Johannesburg, October 4, 2024: Global pharma major Lupin Limited (Lupin) today announced that its South African subsidiary, Pharma Dynamics, has acquired nine brands along with their associated trademarks, from the Medical Nutritional Institute SA (MNI) in South Africa,…
[Lupin Acquires Southern Cross Pharma in Australia - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-southern-cross-pharma-in-australia/): Mumbai, Melbourne, July 30, 2021: Generic Health, the Australia based wholly-owned subsidiary of global pharma major Lupin Limited (Lupin) today announced that it has entered into a definitive agreement under which Lupin will acquire 100% of the shares of…
[Lupin Acquires Medquímica in Brazi - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-medquimica-in-brazi/): Expands presence in the Latin American Market Mumbai: Pharma Major Lupin Limited announced today the acquisition of 100 % equity stake in Medquímica Indústria Farmacêutica S.A., Brazil, (Medquímica) subject to certain closing conditions. The acquisition marks Lupin’s foray…
[Lupin Acquires Specialty Product Portfolio in Germany - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-specialty-product-portfolio-in-germany/): Mumbai: Pharma Major Lupin Limited (Lupin) today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG (Temmler), a part of the Aenova Group, one of the world’s largest pharmaceutical contract…
[Lupin Acquires Stake in Generic Health, Australia - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-stake-in-generic-health-australia/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Acquires Symbiomix Therapeutics LLC - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-symbiomix-therapeutics-llc/): Material Addition to Lupin’s Women’s Health Care Portfolio with Newly Approved Solosec™ for Bacterial Vaginosis (BV) Mumbai: Pharma major Lupin announced that its US subsidiary, Lupin, Inc., has acquired Symbiomix Therapeutics, LLC. Lupin had entered into an option…
[Lupin AGM E-Voting Notice - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-agm-e-voting-notice/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin acquires Worldwide Rights for the Goanna® Brand - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-acquires-worldwide-rights-for-the-goanna-brand/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin and AbbVie Announce Partnership to Develop and Commercialize Novel Oncology Drug to treat Hematological Cancers - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-abbvie-announce-partnership-to-develop-and-commercialize-novel-oncology-drug-to-treat-hematological-cancers/): Mumbai, India: Pharma major Lupin Limited (Lupin) and global biopharmaceutical company AbbVie Inc., today announced that AbbVie has licensed Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program. Through this partnership, AbbVie gains exclusive global rights to…
[Lupin and Amman Pharma Sign Exclusive Licensing and Supply Agreement for Ranibizumab Biosimilar - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-amman-pharma-sign-exclusive-licensing-and-supply-agreement-for-ranibizumab-biosimilar/): Pioneering access to this complex ophthalmic biosimilar medicine in the MENA Region Mumbai, Jordan, November 10, 2023: Global Pharma major Lupin Limited (Lupin) has partnered with Amman Pharmaceuticals Industries (Amman Pharma), a leading pharmaceutical manufacturer with operations across the…
[Lupin and Aptissen announce exclusive distribution agreement of Synolis VA for Canada - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-aptissen-announce-exclusive-distribution-agreement-of-synolis-va-for-canada/): Mumbai, Geneva, Montreal: Lupin Limited (Lupin) and Aptissen S.A. (Aptissen) announced that they have entered into a definitive distribution agreement under which Aptissen has granted Lupin the exclusive rights to market, distribute and sell the current Aptissen products in…
[Lupin and Aspen decide not to pursue their MOU - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-aspen-decide-not-to-pursue-their-mou-2/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin and Aspen decide not to pursue their MOU - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-aspen-decide-not-to-pursue-their-mou/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin and Avas Launch NaMuscla® in Italy - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-avas-launch-namuscla-in-italy/): Enables expanded access to the only EU-approved treatment for myotonia symptoms in adults with non-dystrophic myotonic disorders Mumbai, Zug, January 28, 2025: Global pharma major Lupin Limited (Lupin) and Avas Pharmaceuticals SRL (Avas) today announced the launch of Lupin’s…
[Lupin and Aspen Sign TB Deal - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-aspen-sign-tb-deal/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin and Axantia Enter into a License, Supply and Technology Sharing Agreement for Pegfilgrastim in the Middle East and North Africa - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-axantia-enter-into-a-license-supply-and-technology-sharing-agreement-for-pegfilgrastim-in-the-middle-east-and-north-africa/): Mumbai, Amman, February 1, 2022: Global pharma major, Lupin Limited (Lupin) announced today that they have entered into a License, Supply and Technology Sharing agreement with Axantia Holding (Axantia), a leading pharmaceutical company in the region operating through its…
[Lupin and Biomm Enter into a Distribution and Marketing Agreement for Pegfilgrastim in Brazil - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-biomm-enter-into-a-distribution-and-marketing-agreement-for-pegfilgrastim-in-brazil/): Mumbai, Brazil, December 03, 2021: Global pharma major, Lupin Limited (Lupin) announced today that they have entered into an exclusive distribution and marketing agreement with Biomm SA in Brazil. Under the terms of agreement, Biomm will distribute and…
[Lupin and Birmingham City University Honour Graduates of Master’s Programme in Advancing Diabetes Care - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-birmingham-city-university-honour-graduates-of-masters-programme-in-advancing-diabetes-care/): Mumbai, Birmingham, March 11, 2024: Global pharma major Lupin Limited (Lupin) joined forces with Birmingham City University, UK (BCU) and hosted a convocation ceremony on March 9, 2024, honouring Indian healthcare professionals who completed the Master’s programme in Advancing…
[Lupin and Boehringer Ingelheim announce Partnership to Develop and Commercialize Novel Oncology Drug to treat KRAS-driven Cancers - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-boehringer-ingelheim-announce-partnership-to-develop-and-commercialize-novel-oncology-drug-to-treat-kras-driven-cancers/): Boehringer Ingelheim strengthens its pipeline portfolio for patients with gastrointestinal and lung cancers with this new licensing, development and commercialization agreement Lupin’s proprietary MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s emerging KRAS…
[Lupin and Boehringer Ingelheim Announce Strategic Co-marketing Agreement - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-boehringer-ingelheim-announce-strategic-co-marketing-agreement/): Mumbai: Pharma major Lupin Limited (Lupin) and Boehringer Ingelheim today announced a joint strategic alliance for co-marketing linagliptin, a novel Dipeptidylpeptidase-4 (DPP-4) inhibitor in India. Boehringer Ingelheim, one of the fastest growing multinational pharmaceutical company in India (IMS MAT…
[Lupin and Cornerstone End Development Agreement - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-cornerstone-end-development-agreement/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin and Celon Announce Strategic Development and Licensing Agreement for Generic Advair Diskusi® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-celon-announce-strategic-development-and-licensing-agreement-for-generic-advair-diskusi/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) and Celon Pharma S.A. (Celon) announced today that they have entered into a definitive agreement under which the companies will jointly develop fluticasone/salmeterol dry powder inhaler (DPI) product which is a generic…
[Lupin and DKSH Sign an Exclusive Licensing and Supply Agreement to Market Five Biosimilar Candidates in the Philippines - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-dksh-sign-an-exclusive-licensing-and-supply-agreement-to-market-five-biosimilar-candidates-in-the-philippines/): Mumbai, Philippines, September 07, 2022: Global pharma major, Lupin Limited (Lupin) and DKSH, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, announced today that they have signed an exclusive license and supply…
[Lupin and Dafra decide not to pursue their MoU - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-dafra-decide-not-to-pursue-their-mou/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin and Eli Lilly Expand Partnership in India - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-eli-lilly-expand-partnership-in-india/): Lupin to market Lilly’s rapid-acting Insulin analog Lispro under the brand name Eglucent® Mumbai: Pharma Major Lupin Limited (Lupin) and Eli Lilly and Company (India) Pvt. Ltd. (Lilly) today announced an expansion of their partnership in India with…
[Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-exeltis-announce-reimbursement-approval-of-namuscla-in-spain-for-the-symptomatic-treatment-of-myotonia-in-adults-with-non-dystrophic-myotonic-ndm-disorders/): Agreement enables sustainable patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders Mumbai, Zug, January 09, 2023: Global pharma major Lupin Limited (Lupin) and Exeltis Healthcare S.L (Exeltis) announced today that the Spanish…
[Lupin and European Association of Urology Successfully Conclude Masterclass “Best of EAU19” - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-european-association-of-urology-successfully-conclude-masterclass-best-of-eau19/): Mumbai: Pharma major Lupin Limited (Lupin) announced that it has successfully concluded the third edition of its series of medical symposiums for the Indian urology community. The latest edition, titled Masterclass: Best of EAU19, was organised in collaboration…
[Lupin and Fuji Sign License and Supply Agreement for Commercialization of Nextstellis™ in Vietnam and Philippines - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-fuji-sign-license-and-supply-agreement-for-commercialization-of-nextstellis-in-vietnam-and-philippines/): Mumbai, Philippines, June 12, 2024 – Global pharma major Lupin Limited (Lupin) today announced that it has signed a license and supply agreement with OLIC (Thailand) Limited (OLIC), a subsidiary of the renowned Japanese pharmaceutical company Fuji Pharma Co., Ltd. (Fuji),…
[Lupin and I’rom Enter into an Exclusive Licensing Agreement for Denosumab biosimilar for Japan - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-irom-enter-into-an-exclusive-licensing-agreement-for-denosumab-biosimilar-for-japan/): Mumbai, Tokyo, August 25, 2022: Global pharma major, Lupin Limited (Lupin) announced today that it has entered into an exclusive licensing agreement with I’rom Group Co. Ltd (I’rom), a leading pharmaceutical company in Japan. Under the terms of the…
[Lupin and Ind-Swift launch new anti-diarrhoeal drug - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-ind-swift-launch-new-anti-diarrhoeal-drug/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin and Medicis Enter into Joint Development Agreement - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-medicis-enter-into-joint-development-agreement/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin and Monosol Rx announce licensing agreement for multiple pediatric-focused products - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-monosol-rx-announce-licensing-agreement-for-multiple-pediatric-focused-products/): Warren, NJ & Baltimore, MD and Mumbai, India: Lupin Pharmaceutical Inc., the US subsidiary of pharma major Lupin Limited (collectively Lupin) and MonoSol Rx, a specialty pharmaceutical company have entered into a strategic licensing agreement wherein Lupin would develop…
[Lupin and Huons Sign License and Supply Agreement for Commercialization of Cyclosporine Ophthalmic Nanoemulsionin Mexico - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-huons-sign-license-and-supply-agreement-for-commercialization-of-cyclosporine-ophthalmic-nanoemulsionin-mexico/): Mumbai |Seoul | Mexico City, July 18, 2024 – Global pharma major Lupin Limited (Lupin) today announced that it has signed a license and supply agreement with Huons Co. Ltd for the registration and marketing of Cyclosporine Ophthalmic Nanoemulsion,0.4mL…
[Lupin and Lilly Expand Partnership in India - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-lilly-expand-partnership-in-india/): Exclusive licensing agreement with Eli Lilly enables Lupin to commercialize and distribute Cialis© Mumbai: Pharma major Lupin Limited (Lupin) has launched Cialis© (tadalafil), an oral PDE5 inhibitor, for the treatment of erectile dysfunction (ED) in adult males. Cialis…
[Lupin and Honeywell Move Forward Jointly with Plans for HFO Technology in Inhalers - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-honeywell-move-forward-jointly-with-plans-for-hfo-technology-in-inhalers/): Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants Mumbai, Delhi, May 20, 2025: Global pharma major Lupin…
[Lupin and MCGM Unite to launch Anti-TB Campaign in Mumbai - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-mcgm-unite-to-launch-anti-tb-campaign-in-mumbai/): Covering 24 wards focusing on high-risk population across Mumbai, this will be one of the largest active-case-finding campaigns in India Mumbai: Pharma major Lupin, a pioneer in the fight against Tuberculosis (TB), along with the Municipal Corporation of Greater…
[Lupin and Mylan Launch Nepexto®, Biosimilar Etanercept in Germany - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-mylan-launch-nepexto-biosimilar-etanercept-in-germany/): Nepexto®is Lupin’s biosimilar etanercept approved for all indications of the reference product Enbrel® Nepexto®is available as an injectable in an easy-to-use pre-filled pen and a pre-filled syringe The approval of Nepexto®by the European Medicines Agency (EMA) underlines the…
[Lupin and Mylan announce Positive European Medicines Agency opinion recommending Approval of Nepexto®, Biosimilar Etanercept - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-mylan-announce-positive-european-medicines-agency-opinion-recommending-approval-of-nepexto-biosimilar-etanercept/): MUMBAI, India, HERTFORDSHIRE, England, and PITTSBURGH, U.S: Lupin Limited (Lupin) and Mylan N.V. (NASDAQ: MYL) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval…
[Lupin and Mylan Partner to Commercialize Enbrel® (Etanercept) Biosimilar - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-mylan-partner-to-commercialize-enbrel-etanercept-biosimilar/): Mumbai, HERTFORDSHIRE, England, and PITTSBURGH: Pharma major Lupin Limited (Lupin) and global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that the two companies will partner to commercialize a biosimilar to Enbrel® (etanercept). Through the partnership agreement, Mylan will…
[Lupin and Natco Receive Approval from U.S. FDA for Bosentan Tablets for Oral Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-natco-receive-approval-from-u-s-fda-for-bosentan-tablets-for-oral-suspension/): Mumbai, Naples, February 10, 2025: Global pharma major Lupin Limited (Lupin) and its alliance partner Natco Pharma Limited (Natco), today announced that they have received an approval from the United States Food and Drug Administration (U.S. FDA) for Natco’s…
[Lupin and Mylan Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-mylan-receive-european-marketing-authorization-for-nepexto-biosimilar-etanercept/): MUMBAI, India, HERTFORDSHIRE, England, and PITTSBURGH, U.S: Lupin Limited (Lupin) and Mylan N.V. (NASDAQ: MYL) today announced that the European Commission (EC) has granted marketing authorization for Nepexto®, a biosimilar to Enbrel® (etanercept), for all indications of the reference…
[Lupin and NAPCON Hosts a Walkathon ‘A Step Towards HealThy Lungs’ for COPD Awareness - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-napcon-hosts-a-walkathon-a-step-towards-healthy-lungs-for-copd-awareness/): Tamil Nadu, India, November 20, 2024: Global pharma major Lupin Limited (Lupin) and the National Conference of Pulmonary Diseases (NAPCON) 2024 successfully hosted the second ‘A Step Towards HealThy Lungs Walkathon’ on 20th November 2024, at the Racecourse, Coimbatore,…
[Lupin and Rotary Join Hands to Combat Tuberculosis in Mumbai - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-rotary-join-hands-to-combat-tuberculosis-in-mumbai/): Mumbai: Pharma major and a pioneer in the fight against Tuberculosis (TB), Lupin Limited (Lupin) along with the Rotary Club, Mumbai, District 3140 (Rotary) today announced a joint anti-TB campaign to create awareness, detect and combat TB in Mumbai…
[Lupin and Nichi-Iko announce strategic partnership for commercialization of biosimilar Etanercept in Japan - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-nichi-iko-announce-strategic-partnership-for-commercialization-of-biosimilar-etanercept-in-japan/): Mumbai: Pharma major Lupin and Nichi-Iko announced that the two companies have entered into an agreement for the distribution, promotion and sale of Lupin’s recently-filed biosimilar Etanercept (YLB113) in Japan. Developed by YL Biologics, a joint venture between Lupin’s subsidiary…
[Lupin and Salix Announce Exclusive Distribution Agreement for Canada, Zaxine®, Relistor® and Other Gastroenterology Products - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-salix-announce-exclusive-distribution-agreement-for-canada-zaxine-relistor-and-other-gastroenterology-products/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin and Scope Sign a Distribution Agreement for the Commercialization of Optase® Range of Products in Mexico - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-scope-sign-a-distribution-agreement-for-the-commercialization-of-optase-range-of-products-in-mexico/): Mumbai | Dublin | Mexico City, September 30, 2024 – Global pharma major Lupin Limited (Lupin) today announced that it has signed a distribution agreement with Scope Ophthalmics Ireland (SCOPE) for the registration and marketing of a Moist Heat Mask,…
[Lupin and Sino Universal Pharmaceuticals Sign License and Supply Agreement for Tiotropium DPI in China - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-sino-universal-pharmaceuticals-sign-license-and-supply-agreement-for-tiotropium-dpi-in-china/): Aim to expand healthcare solutions in China Mumbai, Naples, Fuzhou, China, June 16, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP), for the commercialization…
[Lupin and Slurrp Successfully Conclude Lupin Aptivate Achchi Bhookh Quiz - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-slurrp-successfully-conclude-lupin-aptivate-achchi-bhookh-quiz/): India’s Largest Parent-Child Food Quiz Culminates in Mumbai Mumbai, January 6, 2025: LupinLife, the consumer healthcare division of global pharma major Lupin Limited (Lupin) today announced the successful conclusion of the grand finale of the Lupin Aptivate Achchi Bhookh…
[Lupin and SteinCares Enter into License and Supply Agreement for Ranibizumab in Latin America - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-steincares-enter-into-license-and-supply-agreement-for-ranibizumab-in-latin-america/): Mumbai, Costa Rica, May 26, 2025: Global Pharma major Lupin Limited (Lupin) today announced that it has entered into a license and supply agreement with SteinCares, a leading specialty healthcare company in Latin America, for commercialization of Lupin’s…
[Lupin and Symbiotec decide not to pursue their MoU - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-symbiotec-decide-not-to-pursue-their-mou/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin and YL Biologics receives PMDA approval for Etanercept biosimilar in Japan - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-yl-biologics-receives-pmda-approval-for-etanercept-biosimilar-in-japan/): Mumbai: Pharma major Lupin Limited (Lupin) announced that YL Biologics Limited (YLB), a joint venture between Lupin’s subsidiary Lupin Atlantis Holdings SA (LAHSA) and Yoshindo Inc. in Japan, and Lupin (through its Japanese subsidiary, Kyowa Pharmaceutical Industry Co. Ltd)…
[Lupin and Yoshindo’s JV – YL Biologics announces successful outcome of global Phase III study for Etanercept biosimilar in Rheumatoid Arthritis - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-yoshindos-jv-yl-biologics-announces-successful-outcome-of-global-phase-iii-study-for-etanercept-biosimilar-in-rheumatoid-arthritis/): Pune: In their board meeting held at Pune last week, YL Biologics (YLB) announced that a global Phase III clinical trial of its investigational Etanercept biosimilar (YLB113) has met with successful outcome. YLB is the joint venture of Pharma…
[Lupin and Zydus Sign Licensing Agreement for Co-marketing Saroglitazar Mg, a critical treatment for chronic liver diseases in India - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-zydus-sign-licensing-agreement-for-co-marketing-saroglitazar-mg-a-critical-treatment-for-chronic-liver-diseases-in-india/): • Saroglitazar Mg is an innovative drug from Zydus approved by the DCGI to treat chronic liver diseases such as, Non-Alcoholic Fatty Liver Disease(NAFLD) and Non-Alcoholic Steato Hepatitis (NASH). • India is the first country to have a drug…
[Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-zentiva-sign-license-and-supply-agreement-for-commercializing-certolizumab/): Mumbai, July 9, 2025: Global Pharma major Lupin Limited (Lupin) and Zentiva Group (Zentiva), a pan-European pharmaceutical company, have entered into a license and supply agreement for commercialization of Lupin’s biosimilar Certolizumab Pegol, across multiple markets globally. This…
[Lupin and Yabao Announce Strategic Partnership in China - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-and-yabao-announce-strategic-partnership-in-china/): Mumbai, Beijing, April 27, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has entered into a strategic partnership with Yabao Pharmaceutical Co. Inc. (Yabao), to meet the growing demand for quality drugs with pediatric formulations in…
[Lupin Announces Achievement of Key Milestone for its Phase 1 Clinical Stage MALT 1 inhibitor Program - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-achievement-of-key-milestone-for-its-phase-1-clinical-stage-malt-1-inhibitor-program/): Lupin’s proprietary MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor is a protein involved in T-cell and B-cell lymphocyte activation Lupin has received additional USD 25 million as part of successful achievement of key milestones Mumbai, India,…
[Lupin Announces Achievement of Key Milestones for its Clinical Stage MEK Inhibitor Compound - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-achievement-of-key-milestones-for-its-clinical-stage-mek-inhibitor-compound/): Lupin’s proprietary MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s KRAS inhibitor pipeline to address KRAS-driven cancers Lupin has received USD 50 million as part of successful achievement of key milestones Mumbai, India,…
[Lupin Announces Acquisition of French Pharmaceutical Company Medisol - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-acquisition-of-french-pharmaceutical-company-medisol/): Mumbai, France, May 05, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has entered into a definitive agreement to acquire the entire share capital of the French pharmaceutical company, Medisol, subject to approval from the French…
[Lupin Announces Appointment of New Independent Director - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-appointment-of-new-independent-director/): Mumbai, India: Lupin Limited (Lupin), global pharmaceutical company, announced the appointment of Mr. Mark D. McDade as an Independent Director effective January 28, 2021. Mr. McDade is the co-Founder and Partner at Qiming Venture Partners, USA where he led…
[Lupin Announces Closure of Inspection by U.S. FDA at its Nagpur Unit-1 Facility with No Observations - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-closure-of-inspection-by-u-s-fda-at-its-nagpur-unit-1-facility-with-no-observations/): Mumbai, November 15, 2025: Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed a product specific Pre-Approval Inspection at its Unit-1 oral solid dosage manufacturing facility in…
[Lupin Announces Closure of Inspection by U.S. FDA at its Somerset Facility with No Observations - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-closure-of-inspection-by-u-s-fda-at-its-somerset-facility-with-no-observations/): Mumbai, February 1, 2025: Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed a Pre-Approval Inspection (PAI) of Edaravone Oral Suspension, 105 mg/ 5 mL at its manufacturing facility in…
[Lupin announces completion of Kyowa divestiture to Unison - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-completion-of-kyowa-divestiture-to-unison/): Mumbai, EJ Oldenzaal and Tokyo: Pharma major Lupin Limited (Lupin) announced that its subsidiary, Nanomi B.V. has completed the divestiture of the entire stake (99.82%) in Kyowa Pharmaceutical Industry Co. Ltd. (Kyowa) to Unison Capital Partners IV, LPS…
[Lupin Announces Closure of US FDA Inspection at its Injectable Facility with Zero 483 Observations - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-closure-of-us-fda-inspection-at-its-injectable-facility-with-zero-483-observations/): Mumbai, June 14, 2024 – Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed an inspection of its Injectable facility in Nagpur, India. The inspection of the facility was carried out…
[Lupin announces closure of US FDA Audits for its Mandideep and Aurangabad Facilities - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-closure-of-us-fda-audits-for-its-mandideep-and-aurangabad-facilities/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received Establishment Inspection Reports (EIR) for its Mandideep and Aurangabad facilities wherein the US FDA has concluded that the inspections stand closed. The US FDA had conducted audits…
[Lupin Announces Completion of Pharmacovigilance Inspection by the U.S. FDA with No Observations - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-completion-of-pharmacovigilance-inspection-by-the-u-s-fda-with-no-observations/): Mumbai, Baltimore, March 25, 2023: Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed a Post-marketing Adverse Drug Experience (PADE) inspection of the company’s operations. The inspection closed with…
[Lupin announces District Court Ruling on Ramipril - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-district-court-ruling-on-ramipril/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin announces Executive Board Leadership Changes - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-executive-board-leadership-changes/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin announces favorable ruling for generic Yaz® Oral Contraceptive Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-favorable-ruling-for-generic-yaz-oral-contraceptive-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Announces Executive Leadership Change, Dr. Fabrice Egros to assume Corporate Development responsibilities as President, Corporate Development & Growth Markets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-executive-leadership-change-dr-fabrice-egros-to-assume-corporate-development-responsibilities-as-president-corporate-development-growth-markets/): Mumbai, Baltimore,UK, Japan,February 23,2022:Global pharma major, Lupin Limited (Lupin) announced today changes to its executive team with Dr. Fabrice Egros assuming responsibilities for Global Corporate Development as President, Corporate Development and Growth Markets. Dr. Egros takes over the Corporate…
[Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) for the Treatment of Trichomoniasis - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-fda-approval-of-supplemental-new-drug-application-for-solosec-secnidazole-for-the-treatment-of-trichomoniasis/): SOLOSEC® demonstrated a 92.2% clinically and statistically significant cure rate for patients with trichomoniasis based on a landmark Phase 3 clinical trial SOLOSEC® is the first and only single-dose oral prescription antimicrobial agent for the treatment of both…
[Lupin Announces Final FDA Approval of Cefdinir Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-final-fda-approval-of-cefdinir-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Announces Final FDA Approval for Suprax® (Cefixime) Chewable Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-final-fda-approval-for-suprax-cefixime-chewable-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Announces Final FDA Approval for Nabumetone tablets, 500 mg and 750 mg. - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-final-fda-approval-for-nabumetone-tablets-500-mg-and-750-mg/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Announces Health Canada Approval of Tiotropium Bromide Inhalation Powder for Treatment of COPD - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-health-canada-approval-of-tiotropium-bromide-inhalation-powder-for-treatment-of-copd/): Quebec, Mumbai, May 26, 2023: Global pharma major Lupin Limited (Lupin) announced today that its Canada subsidiary, Lupin Pharma Canada Ltd., has received approval from Health Canada to market a generic version of Spiriva® (tiotropium bromide inhalation powder) for…
[Lupin Announces Launch of Generic KEPPRA XR® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-launch-of-generic-keppra-xr-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) in Adolescents for both the Treatment of Bacterial Vaginosis in Females and Trichomoniasis - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-fda-approval-of-supplemental-new-drug-application-for-solosec-secnidazole-in-adolescents-for-both-the-treatment-of-bacterial-vaginosis-in-females-and-trichomoniasis/): Mumbai, Baltimore, February 17, 2022: Lupin Pharmaceuticals Inc., (Lupin) today announced that the U.S. Food and Drug Administration has approved the company’s supplemental New Drug Application (sNDA) to expand the use of SOLOSEC® (secnidazole) in the treatment of bacterial…
[Lupin Announces Final FDA Approval of Generic Hyzaar® and Cozaar® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-final-fda-approval-of-generic-hyzaar-and-cozaar/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin announces fiscal year 2018 Results, Board recommends dividend of 250% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-fiscal-year-2018-results-board-recommends-dividend-of-250/): Mumbai: Pharma Major Lupin Limited reported its financial performance for the fourth quarter and fiscal year ending March 31st, 2018. These audited results were taken on record by the Board of Directors at a meeting held in Mumbai…
[Lupin Announces FDA Filing Acceptance of Supplemental New Drug Application for Solosec® (secnidazole) for the Treatment of Trichomoniasis - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-fda-filing-acceptance-of-supplemental-new-drug-application-for-solosec/): Mumbai, Baltimore: Lupin Pharmaceuticals, Inc., the U.S. based wholly-owned subsidiary of Lupin Limited (Lupin), announced today that the U.S. Food and Drug Administration (FDA) has accepted their supplemental New Drug Application (sNDA) for Solosec® (secnidazole) for the treatment of…
[Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-launch-of-orphan-drug-namuscla-in-germany-and-the-uk-for-the-treatment-of-myotonia-in-non-dystrophic-myotonic-disorders/): Zug, Mumbai: Lupin is pleased to announce that NaMuscla® (mexiletine) has been launched in Germany and the United Kingdom (UK). NaMuscla® is approved across the European Union (EU) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic…
[Lupin Announces Launch of Generic Levaquin® Tablets for the US Market - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-launch-of-generic-levaquin-tablets-for-the-us-market/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Announces Litigation Settlement with Schering-Plough Corporation for Desloratadine® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-litigation-settlement-with-schering-plough-corporation-for-desloratadine/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Announces Litigation Settlement with Wyeth for Venlafaxine Extended Release Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-litigation-settlement-with-wyeth-for-venlafaxine-extended-release-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Announces Licensing Arrangement with NeuClone Inks strategic deal with NeuClone for Cell line Technology - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-licensing-arrangement-with-neuclone-inks-strategic-deal-with-neuclone-for-cell-line-technology/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Announces New Center of Excellence for Inhalation Research in Florida - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-new-center-of-excellence-for-inhalation-research-in-florida/): Mumbai: Pharma Major Lupin Limited (Lupin) today announced the opening of its new Center of Excellence for Inhalation Research in Coral Springs, Florida. Local and state leaders, including Florida Lieutenant Governor Carlos Lopez-Cantera, Florida Department of Economic Opportunity Director…
[Lupin Announces Litigation Settlement with Forest for Memantine Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-litigation-settlement-with-forest-for-memantine-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Announces Litigation Settlement with Forest for Memantine Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-litigation-settlement-with-forest-for-memantine-tablets-2/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin announces Patent License Agreement with Abbott - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-patent-license-agreement-with-abbott/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Announces Licensing Deal for Ranibizumab Biosimilar - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-licensing-deal-for-ranibizumab-biosimilar/): Mumbai, August 12, 2025: Global Pharma major Lupin Limited (Lupin) today announced that it has partnered with Sandoz Group AG (Sandoz), Switzerland, to market and commercialize Lupin’s biosimilar ranibizumab across multiple regions. Under the terms of the agreement,…
[LUPIN announces settlement with SANTARUS and DEPOMED for GLUMETZA Patent Litigation - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-settlement-with-santarus-and-depomed-for-glumetza-patent-litigation/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Announces Positive Topline Results from its Phase 3 Study of Single-Dose Solosec® (secnidazole) for the Treatment of Trichomoniasis - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-positive-topline-results-from-its-phase-3-study-of-single-dose-solosec/): Primary endpoint successfully achieved in Phase 3 clinical trial of 147 patients Solosec® 2g oral granules was generally well-tolerated among study subjects Lupin plans to submit a supplemental New Drug Application for Solosec® to the U.S. FDA for…
[Lupin Announces Successful Completion of UK MHRA Inspection of its Pithampur Facilities - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-successful-completion-of-uk-mhra-inspection-of-its-pithampur-facilities/): Mumbai, Baltimore, March 25, 2023: Global pharma major Lupin Limited (Lupin) today announced the successful completion of the inspection carried out by the UK Medicines and Healthcare products Regulatory Agency (UK MHRA) at its Pithampur facilities in India. The inspection…
[Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at the American Society of Clinical Oncology – Annual Meeting 2025 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025/): Mumbai, Naples, Chicago, May 26, 2025: Global pharma major Lupin Limited (Lupin) will present data from its Phase 1a clinical trial evaluating LNP7457, a PRMT5 inhibitor, at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago,…
[Lupin announces settlement with Warner Chilcott of Loestrin® 24 Fe and Femcon® Fe Patent Litigations - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-settlement-with-warner-chilcott-of-loestrin-24-fe-and-femcon-fe-patent-litigations/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Announces Successful Completion of Phase 3 Trials for Lucentis® Biosimilar - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-successful-completion-of-phase-3-trials-for-lucentis-biosimilar/): LUBT010 is Lupin’s biosimilar that corresponds to Lucentis® (ranibizumab) The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU India, USA, Europe, Russia, August 05, 2024: Global…
[Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp3693-sting-agonist-at-the-esmo-congress-2025/): Mumbai, Naples, Berlin, October 13, 2025: Global pharma major Lupin Limited (Lupin) will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany, from October 17 to October 21,…
[Lupin Announces Plans to Build a New State-of-the-Art Manufacturing Facility in Coral Springs, Florida Extending its Long-Standing Commitment to America’s Patients and Healthcare System - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-plans-to-build-a-new-state-of-the-art-manufacturing-facility-in-coral-springs-florida/): Furthering U.S.-based pharmaceutical capacity in Coral Springs, Florida to produce critical respiratory medicines and to strengthen the company’s position as a global respiratory leader. Media Contact: Elise Titan Email: Elisetitan@lupin.com CORAL SPRINGS, Fla., [October 8, 2025] – Global pharmaceutical leader, Lupin, today announced its plans for a new state-of-the-art pharmaceutical manufacturing…
[Lupin Announces Resolution of USFDA Warning Letter for its Goa and Pithampur Facilities - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-resolution-of-usfda-warning-letter-for-its-goa-and-pithampur-facilities/): Mumbai, July 27, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received correspondence from the US FDA that it has now addressed the concerns raised in the Warning Letter for its facilities in Goa and Pithampur…
[Lupin Announces Strategic Alliance for Emerging Markets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-strategic-alliance-for-emerging-markets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin announces tentative FDA Approval for Metformin Hydrochloride extended-release tablets 500 mg and 1000 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-tentative-fda-approval-for-metformin-hydrochloride-extended-release-tablets-500-mg-and-1000-mg/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin announces tentative FDA Approval for Pregabalin Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-tentative-fda-approval-for-pregabalin-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Announces the Acquisition of Renascience in the United Kingdom - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-the-acquisition-of-renascience-in-the-united-kingdom/): Mumbai/Slough, Berkshire, United Kingdom, April 2, 2025: Lupin Healthcare (UK) Limited, the wholly owned subsidiary of global pharma major Lupin Limited (Lupin) announced today the acquisition of Renascience Pharma Limited (Renascience), a UK-based pharmaceutical company and sole supplier of…
[Lupin Announces the Launch of Cetuximab - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-the-launch-of-cetuximab/): First Biosimilar for Head and Neck Cancer Treatment Mumbai, May 30, 2023: Global pharma major Lupin Limited (Lupin) today announced a strategic collaboration with Enzene Biosciences to launch Cetuximab in India, the first biosimilar developed for Cetuximab. This collaboration…
[Lupin Announces the Launch of its Diagnostics Business - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-the-launch-of-its-diagnostics-business/): Reaffirms its Commitment to Building an Integrated Healthcare Proposition in India Mumbai, India, December 10, 2021: Global pharma major Lupin Limited (Lupin) today announced the launch of Lupin Diagnostics in India. As part of its strategy to provide…
[Lupin Announces U.S. FDA Approval of its First Oral Contraceptive - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-u-s-fda-approval-of-its-first-oral-contraceptive/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin announces U.S. FDA acceptance for Pegfilgrastim Biosimilar application - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-u-s-fda-acceptance-for-pegfilgrastim-biosimilar-application/): Mumbai, Baltimore, June 2, 2021: Global pharma major, Lupin Limited (Lupin) today announced that the U.S. FDA has accepted the Biologics License Application (BLA) for its proposed biosimilar to Neulasta® (pegfilgrastim) through a filing using the 351(k) pathway. Pegfilgrastim…
[Lupin Announces UK MHRA Approval of Lutio® (Tiotropium bromide inhalation powder) for Treatment of COPD - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-uk-mhra-approval-of-lutio-tiotropium-bromide-inhalation-powder-for-treatment-of-copd/): Mumbai, India | Slough, UK, August 26, 2022: Global pharma major Lupin Limited (Lupin) announced today that its UK subsidiary, Lupin Healthcare (UK) Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market a…
[Lupin Appoints Abdelaziz Toumi as CEO of its API CDMO Subsidiary - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-abdelaziz-toumi-as-ceo-of-its-api-cdmo-subsidiary/): Mumbai, June 17, 2024: Global pharma major Lupin Limited (Lupin) today announced the appointment of Abdelaziz Toumi (Abdel) as the Chief Executive Officer of its newly formed subsidiary, Lupin Manufacturing Solutions (LMS). LMS is engaged in the development, manufacture…
[Lupin appoints Alok Sonig as CEO – US Generics and Global Head – Generics R&D & Biosimilars - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-alok-sonig-as-ceo-us-generics-and-global-head-generics-rd-biosimilars/): Mumbai: Pharma major Lupin Limited announced the appointment of Alok Sonig as CEO – US Generics and Global Head – Generics R&D & Biosimilars. Alok will lead and have overall responsibility for the US Generics business including Research &…
[Lupin Appoints Christoph Funke as Chief Technical Operations Officer - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-christoph-funke-as-chief-technical-operations-officer/): Mumbai, March 18, 2024: Global pharma major Lupin Limited (Lupin) today announced the appointment of Christoph Funke to the newly-created position of Chief Technical Operations Officer. With over 30 years of global pharmaceutical manufacturing, supply chain, and technical operations…
[Lupin announces tie-up with European Association of Urology (EAU) - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-announces-tie-up-with-european-association-of-urology-eau/): Kick off 5-city medical symposium for Indian urologists in July 2018 Mumbai: Pharma major Lupin and the European Association of Urology (EAU) today announced a collaboration to further the cause of Urology in India. With this collaboration, Lupin…
[Lupin Appoints Claus Jepsen as President, Global Specialty - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-claus-jepsen-as-president-global-specialty/): Mumbai, Naples, October 21, 2024: Global pharma major Lupin Limited (Lupin) today announced the appointment of Claus Jepsen as President, Global Specialty. He brings over three decades of experience in commercial strategy, portfolio management, and launch planning across Europe,…
[Lupin Appoints Diana Amador-Toro as Senior Vice President, Global Compliance - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-diana-amador-toro-as-senior-vice-president-global-compliance/): Mumbai, Baltimore, April 27, 2022: Global pharma major Lupin Limited (Lupin) today announced the appointment of Diana Amador-Toro as Senior Vice President, Global Compliance. Diana will be responsible for leading Lupin’s Global Compliance function including Training, Internal Audit, and…
[Lupin appoints Dr. Kamal K. Sharma as Advisor to the Company - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-dr-kamal-k-sharma-as-advisor-to-the-company/): Mumbai: Lupin Limited announced today the appointment of Dr. Kamal K. Sharma as Advisor to the company, for a period of one year effective October 1, 2018. During this period, Dr. Sharma will continue to hold the position of…
[Lupin appoints Divakar Kaza as President – Human Resources - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-divakar-kaza-as-president-human-resources/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Appoints Dr. Maurice Chagnaud as President-Europe & Head of Inhalation Strategy - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-dr-maurice-chagnaud-as-president-europe-head-of-inhalation-strategy/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Appoints Dr. Ranjana Pathak as Chief Quality Officer - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-dr-ranjana-pathak-as-chief-quality-officer/): Mumbai, April 3,2024: Global pharma major Lupin Limited (Lupin) today announced the appointment of Dr. Ranjana Pathakas Chief Quality Officer, succeeding Johnny Mikell who will be retiring from the services of the company. With over three decades of industry…
[Lupin Appoints Dr. Kurt Nielsen as President of Lupin – Somerset - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-dr-kurt-nielsen-as-president-of-lupin-somerset/): Mumbai: Pharma major Lupin, today, announced the appointment of Dr. Kurt Nielsen as President of Lupin – Somerset. Kurt will be responsible for overall operations of the Gavis-Novel Somerset business and will be based out of Somerset, New Jersey….
[Lupin appoints Indrajit Banerjee as President – Finance and Planning - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-indrajit-banerjee-as-president-finance-and-planning/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Appoints Fabrice Egros as President of its Asia-Pacific Business - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-fabrice-egros-as-president-of-its-asia-pacific-business/): Mumbai: Pharma major Lupin today announced the appointment of Fabrice Egros as President, Asia Pacific and Japan. He will be based in Tokyo, Japan. Fabrice has over 25 years of experience within the global pharmaceutical industry, having worked in…
[Lupin Appoints J. Alan Butcher as Chief Corporate Development Officer - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-j-alan-butcher-as-chief-corporate-development-officer/): Mumbai: Pharma Major Lupin Limited (Lupin) announced the appointment of J. Alan Butcher as Chief Corporate Development Officer. Alan will lead Lupin’s Global Corporate Development efforts and will be responsible for the Company’s Global M&A, Business Development and…
[Lupin appoints Jim Loerop as Chief Corporate Development Officer - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-jim-loerop-as-chief-corporate-development-officer/): Mumbai: Pharma Major Lupin announced the appointment of Jim Loerop as Chief Corporate Development Officer. Jim will lead Lupin’s overall corporate development efforts and will be responsible for the Company’s global M&A and business development functions. He will integrate…
[Lupin Appoints Johnny Mikell as Global Head of Quality - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-johnny-mikell-as-global-head-of-quality/): Mumbai: Pharma major Lupin Limited (Lupin) announced the appointment of Johnny Mikell as President and Global Head of Quality. Johnny will be based out of Lupin’s US offices and will lead the Company’s Quality function globally; he will help…
[Lupin Appoints Jon Stelzmiller as President of US SpecialtyBusiness - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-jon-stelzmiller-as-president-of-us-specialtybusiness/): Mumbai, Somerset NJ: Pharma major Lupin Limited (Lupin) announced the appointment of Jon Stelzmiller as the President of its U.S. Specialty business. Jon brings to Lupin over 30 years of experience in the specialty segment and will be replacing Nicholas…
[Lupin Appoints Martin Mercer as President of its Latin American Business - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-martin-mercer-as-president-of-its-latin-american-business/): Mumbai: Pharma major Lupin Limited today announced the appointment of Martin Mercer as its President for Latin America. He will be based at Naples, Florida. Martin joins Lupin from Astellas Pharma where he was the Head of Latin America….
[Lupin appoints Ms. Christine Mundkur as an Independent Director - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-ms-christine-mundkur-as-an-independent-director/): Mumbai: Pharma major Lupin Limited (Lupin) announced today the appointment of Ms. Christine Mundkur as an Independent Director with immediate effect. Ms. Mundkur most recently served as Chief Executive Officer and Non-voting Chairman of the Board of Directors for…
[Lupin appoints Mrs. Manju Deshbandhu Gupta as Chairman - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-mrs-manju-deshbandhu-gupta-as-chairman/): Mumbai: The Board of Directors, Lupin Limited announced today the unanimous appointment of Mrs. Manju Deshbandhu Gupta as Chairman. Mrs. Gupta has been a member of the board for over 40 years and has been an important pillar of…
[Lupin appoints New NCE Research Head - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-new-nce-research-head/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin appoints new President for Asia Pacific,Latin America - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-new-president-for-asia-pacificlatin-america/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin appoints Paul McGarty as President for Lupin Pharmaceuticals Inc. - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-paul-mcgarty-as-president-for-lupin-pharmaceuticals-inc/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin appoints Nicholas Hart as President – Specialty for US Business - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-nicholas-hart-as-president-specialty-for-us-business/): Mumbai: Pharma major Lupin announced the appointment of Nicholas (Nick) Hart as President – Specialty for its US business. Nick will lead the Specialty strategic business unit in the United States and will be responsible for Lupin’s Specialty brand…
[Lupin Appoints Rakesh Bhardwaj as Chief Information Officer - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-rakesh-bhardwaj-as-chief-information-officer/): Mumbai, March 07,2024: Global pharma major Lupin Limited (Lupin) today announced the appointment of Rakesh Bhardwaj as Chief Information Officer (CIO). He will be based in Mumbai and lead Lupin’s global Information Technology function and spearhead the company’s digital…
[Lupin Appoints Ramesh Swaminathan as Chief Financial Officer and Head Corporate Affairs - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-ramesh-swaminathan-as-chief-financial-officer-and-head-corporate-affairs/): Mumbai: Pharma Major Lupin Limited (Lupin) announced the appointment of Ramesh Swaminathan as Chief Financial Officer and Head Corporate Affairs. Ramesh will also join the board as Executive Director. Ramesh will lead Lupin’s Finance, Investor Relations,…
[Lupin appoints Ramesh Swaminathan as President Finance & Planning - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-ramesh-swaminathan-as-president-finance-planning/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin appoints Yashwant Mahadik as President – Global HR - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-yashwant-mahadik-as-president-global-hr/): Mumbai: Pharma major Lupin Limited today announced the appointment of Yashwant Mahadik as President – Global Human Resources (HR). He will lead the HR function for Lupin globally. Yash is a seasoned HR professional with nearly three decades of…
[Lupin Appoints Thierry Volle as President – Europe, Middle-East & Africa (EMEA) - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-thierry-volle-as-president-europe-middle-east-africa-emeapress-release-use/): Mumbai: Pharma major Lupin Limited today announced the appointment of Thierry Volle as President of Europe, Middle-East & Africa (EMEA). At Lupin, Thierry will be responsible for the Company’s growth and development in Europe, Russia & CIS, and Middle-east…
[Lupin Appoints Spiro Gavaris as President of U.S. Generics Business - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-spiro-gavaris-as-president-of-u-s-generics-business/): Mumbai, Baltimore, December 08, 2022: Global pharma major Lupin Limited (Lupin) today announced the appointment of Spiro Gavaris as President U.S. Generics business. As part of Lupin’s senior leadership team, Spiro will be responsible for the overall strategy, implementation…
[Lupin Appoints Theresa Stevens as Chief Corporate Development Officer. - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-theresa-stevens-as-chief-corporate-development-officer/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Appoints Yugesh Goutam as President – Global HR - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-appoints-yugesh-goutam-as-president-global-hr/): Mumbai: Pharma major Lupin Limited today announced the appointment of Yugesh Goutam as President – Global Human Resources (HR). Yugesh will lead the HR function for Lupin globally and will be based at the company’s corporate headquarters in Mumbai,…
[Lupin-Aspen sign Joint Venture - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-aspen-sign-joint-venture/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Awarded EcoVadis Silver Medal for Sustainability Excellence, Ranks Among the Top 15% Globally - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-awarded-ecovadis-silver-medal-for-sustainability-excellence-ranks-among-the-top-15-globally/): Mumbai, March 20, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has been awarded “Silver Medal” by EcoVadis for its outstanding sustainability management practices in areas such as Environment, Labor and Human Rights, Ethics and Sustainable…
[Lupin Bio research Centre Completes U.S. FDA Inspection with No Observations - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-bio-research-centre-completes-u-s-fda-inspection-with-no-observations/): Mumbai, India, March 13, 2023: Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed an inspection of its Bioresearch Centre in Pune, India. Lupin Bioresearch Centre conducts BA/BE, PK/PD,…
[Lupin banks on complex generics, speciality products to sustain growth in FY26–27 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-banks-on-complex-generics-speciality-products-to-sustain-growth-in-fy26-27/): Ramesh Swaminathan in an interview with Business Today The United States market remains the company’s strongest growth driver, contributing 40% of total sales and rising 47% year-on-year to ₹2,762 crore. After delivering one of its strongest quarters ever, pharmaceutical…
[Lupin Bioresearch Center Receives Zero Observations from U.S. FDA After Successful Inspection and Assessment - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-bioresearch-center-receives-zero-observations-from-u-s-fda-after-successful-inspection-and-assessment/): Mumbai, November 8, 2025: Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed an onsite clinical inspection from November 3 to November 6, 2025, at its Bioresearch Centre in…
[Lupin Bioresearch Centre completes fifth successful U.S. FDA inspection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-bioresearch-centre-completes-fifth-successful-u-s-fda-inspection/): Mumbai: Pharma major Lupin Limited (Lupin) announced the successful completion of the United States Food and Drug Administration (U.S. FDA) inspection at its Lupin Bioresearch Centre (LBC) without any observations. This is the fifth successive inspection without any 483…
[Lupin Collaborates with Mark Cuban Cost Plus Drug Company and COPD Foundation to Expand Access to Medication for COPD Patients - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-collaborates-with-mark-cuban-cost-plus-drug-company-and-copd-foundation-to-expand-access-to-medication-for-copd-patients/): Mumbai, Naples, September 06, 2023: Global pharma major Lupin Limited (Lupin) today forged a unique collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs), a pioneer in affordable medicines, and the COPD Foundation, dedicated to enhancing the…
[Lupin Carves Out LupinLife Consumer Healthcare - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-carves-out-lupinlife-consumer-healthcare/): Focus on OTC Consumer Wellness Solutions Mumbai, July 1, 2025: Global pharma major Lupin Limited (Lupin), today announced the strategic carve-out of its consumer healthcare business, LupinLife Consumer Healthcare Ltd. (LCH), into a wholly owned subsidiary, effective July…
[Lupin Completes Acquisition of Brands from Anglo-French - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-completes-acquisition-of-brands-from-anglo-french/): Mumbai, April 07, 2022: Global pharma major Lupin Limited (Lupin) announced today the completion of the acquisition of a portfolio of brands from Anglo-French Drugs & Industries Limited (AFDIL) and its Associates. The acquisition will strengthen Lupin’s India Formulation…
[Lupin Completes Acquisition of two Brands from Sanofi in Europe and Canada - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-completes-acquisition-of-two-brands-from-sanofiin-europe-and-canada/): Mumbai, June 05, 2024: Global pharma major Lupin Limited (Lupin) today announced that its European hub entity, Lupin Atlantis Holdings SA, has completed the acquisition of two well-known brands, AaraneTM in Germany and NalcromTM in Canada and the Netherlands,…
[Lupin completes acquistion of pharma dynamics, South Africa - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-completes-acquistion-of-pharma-dynamics-south-africa/): Mumbai, Cape Town: Pharmaceutical Major Lupin announced today, that it has entered into an agreement to acquire the balance 40% equity stake in South African generics major, Pharma Dynamics(PD) from its founders. As per the agreement, the founders will…
[Lupin Completes its Acquisition of GAVIS - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-completes-its-acquisition-of-gavis/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has completed its acquisition of privately held US based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS). Lupin had announced the acquisition on July 23rd 2015. The acquisition enhances…
[Lupin Contributes INR 21 crores Towards COVID-19 Relief Efforts - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-contributes-inr-21-crores-towards-covid-19-relief-efforts/): Mumbai: Pharma major Lupin Limited (Lupin) announced a contribution of INR 21 crores for relief efforts directed towards mitigating the COVID-19 crisis. Lupin’s Global Giving Program comprises of three separate contributions made by its employees, the Company and…
[Lupin confirms ‘security incident’ days after cyber-attack at Dr Reddy’s - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-confirms-security-incident-days-after-cyber-attack-at-dr-reddys/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin cranks up the R&D Engine - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-cranks-up-the-rd-engine/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Diagnostics Achieves NABL Accreditation for All Greenfield Labs - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-diagnostics-achieves-nabl-accreditation-for-all-greenfield-labs/): Now among India’s top fully accredited diagnostic chains Mumbai, India, April 23, 2025: Lupin Diagnostics Limited (LDL), a wholly owned subsidiary of global pharma major Lupin Limited (Lupin) has achieved 100% NABL (National Accreditation Board for Testing and…
[Lupin Diagnostics Expands Presence in South India with New Regional Reference Laboratory in Chennai - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-diagnostics-expands-presence-in-south-india-with-new-regional-reference-laboratory-in-chennai/): Lupin’s First Regional Reference Laboratory in Tamil Nadu Plans to open over 300 collection centers in South India and 50 collection centers in the State by FY25 Chennai, India, December 14, 2023: Global pharma major Lupin Limited (Lupin) today…
[Lupin Diagnostics Expands its Footprint in Central India; Launches Regional Reference Laboratory in Indore - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-diagnostics-expands-its-footprint-in-central-india-launches-regional-reference-laboratory-in-indore/): Indore, India, December 21, 2022: Global pharma major Lupin Limited (Lupin) announced today the launch of its Regional Reference Laboratory in Indore, Madhya Pradesh, as part of its expansion in Central India. Lupin Diagnostics currently operates 325+ LupiMitra (Lupin’s…
[Lupin Diagnostics Expands Presence in South India with New Regional Reference Laboratory in Hyderabad - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-diagnostics-expands-presence-in-south-india-with-new-regional-reference-laboratory-in-hyderabad/): First Regional Reference Laboratory in South India Targets opening 200+collection centers in South India by March 2024 Hyderabad, India, March 01, 2023: Global pharma major Lupin Limited (Lupin) announced today the launch of its new Regional Reference Laboratory inHyderabad,…
[Lupin Diagnostics Launches its First Regional Reference Laboratory in Patna - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-diagnostics-launches-its-first-regional-reference-laboratory-in-patna/): Expanding diagnostics footprint in East India Patna, India | June 15, 2022: Global pharma major Lupin Limited (Lupin) announced today that Lupin Diagnostics has launched its first Regional Reference Laboratory in Patna, Bihar. The new Regional Reference Laboratory at…
[Lupin Diagnostics Launches its First Reference Laboratory in Ranchi - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-diagnostics-launches-its-first-reference-laboratory-in-ranchi/): Expanding its Diagnostics Business footprint in East India Ranchi, India, July 19, 2022: Global pharma major Lupin Limited (Lupin) announced today that Lupin Diagnostics has launched its first Reference Laboratory in Ranchi. The new Reference Laboratory at Ranchi is…
[Lupin Diagnostics Launches Regional Reference Laboratory in Bengaluru, Strengthening Presence in South India - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-diagnostics-launches-regional-reference-laboratory-in-bengaluru-strengthening-presence-in-south-india/): After establishing presence in Hyderabad, this launch expands footprint in South India Bengaluru, India, April 12, 2023: Global pharma major Lupin Limited (Lupin) announced today the launch of its new state-of-the-art Regional Reference Laboratory in Bengaluru, Karnataka, as part…
[Lupin Digital Health and The American College of Cardiology Announce First-Of-Its-Kind Collaboration to Revolutionize In-home Cardiovascular Care in India with Digital Therapeutics - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-digital-health-and-the-american-college-of-cardiology-announce-first-of-its-kind-collaboration-to-revolutionize-in-home-cardiovascular-care-in-india-with-digital-therapeutics/): Mumbai, Washington DC, July 24, 2023: Lupin Digital Health, India’s first evidence-based cardiology digital therapeutics (DTx) platform and the American College of Cardiology (ACC), the global scientific leader in the practice of Cardiology, today announced a first-of-its-kind collaboration to…
[Lupin Digital Health Introduces Comprehensive Post-Procedure Home-Based Care Guide in Collaboration with the American College of Cardiology - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-digital-health-introduces-comprehensive-post-procedure-home-based-care-guide-in-collaboration-with-the-american-college-of-cardiology/): An initiative aimed at improving patient recovery and well-being following cardiac procedures Mumbai, March 22, 2025 – Lupin Digital Health (LDH), India’s leading evidence-based Digital Therapeutics (DTx) platform, today announced the launch of its comprehensive Post-Procedure Home-Based Care Guide…
[Lupin Diagnostics Launches Satellite Laboratory in Vijayawada - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-diagnostics-launches-satellite-laboratory-in-vijayawada/): Continues to Expand its Presence in South India Vijayawada, India, May25, 2023: Global pharma major Lupin Limited (Lupin) announced today the launch of its Satellite Laboratory in Vijayawada, Andhra Pradesh. The move is part of Lupin Diagnostics’ ongoing expansion…
[Lupin Digital Health introduces Digital Therapeutics Certificate for Cardiologists in India in collaboration with the American College of Cardiology - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-digital-health-introduces-digital-therapeutics-certificate-for-cardiologists-in-india-in-collaboration-with-the-american-college-of-cardiology/): Mumbai, Washington DC, January 30, 2024: Lupin Digital Health, India’s first evidence-based cardiology Digital Therapeutics (DTx) platform and the American College of Cardiology (ACC), the global scientific leader in the practice of Cardiology, have announced the introduction of the…
[Lupin Digital Health Launches first-of-its-kind Digital Heart Failure Clinic in India - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-digital-health-launches-first-of-its-kind-digital-heart-failure-clinic-in-india/): Mumbai, August 07, 2023: Lupin Digital Health (LDH), India’s leading Cardiac Digital Therapeutics company, today announced the launch of its newest offering, LyfeTM Digital Heart Failure Clinic in India. This groundbreaking e-clinic aims to help cardiologists and caregivers manage…
[Lupin Digital Health Unveils Results of India’s First Digital Therapeutics Study with ACS Patients - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-digital-health-unveils-results-of-indias-first-digital-therapeutics-study-with-acs-patients/): DTx interventions led to 83% patients bringing and maintaining their vitals in normal range 90% Adherence to Medication, Diet and Exercise, and No Re-hospitalisation in First 30 Day Chennai, March 17, 2023: Lupin Digital Health (LDH), India’s first evidence-based…
[Lupin Digital Health Launches VITALYFE™ - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-digital-health-launches-vitalyfe/): AI-Powered Cardiometabolic Wellness Platform for India’s Workforce Mumbai, October 30, 2025: Lupin Digital Health, India’s leading cardiac digital-therapeutics company, today announced the launch of VITALYFE™, an AI-powered cardiometabolic wellness platform designed to help India’s working professionals reclaim their heart…
[Lupin Digital Health Partners with Medicover Hospitals for Comprehensive Post-Discharge Cardiac Care - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-digital-health-partners-with-medicover-hospitals-for-comprehensive-post-discharge-cardiac-care/): Mumbai, December 16, 2024: Lupin Digital Health, a wholly owned subsidiary of global pharma major Lupin Limited (Lupin) announces a transformative collaboration with Medicover Hospitals to provide state-of-the-art post-operative rehabilitation and care for Medicover’s cardiac patients. This groundbreaking partnership…
[Lupin Digital Health’s Lyfe Platform Receives Class C Medical Device License from CDSCO - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-digital-healths-lyfe-platform-receives-class-c-medical-device-license-from-cdsco/): First chronic condition management platform to be recognized as a Class C ‘Software as a Medical Device’ Mumbai, April 25, 2024: Lupin Digital Health, India’s first evidence-based cardiology Digital Therapeutics (DTx) platform, is proud to announce that its Lyfe…
[Lupin donates Oxygen generation plants in Maharashtra, Madhya Pradesh & Gujarat to aid COVID-19 relief efforts - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-donates-oxygen-generation-plants-in-maharashtra-madhya-pradesh-gujarat-to-aid-covid-19-relief-efforts/): Mumbai, India, June 11, 2021: Global pharma major Lupin Limited (Lupin) through its CSR arm, the Lupin Foundation, is donating five oxygen generation plants to assist the states of Maharashtra, Madhya Pradesh and Gujarat in their ongoing fight…
[Lupin divests Kyowa Criticare to Neopharma group - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-divests-kyowa-criticare-to-neopharma-group/): Mumbai, Osaka: Pharma major Lupin Limited (including its subsidiaries together referred to as Lupin) announced that it has entered into a definitive agreement through its Japanese subsidiary Kyowa (Kyowa Pharmaceutical Industry Co., Ltd.) for the sale of its Japanese…
[Lupin enters dermatology segment in Brazil with launch of Lupin High-End Skin Science - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-enters-dermatology-segment-in-brazil-with-launch-of-lupin-high-end-skin-science/): Mumbai, São Paulo: Pharma major Lupin Limited (Lupin) has entered into the prescription dermatology segment in Brazil with the launch of Fillerina® and Recrexina® under the Lupin High-End Skin Science umbrella. Valued at USD 28 billion, Brazil is the…
[Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus® Brand in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-enters-into-a-marketing-alliance-with-forest-laboratories-inc-for-aerochamber-plus-brand-in-the-us/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Enters into a Non-Exclusive Patent Licensing Agreement with Takeda to Commercialize Vonoprazan, a Novel Gastrointestinal Drug in India - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-enters-into-a-non-exclusive-patent-licensing-agreement-with-takeda-to-commercialize-vonoprazan-a-novel-gastrointestinal-drug-in-india/): Mumbai, September 18, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited (Takeda), to commercialize Vonoprazan Tablets in the Indian market. The drug will…
[Lupin Enters into Collaboration to Promote Zymar to Pediatricians in the U.S. - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-enters-into-collaboration-to-promote-zymar-to-pediatricians-in-the-u-s/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Enters into Licensing Agreement with Alvion to market Cardiometabolic Drugs in the Southeast Asia region - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-enters-into-licensing-agreement-with-alvion-to-market-cardiometabolic-drugs-in-the-southeast-asia-region/): Mumbai, Malaysia, Vietnam, April 05, 2022: Global pharma major, Lupin Limited (Lupin) announced today that they have entered into a licensing agreement with Alvion Pharmaceuticals P.C. (Alvion) to commercialize medicines for Cardiometabolic diseases in the Southeast Asia region. Lupin…
[Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for SUPRAX® 400 mg Tablets in the U.S. - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-enters-into-marketing-alliance-with-ascend-therapeutics-for-suprax-400-mg-tablets-in-the-u-s/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Establishes a New Global Standard in Sustainable Pharma with an S&P Global ESG Score of 91 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-establishes-a-new-global-standard-in-sustainable-pharma-with-an-sp-global-esg-score-of-91/): Mumbai, November 13, 2025: Global pharma leader Lupin Limited (Lupin) today announced that it has achieved an S&P Global ESG Score of 91 for 2025, well above the pharmaceutical industry average of 28. Lupin is now part of…
[Lupin Enters the S&P Global Sustainability Yearbook 2024 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-enters-the-sp-global-sustainability-yearbook-2024/): Mumbai, February 23, 2024: Global pharma major Lupin Limited (Lupin)today announced its debut in the esteemed S&P Global Sustainability Yearbook 2024, underscoring its dedication to corporate sustainability. With a notable Corporate Sustainability Assessment (CSA) score of 69/100, Lupin joins…
[Lupin Expands Branded Play Announces Acquisition of Exclusive US Rights to Alinia® for Oral Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-expands-branded-play-announces-acquisition-of-exclusive-us-rights-to-alinia-for-oral-suspension/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin enters into a co-operation agreement with Kyowa for Japanese market - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-enters-into-a-co-operation-agreement-with-kyowa-for-japanese-market/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin enters into agreement to divest its stake in Kyowa to Unison - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-enters-into-agreement-to-divest-its-stake-in-kyowa-to-unison/): Mumbai, Osaka: Pharma major Lupin Limited (including its subsidiaries, together referred to as ‘Lupin’) announced that it has entered into a definitive agreement for the sale of its entire stake in its Japanese subsidiary Kyowa Pharmaceutical Industry Co.,…
[Lupin enters into Voluntary Licensing Agreement with Lilly to Expand Access for COVID-19 Treatment in India - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-enters-into-voluntary-licensing-agreement-with-lilly-to-expand-access-for-covid-19-treatment-in-india/): Mumbai, India, May 10, 2021: Global pharma major, Lupin Limited (Lupin) today announced that it has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and selling of Lilly’s drug Baricitinib in…
[Lupin Expands Branded Play Announces Acquisition of US Rights to ANTARA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-expands-branded-play-announces-acquisition-of-us-rights-to-antara/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Expands Branded Play Announces Acquisition of Worldwide Rights for its first NDA – AllerNaze™ - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-expands-branded-play-announces-acquisition-of-worldwide-rights-for-its-first-nda-allernaze/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Expands US Pediatric Brands Portfolio Inks Strategic Agreement to Promote Locoid® Lotion to US Pediatricians - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-expands-us-pediatric-brands-portfolio-inks-strategic-agreement-to-promote-locoid-lotion-to-us-pediatricians/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin files INDA for anti-psoriasis - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-files-inda-for-anti-psoriasis/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Foundation Flags off Mobile Medical Van in Palghar to Strengthen Non-Communicable Disease Care - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-foundation-flags-off-mobile-medical-van-in-palghar-to-strengthen-non-communicable-disease-care/): Palghar, Maharashtra, June 09, 2025 – Lupin Human Welfare & Research Foundation (Lupin Foundation), the CSR arm of global pharmaceutical leader Lupin Limited (Lupin), in collaboration with the Public Health Department, Government of Maharashtra, flagged off its third…
[Lupin Foundation is Transforming Communities and Lives in Bharatpur and Alwar - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-foundation-is-transforming-communities-and-lives-in-bharatpur-and-alwar/): Bharatpur, India, July 13, 2022: Lupin Human Welfare and Research Foundation (LHWRF), the Corporate Social Responsibility (CSR) arm of global pharma major Lupin Limited (Lupin) has worked for over 3 decades on the social and economic well-being of families…
[Lupin finalizes patent sale agreement with Servier - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-finalizes-patent-sale-agreement-with-servier/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin forays into the OTC segment with Softovac - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-forays-into-the-otc-segment-with-softovac/): Mumbai: Pharma major Lupin Limited (Lupin) has made a foray into the over-the-counter (OTC) segment under the ‘Lupin Life Consumer Healthcare’ umbrella with the pan-India launch of Softovac. A 34-year old legacy brand, Softovac has been trusted by millions…
[Lupin Extends ‘Jan Kovid’ Helpline for Bhopal and Indore Citizens - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-extends-jan-kovid-helpline-for-bhopal-and-indore-citizens/): Mumbai, India,: Pharma major Lupin Limited (Lupin) today announced the extension of the ‘Jan Kovid’ Helpline (1800-572-6130) for the residents of Bhopal and Indore. Seeking medical help during the lockdown poses a great challenge. This initiative facilitates medical outreach to citizens…
[Lupin Foundation Organizes State-Level Workshop to Enhance Healthcare Systems in Rajasthan - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-foundation-organizes-state-level-workshop-to-enhance-healthcare-systems-in-rajasthan/): Jaipur, April 1, 2025: Lupin Human Welfare & Research Foundation (Lupin Foundation), the CSR arm of global pharma major, Lupin Limited (Lupin), in collaboration with the State Health Department, organized a two-day state-level workshop. Senior medical officers from district…
[Lupin facilitates ‘The Best of ACG’ in association with American College of Gastroenterology - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-facilitates-the-best-of-acg-in-association-with-american-college-of-gastroenterology/): Mumbai: Pharma major Lupin Limited (Lupin) announced an association with the American College of Gastroenterology (ACG) for a new initiative ‘The Best of ACG’. Under the terms of the agreement, ACG will take the best education materials from…
[Lupin Foundation Strengthens Lives Program With Its First Mobile Medical Van ; Flag-Off by Health Minister, Government Of Rajasthan - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-foundation-strengthens-lives-program-with-its-first-mobile-medical-van-flag-off-by-health-minister-government-of-rajasthan/): Mobile medical vans will be used to conduct 18 health camps twice a month at nine health facilities Jaipur, July 28, 2023: Lupin Human Welfare & Research Foundation (LHWRF) strengthened its Desh Bandhu Jan Aarogya Sewa by flagging off…
[Lupin Foundation trains 7000 plus farmers at the Natural Farming Workshop in Bharatpur - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-foundation-trains-7000-plus-farmers-at-the-natural-farming-workshop-in-bharatpur/): A six-day training workshop witnessed attendance from Rajasthan, Uttar Pradesh, Haryana, Himachal Pradesh, Uttarakhand, Madhya Pradesh, Gujarat and Maharashtra The workshop was spearheaded by veteran Indian agriculturist and Padma Shri Awardee Subhash Palekar Mumbai, Bharatpur: Lupin Foundation organised…
[Lupin FY 05 Net Sales up 4% at Rs. 11,611 mn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-fy-05-net-sales-up-4-at-rs-11611-mn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin FY 2006-07 Q1 Sales up by 33% at Rs.4.9 bn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-fy-2006-07-q1-sales-up-by-33-at-rs-4-9-bn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin FY 2003-04 revenue up 22% at Rs 12.3 bn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-fy-2003-04-revenue-up-22-at-rs-12-3-bn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin FY 2006-07 Q2 Net Profit up by 29% at Rs.583 mn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-fy-2006-07-q2-net-profit-up-by-29-at-rs-583-mn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin FY 2006-07 Q3 Net Profit up by 27% at Rs.560 mn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-fy-2006-07-q3-net-profit-up-by-27-at-rs-560-mn-2/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin FY 2006-07 Q3 Net Profit up by 27 % at Rs. 560 mn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-fy-2006-07-q3-net-profit-up-by-27-at-rs-560-mn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Foundation Wins IDMA Corporate Citizen Award 2019 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-foundation-wins-idma-corporate-citizen-award-2019/): Mumbai: Pharma major Lupin Limited (Lupin) announced that its corporate social responsibility (CSR) arm, Lupin Foundation, has won the prestigious Indian Drug Manufacturers’ Association (IDMA) Corporate Citizen Award 2019, at the IDMA 58thAnnual Day Celebrations held in Mumbai…
[Lupin Foundation Wins Award for Excellence in Corporate Social Responsibility at India Pharma Awards 2019 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-foundation-wins-award-for-excellence-in-corporate-social-responsibility-at-india-pharma-awards-2019/): New Delhi: Pharma major Lupin Limited announced that its corporate social responsibility (CSR) arm, the Lupin Foundation won the prestigious award for ‘Excellence in Corporate Social Responsibility’ at the India Pharma Awards 2019 held in Greater Noida (National…
[Lupin FY 2007-08 Q1 Net Profit up 55% to Rs. 784 mn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-fy-2007-08-q1-net-profit-up-55-to-rs-784-mn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin FY 2007-08 Consolidated Net Profit up 32% to Rs. 4083 mn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-fy-2007-08-consolidated-net-profit-up-32-to-rs-4083-mn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin FY 2007-08 Q2 Consolidated Net Profit up 46% to Rs. 756 mn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-fy-2007-08-q2-consolidated-net-profit-up-46-to-rs-756-mn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin FY 2009-10 Consolidated Net Profits up 36% to Rs 6816 mn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-fy-2009-10-consolidated-net-profits-up-36-to-rs-6816-mn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin FY2002-03 net sales up 19% at Rs 10.3 bn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-fy2002-03-net-sales-up-19-at-rs-10-3-bn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin gets DCGI approval to conduct Phase III clinical trials for Migraine NCE - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-gets-dcgi-approval-to-conduct-phase-iii-clinical-trials-for-migraine-nce/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin gets EIR from US FDA for its Ankleshwar Manufacturing Facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-gets-eir-from-us-fda-for-its-ankleshwar-manufacturing-facility/): Mumbai, October 1, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for its Ankleshwar manufacturing facility, located in Gujarat, India….
[Lupin gets MHRA Approval for Lisinopril in UK - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-gets-mhra-approval-for-lisinopril-in-uk/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin gets new Pharmaceutical Research Head - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-gets-new-pharmaceutical-research-head/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin FY2020 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-fy2020-results/): Mumbai: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter and fiscal year ending March 31, 2020. These audited results were taken on record by the Board of Directors at a meeting…
[Lupin FY2025 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-fy2025-results/): Lupin FY2025 Results Mumbai, May 14, 2025: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter and fiscal year ending March 31, 2025. These audited results were taken on record by…
[Lupin FY2022 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-fy2022-results/): Mumbai, May 18, 2022: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter and fiscal year ending March 31, 2022. These audited results were taken on record by the Board of Directors…
[Lupin gets tentative US FDA approval for Sertraline - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-gets-tentative-us-fda-approval-for-sertraline/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin gets tentative US FDA approval for Sertraline - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-gets-tentative-us-fda-approval-for-sertraline-2/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin gets tentative US FDA approval for Trandolapril - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-gets-tentative-us-fda-approval-for-trandolapril/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin gets US FDA approval for Ceftriaxone 10gm vials - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-gets-us-fda-approval-for-ceftriaxone-10gm-vials/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin gets US FDA approval for Lisinopril-HCTZ Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-gets-us-fda-approval-for-lisinopril-hctz-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin gets USFDA approval for Cefdinir Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-gets-usfda-approval-for-cefdinir-suspension/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin gets USFDA approval for Meloxicam - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-gets-usfda-approval-for-meloxicam/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Hosts Second Edition of Aptivate Champion Run for Kids - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-hosts-second-edition-of-aptivate-champion-run-for-kids/): Run Garners Strong Response from Parents and Children Mumbai, January 14, 2024: Lupin Life, the Consumer Healthcare division of Lupin, successfully hosted the second edition of the Aptivate Champion Run for Kids at the MMRDA Ground in Bandra Kurla…
[Lupin has entered into an agreement with GSK Philippines - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-has-entered-into-an-agreement-with-gsk-philippines/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin in alliance with Natco receives FDA approval for Bosentan Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-in-alliance-with-natco-receives-fda-approval-for-bosentan-tablets/): Mumbai, Baltimore: Lupin Limited (Lupin) in alliance with Natco Pharma (Natco) announced that it has received approval for Bosentan Tablets, 62.5 mg and 125 mg, from the United States Food and Drug Administration (FDA) to market a generic version…
[Lupin in alliance with Natco receives FDA approval for Imatinib Mesylate Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-in-alliance-with-natco-receives-fda-approval-for-imatinib-mesylate-tablets/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) and Natco Pharma Limited (Natco) announced the final ANDA approval for Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base) from the United States Food and Drug Administration (FDA) to market…
[Lupin in Alliance with Natco to commercialize generic equivalent of Tykerb® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-in-alliance-with-natco-to-commercialize-generic-equivalent-of-tykerb-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin in Equity Partnership with Pharma Dynamics, South Africa - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-in-equity-partnership-with-pharma-dynamics-south-africa/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Inks Strategic Joint Venture Agreement with Yoshindo Inc. - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-inks-strategic-joint-venture-agreement-with-yoshindo-inc/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Launches Additional Strengths of Generic Lotrel® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-additional-strengths-of-generic-lotrel-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin joins hands with ItalFarmaco to launch Lupenox in India - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-joins-hands-with-italfarmaco-to-launch-lupenox-in-india/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches “Adhero,” first-of-its-kind connected Smart Device in India to support treatment of Respiratory Disease - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-adhero-first-of-its-kind-connected-smart-device-in-india-to-support-treatment-of-respiratory-disease/): First-of-its kind smart device launched in India to track usage pattern of metered dose inhaler (MDI) by patients Reusable device with built-in sensors to track daily usage and consumption pattern Companion app MyAdhero connects the device to smartphones…
[Lupin Launches Aptivate Achi Bhookh Fest in Mumbai and Suburbs - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-aptivate-achi-bhookh-fest-in-mumbai-and-suburbs/): Mumbai, October 14, 2024: LupinLife, the consumer healthcare division of global pharma major Lupin Limited (Lupin) today announced the flag-off of its Aptivate Achi Bhookh Fest in Mumbai and its suburbs. The fest aims to create awareness around the…
[Lupin Launches Atharv Ability – State-of-the-Art, Multi-Disciplinary Neuro-Rehabilitation Center in Mumbai - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-atharv-ability-state-of-the-art-multi-disciplinary-neuro-rehabilitation-center-in-mumbai/): Committed to Improving Health Outcomes for Patients with Neurological Disorders Mumbai, February 14, 2023:Global pharma major Lupin Limited (Lupin) today announced the launch of a world-class Neuro-rehabilitation center, Atharv Ability in Bandra Kurla Complex (BKC), Mumbai, India. The first-of-its-kind…
[Lupin Launches Aptivate Champion Run for Kids Promoting Well-being and Good Eating Habits - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-aptivate-champion-run-for-kids-promotingwell-being-and-good-eating-habits/): Mumbai, India, February 3, 2023: Lupin Life, the Consumer Healthcare division of Lupin, today announced the first-ever Aptivate Champion Run for Kids on February 12, 2023, at MMRDA Grounds, Bandra Kurla Complex, Mumbai. The Aptivate Champion Runwillencourageparents and children…
[Lupin Launches Atorvastatin Calcium Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-atorvastatin-calcium-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier….
[Lupin Launches Authorized Generic for Celebrex® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-for-celebrex-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches Authorized Generic of Femcon® Fe - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-of-femcon-fe/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Launches Authorized Generic Version of Antara® in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-antara-in-the-united-states/): Mumbai, Baltimore, November 03, 2021: Global pharma major Lupin Limited (Lupin) announced the launch of the authorized generic version of Antara® (Fenofibrate) Capsules, 30 mg and 90 mg, of Lupin Atlantis Holdings, S.A. Corporation, a wholly-owned subsidiary of Lupin….
[Lupin Launches Authorized Generic Version of Alinia® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-alinia/): Mumbai, Baltimore: Global pharma major, Lupin Limited (Lupin), today announced the launch of the authorized generic version of Alinia® (nitazoxanide) Tablets, 500 mg of Romark Laboratories, L.C. Nitazoxanide Tablets, 500 mg, are indicated in the treatment of diarrhea caused…
[Lupin Launches Authorized Generic Version of Apriso® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-apriso/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of authorized generic version of Bausch Health’s Apriso® (Mesalamine Extended-Release Capsules 0.375 g) in the U.S. Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) are indicated for the maintenance of remission…
[Lupin Launches Authorized Generic Version of Duexis® in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-duexis-in-the-united-states/): Mumbai, Baltimore, September 15, 2021: Global pharma major Lupin Limited (Lupin) today announced the launch of the authorized generic version of Duexis® (ibuprofen and famotidine) Tablets, 800 mg/26.6 mg, of Horizon Medicines LLC. Ibuprofen and Famotidine Tablets, 800…
[Lupin Launches Authorized Generic Version of Brovana® in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-brovana-in-the-united-states/): Mumbai, Baltimore, June 03, 2021: Global pharma major, Lupin Limited (Lupin), announced the launch of the authorized generic version of Brovana® (arformoterol tartrate) Inhalation Solution 15 mcgꝉ/2 mL, unit-dose vials, of Sunovion Pharmaceuticals Inc. Arformoterol Tartrate Inhalation Solution 15…
[Lupin Launches Authorized Generic Version of PENNSAID® 2% w/w in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-pennsaid-2-w-w-in-the-united-states/): Mumbai, Baltimore, December 09, 2022: Global pharma major Lupin Limited (Lupin) today announced the launch of authorized generic version of PENNSAID® (Diclofenac Sodium Topical Solution), 2% w/w of Horizon Pharma Therapeutics. Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID®)…
[Lupin Launches Authorized Generic version of Vimovo® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-vimovo/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of the authorized generic for Horizon Therapeutics PLC’s Vimovo® (naproxen/esomeprazole magnesium) delayed-release tablets, 375 mg/20 mg and 500 mg/20 mg in the U.S. The product is a combination…
[Lupin Launches Authorized Generic Version of Ravicti® in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-ravicti-in-the-united-states/): Mumbai, Naples, October 24, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States. Glycerol Phenylbutyrate Oral Liquid, 1.1g/mL is indicated for…
[Lupin launches Betamethasone Dipropionate Ointment USP (Augmented) - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-betamethasone-dipropionate-ointment-usp-augmented/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at…
[Lupin launches Basugine™ - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-basugine/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Launches Bosentan Tablets for Oral Suspension in the United States with 180-Day Exclusivity - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-bosentan-tablets-for-oral-suspension-in-the-united-states-with-180-day-exclusivity/): Mumbai, Naples, August 20, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of Bosentan Tablets for Oral Suspension, 32 mg in the United States. This follows the approval received by Lupin’s alliance partner, NATCO Pharma…
[Lupin Launches Bromfenac Ophthalmic Solution, 0.075% in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-bromfenac-ophthalmic-solution-0-075-in-the-united-states/): Mumbai, Baltimore, February 13, 2024: Global pharma major Lupin Limited (Lupin) today announced the launch of Bromfenac Ophthalmic Solution, 0.075%, after having received an approval from the United States Food and Drug Administration (U.S. FDA). Bromfenac Ophthalmic Solution, 0.075%…
[Lupin Launches Branded Finished Dosage in the US Sets up Pediatric Sales Force - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-branded-finished-dosage-in-the-us-sets-up-pediatric-sales-force/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches Budesonide Inhalation Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-budesonide-inhalation-suspension/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of its Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules in the US market, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s…
[Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-bromfenac-ophthalmic-solution-0-07in-the-united-states/): Being the first to file, Lupin is eligible for 180-day exclusivity period Mumbai, Baltimore, January 09, 2024: Global pharma major Lupin Limited (Lupin) today announced the launch of Bromfenac Ophthalmic Solution, 0.07%, after having received an approval from the…
[Lupin launches Clobazam Oral Suspension, 2.5mg/mL - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-clobazam-oral-suspension-2-5mg-ml/): Mumbai, Baltimore: Pharma major Lupin announced the launch of Clobazam Oral Suspension, 2.5mg/mL, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Clobazam Oral Suspension, 2.5mg/mL is the generic version of Lundbeck Pharmaceuticals…
[Lupin launches Ceftriaxone vials in the US market - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-ceftriaxone-vials-in-the-us-market/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Launches Bumetanide Injection, USP in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-bumetanide-injection-usp-in-the-united-states/): Mumbai, Naples, November 19, 2024: Global pharma major Lupin Limited (Lupin) today announced the launch of Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multiple-Dose Vials in the United States, after…
[Lupin launches Clobazam Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-clobazam-tablets/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Clobazam Tablets, 10 mg and 20 mg, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Clobazam Tablets, 10 mg and 20…
[Lupin launches Corcal Bone and Beauty supplement - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-corcal-bone-and-beauty-supplement/): Mumbai: Pharma major Lupin, under its consumer healthcare division – LupinLife announced the launch of Corcal Bone and Beauty, a novel calcium health supplement for women. Made from 100% natural coral grains sourced from Okinawa, Japan, Corcal Bone and…
[Lupin launches Clomipramine Hydrochloride Capsules USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-clomipramine-hydrochloride-capsules-usp/): Mumbai, Baltimore: Pharma major Lupin announced the launch of Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Clomipramine Hydrochloride Capsules USP,…
[Lupin Launches Cyanocobalamin Nasal Spray in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-cyanocobalamin-nasal-spray-in-the-united-states/): Mumbai, Baltimore, February 02, 2024: Global pharma major Lupin Limited (Lupin) today announced the launch of Cyanocobalamin Nasal Spray, 500 mcg/spray (One Spray per Device), after having received an approval from the United States Food and Drug Administration (U.S….
[Lupin Launches Darunavir Tablets in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-darunavir-tablets-in-the-united-states/): Mumbai, Baltimore, June 03, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of Darunavir Tablets 600 mg and 800 mg to market a generic equivalent of Prezista® Tablets of Janssen Products, LP. Darunavir Tablets, 600 mg…
[Lupin Launches Desvenlafaxine Extended-Release Tablets in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-desvenlafaxine-extended-release-tablets-in-the-united-states/): Mumbai, Baltimore, August 26, 2022: Global pharma major Lupin Limited (Lupin) today announced the launch of Desvenlafaxine Extended-Release Tablets, 25 mg, having received an approval from the United States Food and Drug Administration (FDA). Desvenlafaxine Extended-Release Tablets, 25 mg…
[Lupin Launches Diazepam Rectal Gel in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-diazepam-rectal-gel-in-the-united-states/): Mumbai, Baltimore, November 02, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of Diazepam Rectal Gel, 10 mg and 20 mg, Rectal Delivery System, after its wholly owned subsidiary, Novel Laboratories Inc., based in Somerset, New…
[Lupin Launches Divalproex Sodium ER Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-divalproex-sodium-er-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Divalproex Sodium Extended-Release (ER) Tablets USP, 250 mg and 500 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product will…
[Lupin Launches Doxorubicin Hydrochloride Liposome Injection in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-doxorubicin-hydrochloride-liposome-injection-in-the-united-states/): Mumbai, Naples, August 29, 2024: Global pharma major Lupin Limited (Lupin) today announced the launch of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials in the United States, after Lupin’s…
[Lupin launches Doxercalciferol Injection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-doxercalciferol-injection/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. Lupin’s Doxercalciferol Injection,…
[Lupin Launches Doxycycline for Injection USP in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-doxycycline-for-injection-usp-in-the-united-states/): Mumbai, Naples, June 03, 2024: Global pharma major Lupin Limited (Lupin) today announced the launch of Doxycycline for Injection USP, 100 mg/Vial (Single-Dose Vial) in the United States, post approvals from the United States Food and Drug Administration (U.S….
[Lupin Launches Droxidopa Capsules in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-droxidopa-capsules-in-the-united-states/): Mumbai, Baltimore, September 28, 2021: Global pharma major Lupin Limited (Lupin) today announced the launch of Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, having received an approval from the United States Food and Drug Administration (US…
[Lupin Launches Emtricitabine and Tenofovir Disoproxil Fumarate Tablets in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-emtricitabine-and-tenofovir-disoproxil-fumarate-tablets-in-the-united-states/): Mumbai, Baltimore, June 25, 2021: Global pharma major Lupin Limited (Lupin) today announced the launch of Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg/300 mg, having received an approval from the United States Food and Drug Administration (FDA)….
[Lupin Launches Eslicarbazepine Acetate Tablets in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-eslicarbazepine-acetate-tablets-in-the-united-states/): Being the first to file, Lupin is eligible for 180-day shared generic exclusivity Mumbai, Naples, May 7, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has launched Eslicarbazepine Acetate Tablets, 200 mg, 400 mg, 600…
[Lupin launches Ethacrynic Acid Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-ethacrynic-acid-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Ethacrynic Acid Tablets USP, 25 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at…
[Lupin Launches Favipiravir Drug Covihalt® for Treatment of Mild to Moderate COVID-19 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-favipiravir-drug-covihalt-for-treatment-of-mild-to-moderate-covid-19/): Mumbai, India: Pharma major Lupin Limited (Lupin) today announced the launch of its Favipiravir in India under the brand name Covihalt® for the treatment of mild to moderate COVID-19. Favipiravir has received authorization from the Drug Controller General of…
[Lupin Launches Favipiravir Drug Covihalt® for Treatment of Mild to Moderate COVID-19 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-favipiravir-drug-covihalt-for-treatment-of-mild-to-moderate-covid-19-2/): Mumbai, India: Pharma major Lupin Limited (Lupin) today announced the launch of its Favipiravir in India under the brand name Covihalt® for the treatment of mild to moderate COVID-19. Favipiravir has received authorization from the Drug Controller General of…
[Lupin launches first ever Duloxetine 40mg Delayed-Release Capsules in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-first-ever-duloxetine-40mg-delayed-release-capsules-in-the-us/): Mumbai: Pharma major Lupin Limited announced today that its subsidiary Lupin Pharmaceuticals, Inc. (Lupin) has launched its Duloxetine 40 mg Delayed-Release (DR) Capsule, which is the first and only generic Duloxetine formulation to become available in 40 mg dosage…
[Lupin Launches First Generic of Pred Forte® in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-first-generic-of-pred-forte-in-the-united-states/): Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte® Lupin has commenced shipment with a 180-day CGT exclusivity Mumbai, Naples, October 15, 2024: Global pharma major Lupin Limited (Lupin) today announced the launch of the first…
[Lupin Launches First Generic Version of Oracea® (Doxycycline Capsules) in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-first-generic-version-of-oracea-doxycycline-capsules-in-the-united-states/): Mumbai, Naples, April 9,2024: Global pharma major Lupin Limited (Lupin) today announced the launch of first generic version of Oracea® (Doxycycline Capsules, 40 mg), in the United States, after having received an approval from the United States Food and…
[Lupin launches Fluoxetine Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-fluoxetine-tablets-usp-2/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Fluoxetine Tablets USP, 60mg, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Fluoxetine Tablets USP, 60mg, is the generic version of…
[Lupin Launches Formoterol Fumarate Inhalation Solution in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-formoterol-fumarate-inhalation-solution-in-the-united-states/): Mumbai, Baltimore, November 29, 2022: Global pharma major Lupin Limited (Lupin) today announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, to market a generic equivalent of Perforomist® Inhalation Solution, 20 mcg/2 mL, of…
[Lupin launches Fluoxetine Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-fluoxetine-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Fluoxetine Tablets USP, 10 mg and 20 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. Lupin’s Fluoxetine Tablets USP, 10…
[Lupin launches Fluocinonide Ointment USP 0.05% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-fluocinonide-ointment-usp-0-05/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Fluocinonide Ointment USP, 0.05%, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Fluocinonide Ointment USP, 0.05%, is the generic version of…
[Lupin Launches Ganirelix Acetate Injection in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-ganirelix-acetate-injection-in-the-united-states/): Ganirelix is Lupin’s first peptide-based injectable, strengthening the Company’s commitment to innovative healthcare solutions Mumbai, Baltimore, February 15, 2024: Global pharma major Lupin Limited (Lupin) today announced the launch of Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe,…
[Lupin Launches Fosaprepitant for Injection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-fosaprepitant-for-injection/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Fosaprepitant for Injection, 150 mg Single-Dose Vial, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. Fosaprepitant for Injection, 150 mg Single-Dose…
[Lupin launches generic Acticlate® Tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-acticlate-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin announced the launch of its Doxycycline Hyclate Tablets USP, 75 mg and 150 mg having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Doxycycline Hyclate Tablets USP, 75…
[Lupin launches Generic Aciphex® Delayed-Release Tablets, 20 mg in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-aciphex-delayed-release-tablets-20-mg-in-the-us/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Launches Generic Activella® Tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-activella-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. has launched its Amabelz™Tablets (Estradiol and Norethindrone Acetate Tablets USP, 0.5 mg / 0.1 mg and 1 mg / 0.5 mg)having received an…
[Lupin launches generic Ancobon® capsules in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-ancobon-capsules-in-the-us/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of its Flucytosine capsules USP, 250 mg and 500 mg having received an approval from the United States Food and Drug Administration (FDA) earlier. Novel’s Flucytosine Capsules USP, 250…
[Lupin launches Generic Aricept tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-aricept-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Donepezil Hydrochloride Tablets, 23 mg having received approval from the United States Food and Drug Administration (FDA) earlier to market…
[Lupin launches generic Atovaquone Oral Suspension USP in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-atovaquone-oral-suspension-usp-in-the-us/): Mumbai, Baltimore: Pharma major Lupin announced the launch of Atovaquone Oral Suspension USP, 750 mg/5 mL having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Atovaquone Oral Suspension USP, 750 mg/5 mL is…
[Lupin launches generic Axiron® topical solution in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-axiron-topical-solution-in-the-us/): Mumbai, Baltimore: Pharma major Lupin announced the launch of its Testosterone Topical Solution, 30 mg per actuation having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Testosterone Topical Solution, 30 mg per actuation…
[Lupin Launches Generic Cipro® for Oral Suspension in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-cipro-for-oral-suspension-in-the-us/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches generic Clobex® Lotion in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-clobex-lotion-in-the-us/): Mumbai, Baltimore: Pharma major Lupin announced the launch of its Clobetasol Propionate Lotion 0.05% having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Clobetasol Propionate Lotion 0.05% is the generic equivalent of Galderma…
[Lupin launches generic Clobetasol Propionate Ointment USP 0.05% in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-clobetasol-propionate-ointment-usp-0-05-in-the-us/): Mumbai, Baltimore: Pharma major Lupin announced the launch of Clobetasol Propionate Ointment USP 0.05%, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Clobetasol Propionate Ointment USP, 0.05% is the generic equivalent of…
[Lupin launches generic Clobetasol Propionate Cream USP 0.05% in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-clobetasol-propionate-cream-usp-0-05-in-the-us/): Mumbai, Baltimore: Pharma major Lupin announced the launch of its Clobetasol Propionate Cream USP 0.05%, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Clobetasol Propionate Cream USP 0.05% is the generic equivalent…
[Lupin Launches Generic Combivir® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-combivir-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches generic Clobex® Spray, 0.05% in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-clobex-spray-0-05-in-the-us/): Mumbai, Baltimore: Pharma major Lupin announced the launch of its Clobetasol Propionate Spray 0.05% having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Clobetasol Propionate Spray 0.05% is the generic equivalent of Galderma…
[Lupin launches generic Benicar® tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-benicar-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced the launch of its Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Olmesartan Medoxomil…
[Lupin launches Generic Cymbalta® Delayed-Release Capsules 20 mg, 30 mg and 60 mg strengths in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-cymbalta-delayed-release-capsules-20-mg-30-mg-and-60-mg-strengths-in-the-us/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches generic Desoximetasone Topical Spray, 0.25% in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-desoximetasone-topical-spray-0-25-in-the-us/): Mumbai, Baltimore: Pharma major Lupin announced the launch of its Desoximetasone Topical Spray, 0.25%, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Desoximetasone Topical Spray, 0.25% is the generic equivalent of Taro…
[Lupin launches Generic DIOVAN® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-diovan-tablets/): Mumbai, Baltimore: Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched its Valsartan Tablets USP, 40 mg, 80 mg, 160 mg and 320 mg, the generic for Novartis Pharmaceuticals Corporation’s (Novartis)…
[Lupin launches generic Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-drospirenone-ethinyl-estradiol-levomefolate-calcium-tablets-and-levomefolate-calcium-tablets-3-mg-0-02-mg-0-451-mg-and-0-451-mg/): Mumbai, Baltimore: Pharma major Lupin announced the launch of Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg (EQ Beyaz®), having received an approval from the United States Food and Drug…
[Lupin Launches Generic Diovan HCT® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-diovan-hct-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches Generic Epzicom® tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-epzicom-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today the launch of Abacavir and Lamivudine tablets, 600 mg/300 mg having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Abacavir and Lamivudine tablets, 600…
[Lupin Launches Generic Femhrt® Tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-femhrt-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Fyavolv ™ Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/0.0025 mg and 1 mg/0.005 mg) having received an…
[Lupin Launches Generic Exforge® Tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-exforge-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) yesterday has launched its Amlodipine and Valsartan Tablets, 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320 mg, which…
[Lupin Launches Generic Glumetza® HCI ER Tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-glumetza-hci-er-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Metformin HCl ER Tablets, 500 mg and 1000 mg to market a generic equivalent of Santarus Inc.’s Glumetza® HCl ER…
[Lupin launches generic Fosrenol Chewable Tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-fosrenol-chewable-tablets-in-the-us/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Lanthanum Carbonate Chewable Tablets 500 mg (base), 750 mg (base), and 1000 mg (base). Lupin’s alliance partner Natco had received an approval from the United States Food and…
[Lupin Launches Generic Intermezzo® Sublingual Tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-intermezzo-sublingual-tablets-in-the-us/): 1st product launch from the GAVIS pipeline with 180 days exclusivity Mumbai, Baltimore: Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched the first product from its GAVIS pipeline, Zolpidem…
[Lupin launches generic KCl for Oral Solution USP, 20 mEq - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-kcl-for-oral-solution-usp-20-meq/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Potassium Chloride (KCl) for Oral Solution USP, 20 mEq, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. Lupin’s Potassium Chloride…
[Lupin launches generic Kapvay® tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-kapvay-tablets-in-the-us/): Mumbai, Baltimore: Pharma major Lupin announced the launch of its Clonidine Hydrochloride extended-release tablets, 0.1mg, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Clonidine Hydrochloride ER tablets is the generic equivalent of…
[Lupin launches generic Levothyroxine Sodium Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-levothyroxine-sodium-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Levothyroxine Sodium Tablets USP, having received an approval from the United States Food and Drug Administration (FDA) earlier.. Lupin’s Levothyroxine Sodium Tablets USP, is the generic equivalent of…
[Lupin launches generic Lodosyn® tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-lodosyn-tablets-in-the-us/): Mumbai, Baltimore: Pharma major Lupin announced the launch of its Carbidopa Tablets 25mg having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Carbidopa Tablets, 25mg is the generic equivalent of Aton Pharma, Inc.’s…
[Lupin launches generic Methylergonovine Maleate Tabs USP in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-methylergonovine-maleate-tabs-usp-in-the-us/): Mumbai, Baltimore: Pharma major Lupin announced the launch of its Methylergonovine Maleate Tabs USP, 0.2 mg, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Methylergonovine Maleate Tabs USP, 0.2 mg, is the…
[Lupin launches Generic Minastrin® 24 Fe chewable tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-minastrin-24-fe-chewable-tablets-in-the-us/): Lupin is eligible for 180 days of generic drug exclusivity Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today the launch of Mibelas™ 24 Fe (Norethindrone Acetate and Ethinyl Estradiol Chewable Tablets, 1 mg/0.02 mg and Ferrous Fumarate…
[Lupin launches generic Minocycline Hydrochloride ER Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-minocycline-hydrochloride-er-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin announced the launch of Minocycline Hydrochloride Extended-Release Tablets USP 55mg, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Minocycline Hydrochloride ER Tablets USP 55mg is a generic…
[Lupin Launches Generic MS Contin® ER Tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-ms-contin-er-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has launched its Morphine Sulfate ER Tablets 15 mg, 30 mg, 60 mg, 100 mg and 200 mg having received an approval from the United States Food and…
[Lupin launches Generic Niaspan® Tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-niaspan-tablets-in-the-us/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches generic Namenda XR® capsules in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-namenda-xr-capsules-in-the-us/): Mumbai: Pharma major Lupin announced the launch of its Memantine Hydrochloride Extended-Release Capsules, 7mg, 14mg, 21mg, 28mg having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Memantine Hydrochloride ER capsules 7mg, 14mg, 21mg,…
[Lupin launches generic Norco® tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-norco-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin announced the launch of its Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg having received an approval from the United States Food and Drug Administration (FDA)…
[Lupin launches generic Nystatin and Triamcinolone Acetonide Cream USP 100,000 units/gm; 0.1% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-nystatin-and-triamcinolone-acetonide-cream-usp-100000-units-gm-0-1/): Mumbai, Baltimore: Pharma major Lupin announced the launch of Nystatin and Triamcinolone Acetonide Cream USP 100,000 units/gm; 0.1 %, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Nystatin and Triamcinolone Acetonide Cream…
[Lupin Launches Generic Ortho-Cyclen® 28 Tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-ortho-cyclen-28-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has launched its Norgestimate and Ethinyl Estradiol Tablets USP, 0.25 mg/0.035 mg having received approval from the United States Food and Drug Administration (FDA) earlier to market a…
[Lupin Launches Generic Ortho Tri-Cyclen® Lo Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-ortho-tri-cyclen-lo-tablets/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced that its US subsidiary Lupin Pharmaceutical Inc. has launched its Tri-Lo-Marzia™ Tablets (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg) having received approval from…
[Lupin launches Generic Paxil CR® tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-paxil-cr-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today the launch of generic Paxil CR® (Paroxetine) Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg having received an approval from the United States Food and Drug Administration…
[Lupin launches generic Potassium Chloride Oral Solution USP, 20 mEq/15mL (10%) and 40 mEq/15 mL (20%) - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-potassium-chloride-oral-solution-usp/): Mumbai: Pharma major Lupin announced the launch of Potassium Chloride Oral Solution USP, 20 mEq/15mL (10%) and 40 mEq/15 mL (20%), having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Potassium Chloride Oral…
[Lupin Launches Generic Pristiq® Tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-pristiq-tablets-in-the-us/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today the launch of generic Pristiq® (Desvenlafaxine Succinate) Extended-Release Tablets, 50 mg and 100 mg having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Desvenlafaxine Succinate…
[Lupin Launches Generic PhosLo® in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-phoslo-in-the-us/): Mumbai: Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched its Calcium Acetate Capsules, 667 mg (eq. 169 mg Calcium) having received final approval from the United States Food and Drug…
[Lupin launches generic Safyral® tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-safyral-tablets-in-the-us/): Mumbai, Baltimore: Pharma major Lupin announced the launch of its Tydemy™ Tablets (Drospirenone, Ethinyl Estradiol, Levomefolate Calcium, 3mg/0.03mg/0.451mg and Levomefolate Calcium, 0.451mg) having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Tydemy™ (Drospirenone,…
[Lupin Launches Generic Ortho Tri-Cyclen® Tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-ortho-tri-cyclen-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Norgestimate and Ethinyl Estradiol Tablets USP, 0.18 mg / 0.035 mg, 0.215 mg / 0.035 mg and 0.25 mg /…
[Lupin launches Generic Seasonale® Tablets; receives FDA approval - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-seasonale-tablets-receives-fda-approval/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches generic Seroquel XR® tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-seroquel-xr-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced the launch of its Quetiapine Fumarate Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg having received an approval from the United States Food and Drug Administration…
[Lupin Launches Generic Suprep® Bowel Prep Kit in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-suprep-bowel-prep-kit-in-the-united-states/): Mumbai, Baltimore, September 09, 2022: Global pharma major Lupin Limited (Lupin) today announced the launch of Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution, 17.5 g/3.13 g/1.6 g per 6 ounces, having received an approval from the United…
[Lupin launches generic Silodosin Capsules 4mg and 8mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-silodosin-capsules-4mg-and-8mg/): Mumbai, Baltimore: Pharma major Lupin announced the launch of Silodosin Capsules 4mg and 8mg, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Silodosin Capsules 4mg and 8mg; is the generic equivalent of…
[Lupin launches generic Tamiflu® in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-tamiflu-in-the-us/): Mumbai, Baltimore: Pharma major Lupin announced the launch of its Oseltamivir Phosphate Capsules, USP having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Oseltamivir Phosphate Capsules, USP , 30 mg (base), 45 mg…
[Lupin Launches Generic Temovate® Clobetasol Propionate Scalp Application in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-temovate-clobetasol-propionate-scalp-application-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has launched its Clobetasol Propionate Topical Solution USP, 0.05% having received an approval from the United States Food and Drug Administration (FDA) earlier to market a generic version…
[Lupin launches generic Tetrabenazine Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-tetrabenazine-tablets/): Mumbai, Baltimore: Pharma major Lupin announced the launch of Tetrabenazine Tablets, 12.5 mg and 25 mg having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Tetrabenazine Tablets, 12.5 mg and 25 mg are…
[Lupin launches generic Tobramycin Inhalation Solution USP in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-tobramycin-inhalation-solution-usp-in-the-us/): Mumbai, Baltimore: Pharma major Lupin announced the launch of its Tobramycin Inhalation Solution USP, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Tobramycin Inhalation Solution USP, 300 mg/5 ml is the generic…
[Lupin launches Generic TRICOR® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-tricor-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches Generic Trilipix® Delayed-Release Capsules 45 mg & 135 mg in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-trilipix-delayed-release-capsules-45-mg-135-mg-in-the-us/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches Generic Trizivir® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-trizivir-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches generic Topicort® LP Emollient Cream and Topicort® Cream in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-topicort-lp-emollient-cream-and-topicort-cream-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today the launch of its Desoximetasone Cream USP, 0.05% and Desoximetasone Cream USP, 0.25% having received an approval from the United States Food and Drug Administration (FDA) earlier. Desoximetasone Cream USP,…
[Lupin launches generic Vibra-Tabs® Tablet in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-vibra-tabs-tablet-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin announced the launch of its Doxycycline Hyclate Tablet USP, 100 mg having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Doxycycline Hyclate Tablet USP, 100 mg is the…
[Lupin Launches Generic Vfend® Tablets and Vfend® Oral Suspension in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-vfend-tablets-and-vfend-oral-suspension-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has launched its Voriconazole Tablets, 50 mg & 200 mg and Voriconazole Oral Suspension, 40 mg/mL having received an approval from the United States Food and Drug Administration…
[Lupin launches generic Vigamox® Ophthalmic solution in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-vigamox-ophthalmic-solution-in-the-us/): The launched product is from Lupin’s Pithampur manufacturing facility Mumbai: Pharma Major Lupin Limited (Lupin) announced the launch of its Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base) having received an approval from the United States Food and Drug…
[Lupin Launches Glucagon for Injection USP, 1mg/Vial in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-glucagon-for-injection-usp-1mg-vial-in-the-united-states/): Mumbai, Naples, August 11, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the United States. Glucagon for Injection USP, 1mg/vial packaged in an…
[Lupin launches Generic ZYMAXID™ Ophthalmic solution in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-zymaxid-ophthalmic-solution-in-the-us/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches generic Wellbutrin XL® Tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-generic-wellbutrin-xl-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today the launch of its Bupropion Hydrochloride Extended-Release tablets USP (XL), 150 mg and 300 mg having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s…
[Lupin Launches Herbal Business - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-herbal-business/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Launches Humrahi Unique Patient Support Program for Diabetes Management - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-humrahi-unique-patient-support-program-for-diabetes-management/): Mumbai, October 03, 2023: Global pharma major Lupin Limited (Lupin) announced the launch of Humrahi, a patient support program, ushering in a new era of diabetes management through adherence, behavior and transformation. India has the highest prevalence of diabetes…
[Lupin launches Hyalgan® in India Marks foray into the Orthopaedics segment - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-hyalgan-in-india-marks-foray-into-the-orthopaedics-segment/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches Hydrocodone Bitartrate and Acetaminophen tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-hydrocodone-bitartrate-and-acetaminophen-tablets-in-the-us/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today the launch of Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg having received an approval from the United States Food and Drug…
[Lupin launches Imatinib Mesylate Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-imatinib-mesylate-tablets/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Imatinib Mesylate Tablets, 100 mg (base) and 400mg (base).Lupin’s alliance partner Natco had received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. Lupin’s…
[Lupin launches Hydrocortisone Valerate Cream - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-hydrocortisone-valerate-cream/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Hydrocortisone Valerate Cream USP, 0.2%, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. Lupin’s Hydrocortisone Valerate Cream USP, 0.2%, is…
[Lupin Launches Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-ipratropium-bromide-nasal-solution-nasal-spray-0-03-and-0-06-in-the-united-states/): Mumbai, Naples, July 4, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are…
[Lupin launches India’s first chatbot for patients - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-indias-first-chatbot-for-patients/): Ahmedabad: Pharma major Lupin announced the launch of a chatbot named ‘ANYA’ specially designed to provide medically verified information for health-related queries. ANYA is the first bot of its kind to be launched in India for disease awareness. It’s…
[Lupin Launches its First Reference Laboratory in East India Establishing its Diagnostics Business in Kolkata - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-its-first-reference-laboratory-in-east-india-establishing-its-diagnostics-business-in-kolkata/): Kolkata, India, March 10, 2022: Global pharma major Lupin Limited (Lupin) announced today that Lupin Diagnostics has launched its first Reference Laboratory in East India in Kolkata. The new Reference Laboratory at Kolkata has capabilities to conduct a broad…
[Lupin launches its Oral Contraceptive DayseeTM Tablets in the US Market Generic of Seasonique® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-its-oral-contraceptive-dayseetm-tablets-in-the-us-market-generic-of-seasonique-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Launches its Regional Reference Laboratory in Guwahati, Assam - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-its-regional-reference-laboratory-in-guwahati-assam/): Expanding Diagnostics Business footprint in North East India Guwahati, India, April 29, 2022: Global pharma major Lupin Limited (Lupin) announced today that Lupin Diagnostics has launched its Regional Reference Laboratory in Guwahati in North East India. The expansion…
[Lupin Launches Leflunomide Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-leflunomide-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Leflunomide Tablets USP, 10 mg and 20 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured…
[Lupin Launches Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-loteprednol-etabonate-ophthalmic-suspension-0-5-in-the-united-states/): Mumbai, Naples, July 16, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United States. Loteprednol Etabonate Ophthalmic Suspension, 0.5% is bioequivalent to Lotemax® Ophthalmic Suspension, 0.5%, of…
[Lupin Launches Luforbec® 100/6 for Adult Asthma and COPD Treatment in Germany - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-luforbec-100-6-for-adult-asthma-and-copd-treatment-in-germany/): First-ever product launch in the inhalation segment in Germany Frankfurt, Mumbai, July 21, 2023: Hormosan Pharma GmbH (Hormosan), Lupin’s wholly-owned subsidiary in Germany, announced the launch of Luforbec®100/6 (beclometasone 100µg / for moterol 6µg), a fix combination in a…
[Lupin Launches Lurasidone Hydrochloride Tablets in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-lurasidone-hydrochloride-tablets-in-the-united-states/): Mumbai, Baltimore, February 21, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg, to market a generic equivalent of Latuda® Tablets of…
[Lupin Launches Liraglutide Injection in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-liraglutide-injection-in-the-united-states/): Mumbai, Naples, October 3, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen, in the United States. Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use…
[Lupin Launches LYFE, its Digital Therapeutic Solution for Holistic Heart Care - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-lyfe-its-digital-therapeutic-solution-for-holistic-heart-care/): Mumbai, India, January 24, 2023: Lupin Digital Health, a wholly-owned subsidiary of global pharma major Lupin Limited, today announced the launch of its digital therapeutics solution, LYFE. LYFE is India’s only evidence-based holistic heart care programme that significantly reduces…
[Lupin Launches Lapatinib Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-lapatinib-tablets/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced today the launch of Lapatinib Tablets, 250 mg, after Lupin’s alliance partner Natco Pharma Ltd received final approval for its ANDA from the United States Food and Drug Administration (U.S….
[Lupin Launches ‘Jan Kovid’ Helpline for Mumbai Citizens - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-jan-kovid-helpline-for-mumbai-citizens/): Mumbai, India: Pharma major Lupin Limited (Lupin) today announced the launch of the ‘Jan Kovid’ Helpline (1800-572-6130) under the tagline ‘Mann Ka Swaasthya, Tann Ki Suraksha’ for the residents of Mumbai. Seeking medical help during the lockdown poses…
[Lupin Launches Jeet, a Patient Support Program to Raise Awareness of Cardiovascular Disease Among Patients - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-jeet-a-patient-support-program-to-raise-awareness-of-cardiovascular-disease-among-patients/): Program to focus on Cardiovascular disease and associated co-morbid conditions Rewards-based patient support program for medication and heart-healthy lifestyle adherence Mumbai, August 16, 2023: Global pharma major Lupin Limited (Lupin) announced the launch of Jeet, its patient support program…
[Lupin Launches Merzee® Capsules in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-merzee-capsules-in-the-united-states/): Mumbai, Baltimore, April 07, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has launched Merzee® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg, in the US market, under exclusive license, marketing…
[Lupin launches Moxifloxacin Ophthalmic Solution USP 0.5% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-moxifloxacin-ophthalmic-solution-usp-0-5/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Moxifloxacin Ophthalmic Solution USP, 0.5%, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin’s…
[Lupin launches Molnupiravir under the brand name Molnulup for the treatment of COVID-19 in adults in India - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-molnupiravir-under-the-brand-name-molnulup-for-the-treatment-of-covid-19-in-adults-in-india/): Clinical data suggests that it is effective on patients with co-morbidities Mumbai, India, January 07, 2022: Global pharma major Lupin Limited (Lupin) announced the launch of Molnupiravir in India under the brand name Molnulup. This drug has been…
[Lupin launches Mycophenolate Mofetil Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-mycophenolate-mofetil-tablets-usp/): Mumbai, Baltimore: Lupin Limited (Lupin), global pharmaceutical company, announced today the launch of Mycophenolate Mofetil Tablets USP, 500 mg, after Lupin’s alliance partner Concord Biotech Limited (Concord) received an approval for its ANDA from the United States Food and…
[LuaLupin launches Mycophenolic Acid Delayed-Release Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-mycophenolic-acid-delayed-release-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg. Lupin’s alliance partner Concord Biotech Limited (Concord) had received an approval from the United States Food and…
[Lupin launches novel cholesterol-fighter EZEDOC - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-novel-cholesterol-fighter-ezedoc-2/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches Mycophenolate Mofetil Capsules USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-mycophenolate-mofetil-capsules-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Mycophenolate Mofetil Capsules USP, 250 mg. Lupin’s alliance partner Concord Biotech Limited (Concord) had received an approval from the United States Food and Drug Administration (U.S. FDA)…
[Lupin Launches Minzoya TM (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets) in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-minzoya-tm-levonorgestrel-and-ethinyl-estradiol-tablets-usp-and-ferrous-bisglycinate-tablets-in-the-united-states/): Mumbai, Naples, January 13, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of MinzoyaTM (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets), 0.1 mg/0.02 mg and 36.5 mg in the United States, after having…
[Lupin Launches Mirabegron Extended-Release Tablets in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-mirabegron-extended-release-tablets-in-the-united-states/): Mumbai, Naples, April 20, 2024: Global pharma major Lupin Limited (Lupin) today announced the launch of Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S….
[Lupin Launches Mirabegron Extended-Release Tablets in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-mirabegron-extended-release-tablets-in-the-united-states-2/): Mumbai, Naples, September 04, 2024: Global pharma major Lupin Limited (Lupin) today announced the launch of Mirabegron Extended-Release Tablets, 50 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S….
[Lupin Launches novel fixed-dose triple drug combination DIFIZMA® DPI to Treat Inadequately Controlled Asthma - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-novel-fixed-dose-triple-drug-combination-difizma-dpi-to-treat-inadequately-controlled-asthma/): Mumbai, January 05, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of a novel fixed-dose triple drug combination (FDC) of Indacaterol, Glycopyrronium and Mometasone for managing inadequately controlled asthma amongst patients. The company has launched this…
[Lupin launches novel cholesterol-fighter EZEDOC - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-novel-cholesterol-fighter-ezedoc/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Launches Novel Injectable Iron Formulation Under Brand Names “ISOFER” and “JILAZO” in India - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-novel-injectable-iron-formulation-under-brand-names/): Acquires exclusive marketing rights from Pharmacosmos A/S, Denmark Mumbai: Pharma major Lupin Limited (Lupin) announced today that it has launched a novel Iron Isomaltoside 1000 injectable iron formulation under two brand names “ISOFER” and “JILAZO” in India. Lupin…
[Lupin Launches Paliperidone Extended-Release Tablets in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-paliperidone-extended-release-tablets-in-the-united-states/): Mumbai, Baltimore, October 20, 2022: Global pharma major Lupin Limited (Lupin) today announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg, to market a generic equivalent of Invega® Extended-Release Tablets, 1.5 mg,…
[Lupin Launches Penicillamine Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-penicillamine-tablets-usp/): Mumbai, Baltimore: Global pharma major Lupin Limited (Lupin) today announced the launch of Penicillamine Tablets USP, 250 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. Penicillamine Tablets USP, 250 mg,…
[Lupin Launches Posaconazole Delayed-Release Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-posaconazole-delayed-release-tablets/): Mumbai, Baltimore: Global pharma major Lupin Limited (Lupin) today announced the launch of Posaconazole Delayed-Release Tablets, 100 mg, after its alliance partner AET Pharma US Inc. (part of Tiefenbacher Group) received an approval for its ANDA from the United…
[Lupin Launches Propranolol Long-Acting Capsules to Improve Heart Health in Canada - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-propranolol-long-acting-capsules-to-improve-heart-health-in-canada/): Montreal, Canada, August 29, 2023 – Lupin Pharma Canada Ltd., a wholly-owned subsidiary of Lupin Limited (Lupin), today announced the launch of Propranolol LA (long-acting) capsules, 60 mg, 80 mg, 120 mg and 160 mg, in Canada. Propranolol LA…
[Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-rivaroxaban-tablets-usp-2-5mg-in-the-united-states/): Mumbai, Naples, March 07, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the U.S. FDA. Rivaroxaban Tablets USP,…
[Lupin Launches Rocuronium Bromide Injection in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-rocuronium-bromide-injection-in-the-united-states/): Mumbai, Baltimore, November 08, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of Rocuronium Bromide Injection, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) Multiple-Dose Vials, after Lupin’s alliance partner Caplin Steriles Limited…
[Lupin Launches Prucalopride Tablets in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-prucalopride-tablets-in-the-united-states/): Mumbai, Naples, June 26, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of Prucalopride Tablets, 1 mg, and 2 mg, in the United States, following the recent approval of its Abbreviated New Drug Application (ANDA)…
[Lupin Launches Rivaroxaban for Oral Suspension in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-rivaroxaban-for-oral-suspension-in-the-united-states/): Mumbai, Naples, October 1, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States. Rivaroxaban for Oral Suspension, 1 mg/mL is bioequivalent to Xarelto® for Oral Suspension,…
[Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™ - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-risperidone-long-acting-injectable-with-180-day-cgt-exclusivity-in-the-u-s-the-first-product-from-its-proprietary-long-acting-injectable-platform-precisionsphere/): Mumbai, November 14, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, Single-Dose Vials, with 180-day CGT exclusivity…
[Lupin Launches Rufinamide Oral Suspension in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-rufinamide-oral-suspension-in-the-united-states/): Mumbai, Baltimore, June 23, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of Rufinamide Oral Suspension, 40 mg/mL to market a generic equivalent of Banzel® Oral Suspension, 40 mg/mL of Eisai Inc. Rufinamide Oral Suspension (RLD…
[Lupin Launches Rymti® Biosimilar Etanercept in Canada - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-rymti-biosimilar-etanercept-in-canada/): Rymti® is Lupin’s first biosimilar launch in Canada Rymti® is approved for all indications of the reference product Enbrel® Rymti® is available as an injectable in an easy-to-use pre-filled pen and a pre-filled syringe The approval of Rymti®…
[Lupin Launches Rufinamide Tablets USP in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-rufinamide-tablets-usp-in-the-united-states/): Mumbai, Baltimore, December 05, 2022: Global pharma major Lupin Limited (Lupin) today announced the launch of Rufinamide Tablets USP, 200 mg and 400 mg, to market a generic equivalent of Banzel® Tablets, 200 mg and 400 mg, of Eisai…
[Lupin launches Sciflix a mobile-friendly learning platform for post graduate students specializing in pulmonology - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-sciflix-a-mobile-friendly-learning-platform-for-post-graduate-students-specializing-in-pulmonology/): Mumbai, India, November 30, 2021: Global pharma major Lupin Limited (Lupin) announced today the launch of Sciflix, an educational mobile adaptable website for medical students who are pursuing post-graduation with chest specialization. Curated by Lupin for clinical enhancement, Sciflix…
[Lupin Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-sacubitril-and-valsartan-combination-drug-for-heart-failure-patients/): Mumbai, India, January 18, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of combination drug Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in India. This drug combination is indicated for patients with Heart…
[Lupin Launches Sildenafil for Oral Suspension in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-sildenafil-for-oral-suspension-in-the-united-states/): Mumbai, Baltimore, September 29, 2022: Global pharma major Lupin Limited (Lupin) today announced the launch of Sildenafil for Oral Suspension, 10 mg/mL, having received an approval from the United States Food and Drug Administration (FDA). Sildenafil for Oral Suspension,…
[Lupin Launches Sevelamer Hydrochloride Tablets in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-sevelamer-hydrochloride-tablets-in-the-united-states/): Mumbai, Baltimore, March 01, 2022: Global pharma major Lupin Limited (Lupin) today announced the launch of Sevelamer Hydrochloride Tablets, 800 mg, having received an approval from the United States Food and Drug Administration (FDA). The product will be manufactured…
[Lupin Launches Second Edition of Aptivate Champion Run for Kids Promoting Children’s Well-being Through Fitness and Nutrition - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-second-edition-of-aptivate-champion-run-for-kids-promoting-childrens-well-being-through-fitness-and-nutrition/): Mumbai, January 08, 2024: Lupin Life, the consumer healthcare business of global pharma major Lupin Limited (Lupin), today announced the second edition of the Aptivate Champion Run for Kids scheduled on January 14, 2024, at MMRDA Grounds, Bandra Kurla…
[Lupin launches Sildenafil Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-sildenafil-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. Lupin’s Sildenafil…
[Lupin launches Solosec™ (secnidazole) 2g Oral Granules in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-solosec-secnidazole-2g-oral-granules-in-the-us/): First and only single-dose oral therapy for bacterial vaginosis – the most common vaginal infection – approved by the U.S. FDA in 2017 Mumbai, Baltimore: Pharma major Lupin announced the launch of Solosec™ (secnidazole) 2g oral granules in…
[Lupin Launches Softovac Liquifibre, a first-of-its-kind liquid fibre - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-softovac-liquifibre-a-first-of-its-kind-liquid-fibre/): Mumbai, December 21, 2023: Lupin Life, the consumer healthcare business of global pharma major, Lupin Limited (Lupin) today announced the launch of Softovac Liquifibre, a 100% Ayurvedic liquid laxative. With this, the company enters the Indian liquid laxative market…
[Lupin Launches SUPRAX ®400 mg Tablets in the US - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-suprax-400-mg-tablets-in-the-us/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin launches Tadalafil Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-tadalafil-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Tadalafil…
[Lupin launches Tacrolimus Capsules USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-tacrolimus-capsules-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced today the launch of Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg, after Lupin’s alliance partner Concord Biotech Limited (Concord) received an approval for its ANDA from the United…
[Lupin Launches Tavaborole Topical Solution in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-tavaborole-topical-solution-in-the-united-states/): Mumbai, Baltimore, July 13, 2021: Global pharma major Lupin Limited (Lupin) today announced the U.S. launch of Tavaborole Topical Solution, 5% having received an approval from the United States Food and Drug Administration (FDA). The product will be…
[Lupin launches Testosterone Gel - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-testosterone-gel/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), having received an approval from the United States Food and Drug Administration (FDA). Lupin’s Testosterone Gel, 1.62% (20.25 mg/1.25 g…
[Lupin Launches Thiamine Hydrochloride Injection USP in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-thiamine-hydrochloride-injection-usp-in-the-united-states/): Mumbai, Baltimore, June 19, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of Thiamine Hydrochloride Injection USP, 200 mg/2 mL (100 mg/mL) Multiple-dose Vials,after Lupin’s alliance partner Caplin Steriles Limited (Caplin) received an approval for its…
[Lupin Launches Tolvaptan Tablets in the U.S. with 180-Day Exclusivity - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-tolvaptan-tablets-in-the-u-s-with-180-day-exclusivity/): Mumbai, Naples, May 13, 2025: Following the recent approval received from the United States Food and Drug Administration (U.S. FDA), global pharma major Lupin Limited (Lupin) today announced the launch of Tolvaptan Tablets, 15 mg, 30 mg, 45…
[Lupin Launches Tiotropium Dry Powder Inhaler for the Treatment of COPD in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-tiotropium-dry-powder-inhaler-for-the-treatment-of-copd-in-the-united-states/): Mumbai, Baltimore, August 16, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, for the treatment of chronic obstructive pulmonary disease (COPD) in the US. Tiotropium Bromide Inhalation Powder, 18…
[Lupin Launches Turqoz®(Norgestrel and Ethinyl Estradiol) Tablets USP in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-turqoznorgestrel-and-ethinyl-estradiol-tablets-uspin-the-united-states/): Mumbai, Baltimore, December 01, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of Turqoz® (Norgestrel and Ethinyl Estradiol) Tablets USP,0.3 mg/0.03 mg, after having received an approval from the United States Food and Drug Administration (U.S….
[Lupin Launches Varenicline Tablets in the United States - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-varenicline-tablets-in-the-united-states/): Mumbai, Baltimore, January 10, 2024: Global pharma major Lupin Limited (Lupin) today announced the launch of Varenicline Tablets, 0.5 mg and 1 mg,after having received an approval from the United States Food and Drug Administration (U.S. FDA). Varenicline Tablets,…
[Lupin Launches World’s First Fixed-dose Triple Combination Drug, Vilfuro-G® for COPD Management in India - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-worlds-first-fixed-dose-triple-combination-drug-vilfuro-g-for-copd-management-in-india/): Mumbai, November 23, 2023: Global pharma major Lupin Limited (Lupin) announced that it has launched the world’s first fixed-dose triple combination drug (FDC) under the brand name Vilfuro-G® for the effective management of chronic obstructive pulmonary disease (COPD) in…
[Lupin Launches Zaxine® in Canada - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-zaxine-in-canada/): Mumbai, Montreal: Pharma Major Lupin Limited announced today that its Canadian subsidiary, Lupin Pharma Canada Limited (collectively Lupin) has launched its first Brand product Zaxine® under a strategic licensing agreement with the North Carolina based GI specialty company Salix…
[Lupin launchesGeneric Geodon® Capsules Receives final FDA Approval for its Generic Geodon® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launchesgeneric-geodon-capsules-receives-final-fda-approval-for-its-generic-geodon-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Launches Zileuton Extended-Release Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launches-zileuton-extended-release-tablets/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Zileuton Extended-Release Tablets, 600 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin’s Nagpur…
[Lupin launchesGeneric SEROQUEL® Tablets Receives final FDA Approval for its Generic SEROQUEL® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-launchesgeneric-seroquel-tablets-receives-final-fda-approval-for-its-generic-seroquel-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin LCTL Divestment - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-lctl-divestment/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin licenses us rights for proprietary bioadhesive technology for rifaximin to salix pharmaceuticals - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-licenses-us-rights-for-proprietary-bioadhesive-technology-for-rifaximin-to-salix-pharmaceuticals/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Life announces association with Vikram Vedha as official energy partner with its Be One health and wellness supplement - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-life-announces-association-with-vikram-vedha-as-official-energy-partner-with-its-be-one-health-and-wellness-supplement/): Mumbai, India, October 1, 2022: Lupin Life, the consumer healthcare arm of global pharma major, Lupin Limited, today announced the association of Be One, Lupin’s 100% Ayurvedic health and wellness supplement, as the official Energy-Partner for Vikram Vedha, the…
[Lupin Limited places US $ 100 million Foreign Currency Convertible Bonds - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-limited-places-us-100-million-foreign-currency-convertible-bonds/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Limited – Quarter I Results, FY2016 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-limited-quarter-i-results-fy2016/): Mumbai: Pharma Major Lupin Limited reported its performance for the first quarter ending 30th June, 2015. These unaudited results were taken on record by the Board of Directors at a meeting in Mumbai today. Key financial & performance highlights…
[Lupin Limited – Quarter II Results, FY2016 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-limited-quarter-ii-results-fy2016/): Mumbai: Pharma Major Lupin Limited reported its performance for the second quarter ending 30th September, 2015. These unaudited results were taken on record by the Board of Directors at a meeting in Mumbai today. Key financial & performance highlights…
[Lupin makes a hearty entry into Guinness World Records Creates awareness on monitoring heart rate as an indicator of overall health - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-makes-a-hearty-entry-into-guinness-world-records-creates-awareness-on-monitoring-heart-rate-as-an-indicator-of-overall-health/): Mumbai, India, October 24, 2021: Global pharma major Lupin Limited (Lupin) has achieved a significant milestone by setting a new GUINNESS WORLD RECORDS™ title for creating the Largest book sentence. The title was developed with 4,921 book copies to display…
[Lupin Makes an Acquisition in Germany - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-makes-an-acquisition-in-germany/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Limited – Quarter III Results, FY2016 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-limited-quarter-iii-results-fy2016/): Mumbai: Pharma Major Lupin Limited reported its performance for the third quarter ending 31st December, 2015. These unaudited results were taken on record by the Board of Directors at a meeting in Mumbai today. Key financial & performance highlights…
[Lupin Manufacturing Solutions Unveils Dedicated Oncology Block at Vizag, India - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-manufacturing-solutions-unveils-dedicated-oncology-block-at-vizag-india/): Expanding Global CDMO Capabilities New facility strengthens High Potent API development and manufacturing for Oncology Products Mumbai, November 12, 2025: Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of global pharma major Lupin Limited (Lupin), today announced the commissioning of…
[Lupin named amongst AON Best Employers India 2016 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-named-amongst-aon-best-employers-india-2016/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it was recognized as AON Best Employers India 2016. Lupin is the only pharmaceutical company on the list this year and part of 25 organizations to feature on the list….
[Lupin Net Profit up 38 % – Q3, FY 2009-10 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-net-profit-up-38-q3-fy-2009-10/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Net Profit up 77% at Rs. 400 mn; Net Sales up 10% at Rs. 2629 mn;Debt Equity Ratio improves to 0.85:1 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-net-profit-up-77-at-rs-400-mn-net-sales-up-10-at-rs-2629-mndebt-equity-ratio-improves-to-0-851/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Net Profit up by 25 % in Q1, FY 2009-10 Outpacing and Outperforming Markets globally - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-net-profit-up-by-25-in-q1-fy-2009-10-outpacing-and-outperforming-markets-globally/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Net Profit up by 34 % in Q2, FY 2010-11 Robust Growth, Strong Profits - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-net-profit-up-by-34-in-q2-fy-2010-11-robust-growth-strong-profits/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Net Profit up by 39 % in Q3, FY 2010-11 Sustained Growth, Strong Profits. - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-net-profit-up-by-39-in-q3-fy-2010-11-sustained-growth-strong-profits/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Net Profit up by 40 % in Q1, FY 2010-11 Consistent Growth, Strong Profits - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-net-profit-up-by-40-in-q1-fy-2010-11-consistent-growth-strong-profits/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Net Sales up 10% at Rs. 2,796 mn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-net-sales-up-10-at-rs-2796-mn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-neurosciences-announces-positive-chmp-opinion-for-namuscla/): Zug, Mumbai: Lupin Neurosciences, a specialty pharma division of Lupin Ltd, today announces that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the…
[Lupin Partners with Global Agencies to Increase Patient Access to Tuberculosis Prevention Treatment - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-partners-with-global-agencies-to-increase-patient-access-to-tuberculosis-prevention-treatment/): Makes Rifapentine based treatment available at an affordable price to support TB prevention in low-and middle-income countries Mumbai, October 7, 2022: Global pharma major, Lupin Limited (Lupin) announced that it has reached an agreement with Unitaid, The Aurum Institute,…
[Lupin Partners with TTP plc UK for Soft-mist Inhalation Technology Platform - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-partners-with-ttp-plc-uk-for-soft-mist-inhalation-technology-platform/): Mumbai, Somerset, New Jersey, December 02, 2021: Lupin Inc., a wholly-owned subsidiary of global pharma major, Lupin Limited (Lupin) has entered into an agreement with TTP plc (The Technology Partnership plc) to acquire the exclusive worldwide rights to develop,…
[Lupin Pharma Canada Announces Partnership with Endoceutics for the commercialization of Intrarosa® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-pharma-canada-announces-partnership-with-endoceutics-for-the-commercialization-of-intrarosa/): Brings to the Canadian market the first prescription drug for the local treatment of postmenopausal vulvovaginal atrophy, a long-awaited innovation in women’s health. Mumbai, Quebec, Canada: Lupin Pharma, a subsidiary of global pharma major Lupin Ltd, today announced a…
[Lupin Pharmaceuticals, Inc. and Cornerstone BioPharma, Inc.Enter Co-Promotion Agreement for Suprax® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-pharmaceuticals-inc-and-cornerstone-biopharma-inc-enter-co-promotion-agreement-for-suprax/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-pharmaceuticals-inc-issues-voluntary-recall-of-ceftriaxone-for-injection-usp-250mg-500mg-1g-and-2g/): BALTIMORE–(BUSINESS WIRE)– Lupin Pharmaceuticals, Inc. is voluntarily recalling 5 lots of Ceftriaxone for Injection, USP, 250mg, 10 lots of Ceftriaxone for Injection, USP, 500mg, 24 lots of Ceftriaxone for Injection, USP, 1g and 3 lots of Ceftriaxone for Injection,…
[Lupin PR – Lupin Launches InspiraChamber Anti-Static Valved Holding Chamber_ Expands US Brands Portfolio - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-pr-lupin-launches-inspirachamber-anti-static-valved-holding-chamber_-expands-us-brands-portfolio/): Mumbai, Baltimore: Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched the all new InspiraChamber® Anti-Static Valved Holding Chamber (VHC) under a strategic licensing agreement with the New Jersey based respiratory…
[Lupin promoters, Newbridge call off discussions - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-promoters-newbridge-call-off-discussions/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Presents Phase 3 Data for Solosec® (secnidazole) Demonstrating Significant Response Rate in Female Patients with Trichomoniasis - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-presents-phase-3-data-for-solosec-secnidazole-demonstrating-significant-response-rate-in-female-patients-with-trichomoniasis/): Results presented at the 2020 Infectious Diseases Society for Obstetrics & Gynecology (IDSOG) Virtual Annual Meeting Single-dose treatment with Solosec®resulted in a highly statistically significant response rate, or microbiological cure, in 92-95% of patients versus 1.5-1.7% in placebo…
[Lupin Q1 FY 2003-04 net profit up 38% at Rs 280.6 mn; sales up 23% at Rs 2,769 mn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q1-fy-2003-04-net-profit-up-38-at-rs-280-6-mn-sales-up-23-at-rs-2769-mn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Q1 FY03 sales at Rs 2514 million, up 8%; net up 26% at Rs 203 million - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q1-fy03-sales-at-rs-2514-million-up-8-net-up-26-at-rs-203-million/): ● Exports up 51% at Rs 923 million contributing 37% of total Q1 revenues. Exports to advanced markets more than double ● Profit before tax rises by 50% to Rs 266 million ● 2 ANDAs filed for Cefixime dry…
[Lupin Q2 FY 08-09 – Strong Performance & Strategic Growth - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q2-fy-08-09-strong-performance-strategic-growth/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Q2 FY 2003-04 net profit before extraordinary items at Rs.518 mn,up 86%; sales up 36% at Rs 3609 mn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q2-fy-2003-04-net-profit-before-extraordinary-items-at-rs-518-mnup-86-sales-up-36-at-rs-3609-mn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Q1 FY2024 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q1-fy2024-results/): Mumbai, August 03, 2023: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending June 30, 2023. These unaudited results were taken on record by the Board of Directors at a meeting…
[Lupin Q1 FY2023 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q1-fy2023-results/): Mumbai, August 03, 2022: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending June 30, 2022. These unaudited results were taken on record by the Board of Directors at a meeting…
[Lupin Q1 FY2025 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q1-fy2025-results/): Mumbai, August 06, 2024: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending June 30, 2024. The unaudited results were taken on record by the Board of Directors at a meeting…
[Lupin Q1 FY2026 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q1-fy2026-results/): Mumbai, August 05, 2025: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending June 30, 2025. These unaudited results were taken on record by the Board of Directors at a…
[Lupin Q2 FY2023 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q2-fy2023-results/): Mumbai, November 09, 2022: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending Sept 30, 2022. These unaudited results were taken on record by the Board of Directors at a meeting…
[Lupin Q2 FY2024 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q2-fy2024-results/): Mumbai, November 08, 2023: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending September 30, 2023. These unaudited results were taken on record by the Board of Directors at a meeting…
[Lupin Q2 FY2025 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q2-fy2025-results/): Mumbai, November 07, 2024: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending September 30, 2024. The unaudited results were taken on record by the Board of Directors at a meeting…
[Lupin Q2 FY2026 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q2-fy2026-results/): Mumbai, November 06, 2025: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending September 30, 2025. These unaudited results were taken on record by the Board of Directors at a meeting…
[Lupin Q2 Net Profit up 39% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q2-net-profit-up-39/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Q2 sales up 23% at Rs. 2,985 mn; profit before tax up 35% at Rs. 353 mn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q2-sales-up-23-at-rs-2985-mn-profit-before-tax-up-35-at-rs-353-mn/): ● Total exports increase by 47% to Rs. 939 mn ● Exports to advanced markets at Rs. 266 mn ● ANDA filed with USFDA for Cefuroxime Axetil Tablets ● First IND filing for anti-migraine molecule LLL 2011 BSE: 500257…
[Lupin Q2FY06 Net Profit Soars 158% to Rs. 452 million - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q2fy06-net-profit-soars-158-to-rs-452-million/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Q3 FY 08-09 – Strong Growth & Consistent Performance - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q3-fy-08-09-strong-growth-consistent-performance/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Q3 FY0708 Consolidated Net Profit up 192% to Rs. 1809 Mn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q3-fy0708-consolidated-net-profit-up-192-to-rs-1809-mn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Q3 FY2023 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q3-fy2023-results/): Mumbai, February 09, 2023: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending Dec 31, 2022 today. These unaudited results were taken on record by the Board of Directors at a…
[Lupin Q3 FY2024 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q3-fy2024-results/): Mumbai, February 07, 2024: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending December 31, 2023. These unaudited results were taken on record by the Board of Directors at a…
[Lupin Q3 sales up 19% at Rs. 2868 mn; net profit up 23% at Rs. 227mn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q3-sales-up-19-at-rs-2868-mn-net-profit-up-23-at-rs-227mn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Q3 FY2025 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q3-fy2025-results/): Mumbai, February 12, 2025: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending December 31, 2024. The unaudited results were taken on record by the Board of Directors at a meeting…
[Lupin Q4 & FY 2008-09 Results – Consistent Performance & Solid Growth - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q4-fy-2008-09-results-consistent-performance-solid-growth/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Q3 FY2020 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q3-fy2020-results/): Mumbai: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter and nine monthsended December 31, 2019. These results were taken on record by the Board of Directors at a meeting held in…
[Lupin Q4 FY2021 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q4-fy2021-results/): Mumbai: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter and fiscal year ending March 31, 2021. These audited results were taken on record by the Board of Directors at a meeting…
[Lupin Q4 FY2024 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q4-fy2024-results/): Mumbai, May 06, 2024: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter and fiscal year ending March 31, 2024. These audited results were taken on record by the Board of Directors…
[Lupin Q4 FY2023 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-q4-fy2023-results/): Mumbai, May 09, 2023: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter and fiscal year ending March 31, 2023. These audited results were taken on record by the Board of Directors…
[Lupin Quarter I, FY 2020 – Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-quarter-i-fy-2020-results/): Mumbai: Pharma major Lupin Limited reported its financial performance for the first quarter ending June 30, 2019. These results were taken on record by the Board of Directors at a meeting held in Mumbai today. Key Financial & Performance…
[Lupin Quarter 1 FY2021 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-quarter-1-fy2021-results/): Mumbai: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending June 30, 2020. These unaudited results were taken on record by the Board of Directors at a meeting held today. Financial…
[Lupin Quarter I FY2022 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-quarter-i-fy2022-results/): Mumbai, August 10, 2021: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending June 30, 2021. These unaudited results were taken on record by the Board of Directors at a…
[Lupin Quarter II, FY2018 – Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-quarter-ii-fy2018-results/): Mumbai: Pharma Major Lupin Limited reported its financial performance for the second quarter ending September 30th, 2017. These results were taken on record by the Board of Directors at a meeting held in Mumbai today. Key Financial & Performance…
[Lupin Quarter 3 FY2022 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-quarter-3-fy2022-results/): Mumbai, February 3, 2022: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending December 31, 2021. These unaudited results were taken on record by the Board of Directors at a meeting…
[Lupin Quarter II, FY 2020 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-quarter-ii-fy-2020-results/): Mumbai: Pharma major Lupin Limited reported its financial performance for the quarter and six months ended September 30, 2019. These results were taken on record by the Board of Directors at a meeting held in Mumbai today. Key…
[Lupin Quarter II, FY2019 – Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-quarter-ii-fy2019-results/): Mumbai: Pharma major Lupin Limited reported its financial performance for the second quarter and six months ended September 30th, 2018. These results were taken on record by the Board of Directors at a meeting held in Mumbai today….
[Lupin Quarter II FY2021 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-quarter-ii-fy2021-results/): Mumbai: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending September 30, 2020. These unaudited results were taken on record by the Board of Directors at a meeting held today. Financial…
[Lupin Quarter III, FY2019 – Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-quarter-iii-fy2019-results/): Mumbai: Pharma major Lupin Limited reported its financial performance for the quarter ended December 31st, 2018. These results were taken on record by the Board of Directors at a meeting held in Mumbai today. Key Financial & Performance Highlights…
[Lupin – Ranbaxy Sign TB deal - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-ranbaxy-sign-tb-deal/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Quarter III Results, FY201 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-quarter-iii-results-fy201/): Sales up 31.5%, EBITDA up 44.6% and Net profits up 20.7% Mumbai: Pharma Major Lupin Limited reported its performance for the third quarter ending December 31st, 2016. These results were taken on record by the Board of Directors at…
[Lupin Quarter III, FY2018 – Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-quarter-iii-fy2018-results/): Mumbai: Pharma Major Lupin Limited reported its financial performance for the third quarter ending December 31st, 2017. These results were taken on record by the Board of Directors at a meeting held in Mumbai today. Key Financial & Performance…
[Lupin Raises Awareness about Mental Health by Partnering with Singer Shaan to Relaunch the Iconic Song ‘Tanha Dil Tanha Safar’ - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-raises-awareness-about-mental-health-by-partnering-with-singer-shaan-to-relaunch-the-iconic-song-tanha-dil-tanha-safar/): Mumbai, India: With the objective of raising awareness about mental health, global pharma major Lupin Limited (Lupin) announced that it is partnering with Shaan, famous Indian playback singer, for the re-launch of Shaan’s iconic hit song, ‘Tanha Dil Tanha…
[Lupin Quarter II FY2022 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-quarter-ii-fy2022-results/): Mumbai, October 27, 2021: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending September 30, 2021. These unaudited results were taken on record by the Board of Directors at a…
[Lupin Receives “A-” Leadership Rating from CDP in Two Categories – Climate Change and Water Security - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-a-leadership-rating-from-cdp-in-two-categories-climate-change-and-water-security/): Mumbai, February 19, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received an “A-” leadership rating from CDP for its outstanding performance in climate change and water security. This rating reflects Lupin’s leadership in environmental…
[Lupin Receives Approval for Acotiamide Tablets to Treat Functional Dyspepsia - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-acotiamide-tablets-to-treat-functional-dyspepsia/): First-in-class product for the Indian market Mumbai: Pharmaceutical Major Lupin Limited (Lupin) announced today that it has received approval for Acotiamide 100 mg Tablets from the Central Drugs Standard Control Organisation (CDSCO). Lupin shall commence promoting the product…
[Lupin Quarter III FY2021 Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-quarter-iii-fy2021-results/): Mumbai: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending December 31, 2020. These unaudited results were taken on record by the Board of Directors at a meeting held today. Financial…
[Lupin Receives Approval for Albendazole Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-albendazole-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Albendazole Tablets USP, 200 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Albenza® Tablets, 200 mg,…
[Lupin receives approval for Bepotastine Tablets – a new second generation Antihistamine - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-bepotastine-tablets/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received approval for Bepotastine Tablets from the Central Drugs Standard Control Organisation (CDSCO). Lupin shall commence promoting the product in India shortly. Bepotastine is a new second generation…
[Lupin receives approval for Betamethasone Dipropionate Ointment USP (Augmented) - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-betamethasone-dipropionate-ointment-usp-augmented/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Diprolene®…
[Lupin Receives Approval For Conducting Phase II Trials For LLL-3348 (Desoris) - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-conducting-phase-ii-trials-for-lll-3348-desoris/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives Approval for Droxidopa Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-droxidopa-capsules/): Mumbai, Baltimore, February 19, 2021: Global pharma major Lupin Limited (Lupin) today announced that it has received approval for its Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, from the United States Food and Drug Administration, to market…
[Lupin Q1 FY06 Net Profit doubles to Rs. 432 million - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-colesevelam-hydrochloride-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives Approval for Dimethyl Fumarate Delayed-Release Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-dimethyl-fumarate-delayed-release-capsules/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent…
[Lupin Receives Approval for Generic Albuterol Sulphate MDI - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-generic-albuterol-sulphate-mdi/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced today that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Albuterol Sulfate Inhalation Aerosol, 90 mcg (base)/actuation, a generic version of ProAir® HFA….
[Lupin receives approval for Leflunomide Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-leflunomide-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Leflunomide Tablets USP, 10 mg and 20 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent…
[Lupin Receives Approval for Meloxicam Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-meloxicam-capsules/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Meloxicam Capsules, 5 mg and 10 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Vivlodex® Capsules,…
[Lupin Receives Approval for Sevelamer Carbonate Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-sevelamer-carbonate-tablets/): Mumbai, Baltimore: Lupin Limited (Lupin), global pharmaceutical company, announced today that it has received approval for its Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration, to market a generic equivalent of Renvela® Tablets, 800…
[Lupin Receives Approval for Rufinamide Oral Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-rufinamide-oral-suspension/): Mumbai, Baltimore: Lupin Limited (NSE: Lupin), global pharmaceutical company, announced today that it has received approval for its Rufinamide Oral Suspension, 40 mg/mL, from the United States Food and Drug Administration, to market a generic equivalent of Banzel® Oral…
[Lupin Receives Approval for Sulfamethoxazole and Trimethoprim Oral Suspension USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-sulfamethoxazole-and-trimethoprim-oral-suspension-usp/): Mumbai, Baltimore: Lupin Limited (Lupin), global pharmaceutical company, announced today that it has received approval for its Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, from the United States Food and Drug Administration, to market…
[Lupin Receives Approval for Tavaborole Topical Solution - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-tavaborole-topical-solution/): Mumbai, Baltimore: Global pharma major Lupin Limited (Lupin) today announced that it has received approval for its Tavaborole Topical Solution, 5%, from the United States Food and Drug Administration, to market a generic equivalent of Kerydin® Topical Solution, 5%,…
[Lupin Receives Approval from U.S. FDA for Arformoterol Tartrate Inhalation Solution15 mcg (base)/2 ml - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-arformoterol-tartrate-inhalation-solution15-mcg-base-2-ml/): Mumbai, Baltimore, February 08, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Arformoterol Tartrate Inhalation Solution 15…
[Lupin Receives Approval from U.S. FDA for Allopurinol Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-allopurinol-tablets/): Mumbai, Baltimore, December 15,2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Allopurinol Tablets USP, 100 mg…
[Lupin Receives Approval for Trientine Hydrochloride Capsules USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-for-trientine-hydrochloride-capsules-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Trientine Hydrochloride Capsules USP, 250 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Syprine® Capsules,…
[Lupin Receives Approval from U.S. FDA for Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-abacavir-dolutegravir-and-lamivudine-tablets-for-oral-suspension/): Mumbai, Naples, January 24, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) under the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)…
[Lupin Receives Approval from TGA Australia for Tiotropium Dry Powder for Inhaler for Treatment of COPD - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-tga-australia-for-tiotropium-dry-powder-for-inhaler-for-treatment-of-copd/): Mumbai, Melbourne, July 26, 2023: Global pharma major Lupin Limited (Lupin) announced today that its wholly owned subsidiary in Australia, Generic Health Pty Ltd, has received approval for Tiotropium 18 micrograms powder for inhalation in capsules for use with…
[Lupin Receives Approval from U.S. FDA for Aripiprazole Tablets, USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-aripiprazole-tablets-usp/): Mumbai, Baltimore, March 19, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Aripiprazole Tablets USP, 2…
[Lupin Receives Approval from U.S. FDA for Azilsartan Medoxomil Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-azilsartan-medoxomil-tablets/): Mumbai, Baltimore, July 25, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Azilsartan Medoxomil Tablets, 40 mg…
[Lupin Receives Approval from U.S. FDA for Brimonidine Tartrate Ophthalmic Solution, 0.1% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-brimonidine-tartrate-ophthalmic-solution-0-1/): Mumbai, Naples, August 27, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Brimonidine Tartrate Ophthalmic Solution,…
[Lupin Receives Approval from U.S. FDA for Brivaracetam Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-brivaracetam-tablets/): Mumbai, Baltimore, December 21, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Brivaracetam Tablets, 10…
[Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.07% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-bromfenac-ophthalmic-solution-0-07/): Mumbai, Baltimore, November 23,2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Bromfenac Ophthalmic Solution, 0.07%, to…
[Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-bromfenac-ophthalmic-solution-0-075/): Mumbai, Baltimore, February 06, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Bromfenac Ophthalmic Solution, 0.075%,…
[Lupin Receives Approval from U.S. FDA for Cyanocobalamin Nasal Spray - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-cyanocobalamin-nasal-spray/): Mumbai, Baltimore, July03, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Cyanocobalamin Nasal Spray,500 mcg/spray(One Spray…
[Lupin Receives Approval from U.S. FDA for Chlorpromazine Hydrochloride Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-chlorpromazine-hydrochloride-tablets-usp/): Mumbai, Baltimore, July 14, 2023: Global pharma major Lupin Limited (Lupin) today announced that its wholly-owned subsidiary, Lupin Inc., based in Somerset, New Jersey, has received approval from the United States Food and Drug Administration (U.S. FDA) for its…
[Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.09% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-bromfenac-ophthalmic-solution-0-09/): Mumbai, Baltimore, August 16, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Bromfenac Ophthalmic Solution, 0.09%,…
[Lupin Receives Approval from U.S. FDA for Bumetanide Injection, USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-bumetanide-injection-usp/): Mumbai, Naples, September 18, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Bumetanide Injection USP,…
[Lupin Appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-darunavir-tablets-2/): Mumbai, Baltimore, October 6, 2022: Global pharma major Lupin Limited (Lupin) today announced the appointment of Dr. Shahin Fesharaki as Global Chief Scientific Officer. Dr. Fesharaki will be responsible for Lupin’s global research and development efforts across branded, generics…
[Lupin Receives Approval from U.S. FDA for Darunavir Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-darunavir-tablets/): Mumbai, Baltimore, October 4, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Darunavir Tablets, 600…
[Lupin Receives Approval from U.S. FDA for Desvenlafaxine Extended-Release Tablets 25 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-desvenlafaxine-extended-release-tablets-25-mg/): Mumbai, Baltimore, April 14, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Desvenlafaxine Extended-Release Tablets, 25 mg…
[Lupin Receives Approval from U.S. FDA for Diazepam Rectal Gel - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-diazepam-rectal-gel/): Mumbai, Baltimore, June01, 2023: Global pharma major Lupin Limited (Lupin) today announced that its wholly-owned subsidiary, Novel Laboratories Inc., based in Somerset, New Jersey, has received approval from the United States Food and Drug Administration (U.S. FDA) for its…
[Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-diclofenac-sodium-topical-solution-usp-2-w-w/): Mumbai, Baltimore, September 22, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Diclofenac Sodium Topical Solution USP,…
[Lupin Receives Approval from U.S. FDA for Doxycycline for Injection USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-doxycycline-for-injection-usp/): Mumbai, Baltimore, March 15, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Doxycycline for Injection USP,…
[Lupin Receives Approval from U.S. FDA for Doxycycline Hyclate Delayed-Release Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-doxycycline-hyclate-delayed-release-tablets-usp/): Mumbai, Baltimore, August 14, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Doxycycline Hyclate Delayed-Release Tablets…
[Lupin Receives Approval from U.S. FDA for Efinaconazole Topical Solution - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-efinaconazole-topical-solution/): Mumbai, Baltimore, March 03, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Efinaconazole Topical Solution, 10%to market…
[Lupin Receives Approval from U.S. FDA for Emtricitabine and Tenofovir Alafenamide Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-emtricitabine-and-tenofovir-alafenamide-tablets/): Mumbai, Naples, July 31, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) under the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)…
[Lupin Receives Approval from U.S. FDA for Emtricitabine and Tenofovir Alafenamide Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-emtricitabine-and-tenofovir-alafenamide-tablets-2/): Being the first to file, Lupin is eligible for 180-day shared generic exclusivity Mumbai, Naples, December 18, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration…
[Lupin Receives Approval from U.S. FDA for Dronedarone Tablets, USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-dronedarone-tablets-usp/): Mumbai, Baltimore, February 01, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dronedarone Tablets USP, 400…
[Lupin Receives Approval from U.S. FDA for Eslicarbazepine Acetate Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-eslicarbazepine-acetate-tablets/): Mumbai, Naples, March 28, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Eslicarbazepine Acetate Tablets,…
[Lupin Receives Approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-fesoterodine-fumarate-extended-release-tablets/): Mumbai, Baltimore, January 06, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Fesoterodine Fumarate Extended-Release Tablets, 4…
[Lupin Receives Approval from U.S. FDA for Febuxostat Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-febuxostat-tablets/): Mumbai, Baltimore, January 18, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Febuxostat Tablets, 40 mg…
[Lupin Receives Approval from U.S.FDA for Fluconazole Tablets, USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-fluconazole-tablets-usp/): Mumbai, Baltimore, October 23, 2023: Global pharma major Lupin Limited (Lupin) today announced that ithas received approval from the United States Food and Drug Administration (U.S.FDA) for its Abbreviated New Drug Application for Fluconazole Tablets USP, 50 mg, 100…
[Lupin Receives Approval from U.S. FDA for Fluocinolone Acetonide Body Oil - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-fluocinolone-acetonide-body-oil/): Mumbai, Baltimore, August 08, 2023: Global pharma major Lupin Limited (Lupin) today announced that its wholly-owned subsidiary, Novel Laboratories Inc., based in Somerset, New Jersey, has received approval from the United States Food and Drug Administration (U.S. FDA) for…
[Lupin Receives Approval from U.S. FDA for Fluocinolone Acetonide Topical Oil - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-fluocinolone-acetonide-topical-oil/): Mumbai, Baltimore, August 02, 2023: Global pharma major Lupin Limited (Lupin) today announced that its wholly-owned subsidiary, Novel Laboratories Inc., based in Somerset, New Jersey, has received approval from the United States Food and Drug Administration (U.S. FDA) for…
[Lupin Receives Approval from U.S. FDA for Iloperidone Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-iloperidone-tablets/): Mumbai, Baltimore, May 06, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Iloperidone Tablets, 1 mg, 2…
[Lupin Receives Approval from U.S. FDA for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-ipratropium-bromide-nasal-solution-nasal-spray-0-03/): Mumbai, Naples, February 10, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal…
[Lupin Receives Approval from U.S.FDA for Ganirelix Acetate Injection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-ganirelix-acetate-injection/): Mumbai, Baltimore, November 17, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S.FDA) for its Abbreviated New Drug Application for Ganirelix Acetate Injection, 250 mcg/0.5…
[Lupin Receives Approval from U.S. FDA for Formoterol Fumarate Inhalation Solution - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-formoterol-fumarate-inhalation-solution/): Mumbai, Baltimore, August 24, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Formoterol Fumarate Inhalation Solution, 20…
[Lupin Receives Approval from U.S. FDA for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.06% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-ipratropium-bromide-nasal-solution-nasal-spray-0-06/): Mumbai, Naples, January 28, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal…
[Lupin Receives Approval from U.S. FDA for Lenalidomide Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-lenalidomide-capsules/): Mumbai, Naples, September 17, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Lenalidomide Capsules, 2.5 mg,…
[Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-loteprednol-etabonate-ophthalmic-gel/): Being the exclusive first-to-file, Lupin is eligible for 180-day generic exclusivity Mumbai, Naples, July 1, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S….
[Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.5% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-loteprednol-etabonate-ophthalmic-suspension-0-5/): Mumbai, Naples, April 25, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension,…
[Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.2% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-loteprednol-etabonate-ophthalmic-suspension-0-2/): Mumbai, Baltimore, December 27, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension,…
[Lupin Receives Approval from U.S. FDA for Meclizine Hydrochloride Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-meclizine-hydrochloride-tablets-usp/): Mumbai, Baltimore, August 12, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Meclizine Hydrochloride Tablets USP, 12.5…
[Lupin Receives Approval from U.S. FDA for Midostaurin Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-midostaurin-capsules/): Mumbai, Naples, May 16, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Midostaurin Capsules, 25 mg,…
[Lupin Receives Approval from U.S. FDA for Metoprolol Succinate Extended-Release Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-metoprolol-succinate-extended-release-tablets-usp/): Mumbai, Baltimore, August 16, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Metoprolol Succinate Extended-Release Tablets…
[Lupin Receives Approval from U.S. FDA for Minzoya (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets) - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-minzoya-tm-levonorgestrel-and-ethinyl-estradiol-tablets-usp-and-ferrous-bisglycinate-tablets/): Mumbai, Baltimore, February 16,2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for MinzoyaTM (Levonorgestrel and Ethinyl Estradiol…
[Lupin Receives Approval from U.S. FDA for Mirabegron Extended-Release Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-mirabegron-extended-release-tablets/): Mumbai, Baltimore, September 29, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Mirabegron Extended-Release Tablets, 25 mg…
[Lupin Receives Approval from U.S. FDA for Obeticholic Acid Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-obeticholic-acid-tablets/): Mumbai, Baltimore, May31, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Obeticholic Acid Tablets, 5 mg…
[Lupin Receives Approval from U.S. FDA for Mixed Salts of a Single-Entity Amphetamine Extended-Release Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-mixed-salts-of-a-single-entity-amphetamine-extended-release-capsules/): Mumbai, Naples, November 19, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Dextroamphetamine Saccharate, Amphetamine…
[Lupin Receives Approval from U.S. FDA for Paliperidone Extended-Release Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-paliperidone-extended-release-tablets/): Mumbai, Baltimore, June 30, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Paliperidone Extended-Release Tablets 1.5 mg,…
[Lupin Receives Approval from U.S. FDA for Pirfenidone Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-pirfenidone-capsules/): Mumbai, Baltimore, August 29, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Pirfenidone Capsules, 267 mg,…
[Lupin Receives Approval from U.S. FDA for Pirfenidone Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-pirfenidone-tablets/): Mumbai, Baltimore, August 25, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Pirfenidone Tablets, 267 mg…
[Lupin Receives Approval from U.S. FDA for Pitavastatin Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-pitavastatin-tablets/): Mumbai, Baltimore, November 21,2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S.FDA) for its Abbreviated New Drug Application for Pitavastatin Tablets, 1 mg, 2 mg,…
[Lupin Receives Approval from U.S. FDA for Prasugrel Tablets, USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-prasugrel-tablets-usp/): Mumbai, Baltimore, January 10, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA), Prasugrel Tablets USP, 5…
[Lupin Receives Approval from U.S. FDA for Prednisolone Acetate Ophthalmic Suspension USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-prednisolone-acetate-ophthalmic-suspension-usp/): Lupin was granted Competitive Generic Therapy designation for this product Being the first approved applicant, Lupin is eligible for 180daysof CGT exclusivity Mumbai, Naples, August 5,2024: Global pharma major Lupin Limited (Lupin) today announced that it has received…
[Lupin Receives Approval from U.S. FDA for Pregabalin Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-pregabalin-capsules/): Mumbai, Baltimore, May 06, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Pregabalin Capsules, 25 mg, 50…
[Lupin Receives Approval from U.S. FDA for Propranolol Hydrochloride Extended-Release Capsules USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-propranolol-hydrochloride-extended-release-capsules-usp/): Mumbai, Baltimore, January 14, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Propranolol Hydrochloride Extended-Release Capsules…
[Lupin Receives Approval from U.S. FDA for Prucalopride Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-prucalopride-tablets/): Mumbai, Naples, June 25, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Prucalopride Tablets, 1…
[Lupin Receives Approval from U.S. FDA for Rivaroxaban for Oral Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-rivaroxaban-for-oral-suspension/): Mumbai, Naples, September 30, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Rivaroxaban for Oral Suspension,…
[Lupin Receives Approval from U.S. FDA for Raltegravir Tablets USP, 600 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-raltegravir-tablets-usp-600-mg/): Being the exclusive first-to-file, Lupin is eligible for 180-day generic exclusivity Mumbai, Naples, May 8, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S….
[Lupin Receives Approval from U.S. FDA for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-rivaroxaban-tablets-usp-10-mg-15-mg-and-20-mg/): Mumbai, Naples, May 15, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Rivaroxaban Tablets USP, 10…
[Lupin Receives Approval from U.S. FDA for Rufinamide Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-rufinamide-tablets-usp/): Mumbai, Baltimore, August 18, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Rufinamide Tablets USP, 100 mg,…
[Lupin Receives Approval from U.S. FDA for Sevelamer Carbonate for Oral Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-sevelamer-carbonate-for-oral-suspension/): Approval from Lupin’s Goa Facility Mumbai, Baltimore, December 25, 2021: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application…
[Lupin Receives Approval from U.S. FDA for Sildenafil for Oral Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-sildenafil-for-oral-suspension/): Mumbai, Baltimore, March 24, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Sildenafil for Oral Suspension, 10…
[Lupin Receives Approval from U.S. FDA for Tenofovir Alafenamide Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-tenofovir-alafenamide-tablets/): Mumbai, Baltimore, March 31, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Tenofovir Alafenamide Tablets,25 mg,…
[Lupin Receives Approval from U.S. FDA for Tiotropium Dry Powder Inhaler - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-tiotropium-dry-powder-inhaler/): Mumbai, Baltimore, June21, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Tiotropium Bromide Inhalation Powder, 18…
[Lupin Receives Approval from U.S. FDA for Tolvaptan Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-tolvaptan-tablets/): Being the exclusive first-to-file, Lupin is eligible for 180-day generic exclusivity Mumbai, Naples, April 24, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S….
[Lupin Receives Approval from U.S. FDA for Topiramate Extended-Release Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-topiramate-extended-release-capsules/): Mumbai, Naples, July 12, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Topiramate Extended-Release Capsules, 25…
[Lupin Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-travoprost-ophthalmic-solution-usp/): Mumbai, Naples, May 06, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Travoprost Ophthalmic Solution USP,…
[Lupin Receives Approval from U.S. FDA for Valbenazine Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-valbenazine-capsules/): Being the first to file, Lupin is eligible for 180-day shared generic exclusivity Mumbai, Naples, April 8,2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S….
[Lupin Receives Approval from U.S. FDA for Varenicline Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-varenicline-tablets/): Mumbai, Baltimore, December 06, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Varenicline Tablets, 0.5 mg…
[Lupin Receives Approval from US FDA for Brexpiprazole Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-us-fda-for-brexpiprazole-tablets/): Mumbai, Baltimore, March 21, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Brexpiprazole Tablets, 0.25 mg,…
[Lupin Receives Approval from U.S. FDA for Vigabatrin for Oral Solution USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-vigabatrin-for-oral-solution-usp/): Mumbai, Baltimore, March 11, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Vigabatrin for Oral Solution USP,…
[Lupin Receives Approval from US FDA for Glycopyrrolate Injection, USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-us-fda-for-glycopyrrolate-injection-usp/): First Approval from Lupin’s injectable facility in Nagpur Mumbai, Baltimore, February 09, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated…
[Lupin Receives Approval from US FDA for Turqoz® (Norgestrel and Ethinyl Estradiol Tablets USP) - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-approval-from-us-fda-for-turqoz-norgestrel-and-ethinyl-estradiol-tablets-usp/): Mumbai, Baltimore, August 01, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Turqoz® (Norgestrel and Ethinyl…
[Lupin Receives “Best New Manufacturer of the Year” Award fromAmerisourceBergen - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-best-new-manufacturer-of-the-year-award-fromamerisourcebergen/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives DCGI Approval to conduct Combined Phase IIb/III Clinical Trials for it’s herbal Psoriasis NCE - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-dcgi-approval-to-conduct-combined-phase-iib-iii-clinical-trials-for-its-herbal-psoriasis-nce/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives DCGI approval to conduct Phase II Clinical Trials for Psoriasis NCE - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-dcgi-approval-to-conduct-phase-ii-clinical-trials-for-psoriasis-nce/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives EIR for Pharmacovigilance inspection from the U.S. FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-for-pharmacovigilance-inspection-from-the-u-s-fda/): Mumbai: Pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for the Post-marketing Adverse Drug Experience (PADE) inspection, indicating successful closure of…
[Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-aurangabad-csn-facility/): Mumbai, November 12, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Chhatrapati Sambhajinagar (Aurangabad) facility, following a product-specific Pre-Approval…
[Lupin Receives EIR from U.S. FDA for its Dabhasa Facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-dabhasa-facility/): Mumbai, India, July 12, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility located in Dabhasa,…
[Lupin Receives EIR from U.S. FDA for its Aurangabad Manufacturing Facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-aurangabad-manufacturing-facility/): Mumbai, Naples, April 23, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Aurangabad manufacturing facility. The inspection…
[Lupin Receives EIR from U.S. FDA for its Mandideep Unit-2 Manufacturing Facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-mandideep-unit-2-manufacturing-facility/): Mumbai, October 31, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Mandideep Unit-2 manufacturing facility. The EIR was issued post…
[Lupin Receives EIR from U.S. FDA for its Nagpur Unit-1 Manufacturing Facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-nagpur-unit-1-manufacturing-facility/): Mumbai, September 29, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Nagpur Unit-1 manufacturing facility that manufactures oral solid dosage…
[Lupin Receives EIR from U.S. FDA for its Pithampur Unit-1 Facility with VAI Classification - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-pithampur-unit-1-facility-with-vai-classification/): Mumbai, January 8, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Pithampur Unit-1 manufacturing facility that manufactures both APIs and…
[Lupin Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-pithampur-unit-2-manufacturing-facility/): Mumbai, July 11, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Pithampur Unit-2 manufacturing facility that manufactures oral solids and…
[Lupin Receives EIR from U.S. FDA for its Pithampur Unit-3 Facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-pithampur-unit-3-facility/): Mumbai, November 5, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Pithampur Unit-3 facility, following an inspection from July…
[Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-somerset-manufacturing-facility/): Mumbai, June 22, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey, with a…
[Lupin receives EIR from US FDA for Aurangabad, April 2017 Inspection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-us-fda-for-aurangabad-april-2017-inspection/): Mumbai: Pharma Major Lupin Limited (Lupin) announced that it has received notification that the inspection carried out by the US FDA in April 2017 at its Aurangabad facility is now closed and the agency has issued an Establishment Inspection…
[Lupin receives EIR from US FDA for Goa, July 2015 Inspection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-us-fda-for-goa-july-2015-inspection/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received notification that the inspection carried out by the US FDA in July 2015 at its Goa facility is now closed and the agency has issued an Establishment…
[Lupin receives EIR from US FDA for Goa, March 2016 Inspection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-us-fda-for-goa-march-2016-inspection/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received notification that the inspection carried out by the US FDA in March 2016 at its Goa facility is now closed and the agency has issued an Establishment…
[Lupin Receives EIR from US FDA for its API Manufacturing Facility in Vizag - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-us-fda-for-its-api-manufacturing-facility-in-vizag/): Mumbai, June 19, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its API manufacturing facility located in Visakhapatnam (Vizag),…
[Lupin Receives EIR from US FDA for its Injectable Facility in Nagpur - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-us-fda-for-its-injectable-facility-in-nagpur-2/): Mumbai, April 17, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA), for drug-medical device combination products at its injectable facility in Nagpur, India….
[Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-somerset-manufacturing-facility-2/): Mumbai, February 21, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey,…
[Lupin Receives EIR from US FDA for its Injectable Facility in Nagpur - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-eir-from-us-fda-for-its-injectable-facility-in-nagpur/): Mumbai, February 17, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its new injectable facility located in Nagpur, India. The EIR…
[Lupin receives FDA approval for Atorvastatin Calcium Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-atorvastatin-calcium-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, from the United States Food and Drug Administration (FDA) to market a generic…
[Lupin receives FDA approval for Azacitidine for Injection, 100 mg Single-Dose Vial - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-azacitidine-for-injection-100-mg-single-dose-vial/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Azacitidine for Injection, 100 mg Single-Dose Vial from the United States Food and Drug Administration (FDA) to market a generic version of Celgene Corporation’s Vidaza®. With…
[Lupin receives FDA approval for Budesonide Inhalation Suspension, 0.5 mg/2 mL - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-budesonide-inhalation-suspension-0-5-mg-2-ml/): Mumbai, Baltimore:Pharma major Lupin announced that it has received approval for its Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules from the United States Food and Drug Administration (FDA) to market a generic version of AstraZeneca Pharmaceuticals LP’s (AstraZeneca)…
[Lupin receives FDA approval for Clobazam Oral Suspension, 2.5 mg/mL - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-clobazam-oral-suspension-2-5-mg-ml/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Clobazam Oral Suspension, 2.5 mg/mL from the United States Food and Drug Administration (FDA) to market a generic version of Lundbeck Pharmaceuticals LLC’s Onfi Oral Suspension,…
[Lupin receives FDA approval for Clomipramine HCl Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-clomipramine-hcl-capsules/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg from the United States Food and Drug Administration (FDA) to market a generic version of…
[Lupin receives FDA approval for Decitabine for Injection, 50 mg/vial, Single-Dose Vial - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-decitabine-for-injection-50-mg-vial-single-dose-vial/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Decitabine for Injection, 50 mg/vial, Single-Dose Vial from the United States Food and Drug Administration (FDA) to market a generic version of Otsuka Pharmaceutical Co. Ltd.’s…
[Lupin receives FDA approval for Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-doxercalciferol-injection-4-mcg-2-ml-2-mcg-ml-multi-dose-vials/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials from the United States Food and Drug Administration (FDA) to market a generic version of Sanofi Genzyme’s…
[Lupin receives FDA approval for Fluocinonide Topical Solution - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-fluocinonide-topical-solution/): Mumbai: Pharma Major Lupin Limited (Lupin) announced that it has received final approval for its Fluocinonide Topical Solution USP, 0.05% from the United States Food and Drug Administration (FDA) to market a generic version of County Line Pharmaceuticals, LLC’s…
[Lupin receives FDA approval for Famotidine for Oral Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-famotidine-for-oral-suspension/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for Fluoxetine Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-fluoxetine-tablets-usp-2/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Fluoxetine Tablets USP, 60mg, from the United States Food and Drug Administration (FDA) to market a generic version of Alvogen’s Fluoxetine Tablets, 60mg. Lupin’s Fluoxetine Tablets…
[Lupin receives FDA approval for Fluoxetine Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-fluoxetine-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Fluoxetine Tablets USP, 10 mg and 20 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Eli…
[Lupin receives FDA approval for generic Acticlate® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-acticlate-tablets/): Mumbai: Pharma Major Lupin announced that it has received final approval for its Doxycycline Hyclate Tablets USP, 75 mg and 150 mg from the United States Food and Drug Administration (FDA) to market a generic version of Aqua Pharmaceuticals,…
[Lupin Receives FDA Approval for Generic Activella® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-activella-tablets/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Amabelz™ Tablets (Estradiol and Norethindrone Acetate Tablets USP, 0.5 mg / 0.1 mg and 1 mg / 0.5 mg) from the United States Food…
[Lupin Receives FDA Approval for Generic Ambien CR® Extended-release Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-ambien-cr-extended-release-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for generic Ancobon® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-ancobon-capsules/): Mumbai: Pharma Major Lupin Limited (Lupin) announced that it has received final approval for its Flucytosine Capsules USP, 250 mg and 500 mg from the United States Food and Drug Administration (FDA) to market a generic version of Valeant…
[Lupin receives FDA Approval for Generic Aricept® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-aricept-tablets/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Donepezil Hydrochloride Tablets, 23 mg from the United States Food and Drug Administration (FDA) to market a generic version of Eisai Inc.’s…
[Lupin receives FDA approval for Generic Avapro® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-avapro-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for generic Axiron® topical solution - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-axiron-topical-solution/): Mumbai: Pharma Major Lupin announced that it has received final approval for its Testosterone Topical Solution, 30 mg per actuation from the United States Food and Drug Administration (FDA) to market a generic version of Eli Lilly and Company’s…
[Lupin Receives FDA Approval for Generic Actos® Tablets. - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-actos-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for Fenofibrate Tablets, 54 mg and 160 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-fenofibrate-tablets-54-mg-and-160-mg/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced today that it has received final approval for its Fenofibrate Tablets 54 mg and 160 mg from the United States Food and Drugs Administration (FDA) to market a generic version of…
[Lupin receives FDA approval for generic Atovaquone Oral Solution USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-atovaquone-oral-solution-usp/): Mumbai: Pharma major Lupin announced that it has received approval for its Atovaquone Oral Suspension USP, 750 mg/5 mL from the United States Food and Drug Administration (FDA) to market a generic version of GlaxoSmithKline LLC’s Mepron Oral Suspension,…
[Lupin receives FDA approval for generic Benicar® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-benicar-tablets/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg from the United States Food and Drug Administration (FDA) to market generic version…
[Lupin Receives FDA Approval for Generic Celebrex® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-celebrex-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for generic Clobex® Lotion - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-clobex-lotion/): Mumbai: Pharma Major Lupin announced that it has received final approval for its Clobetasol Propionate Lotion, 0.05% from the United States Food and Drug Administration (FDA) to market a generic version of Galderma Laboratories, L.P.’s Clobex® Lotion, 0.05%. Lupin’s…
[Lupin receives FDA approval for generic Clobex® Spray, 0.05% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-clobex-spray-0-05/): Mumbai, Baltimore: Pharma major Lupin announced that it has received final approval for its Clobetasol Propionate Spray, 0.05% from the United States Food and Drug Administration (FDA) to market a generic version of Galderma Laboratories, L.P.’s Clobex® Spray, 0.05%….
[Lupin receives FDA approval for generic Corgard® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-corgard-tablets/): Mumbai: Pharma Major Lupin announced that it has received final approval for its Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg from the United States Food and Drug Administration (FDA) to market a generic version of US…
[Lupin receives FDA approval for generic Crestor® tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-crestor-tablets/): Mumbai: Pharma Major Lupin Limited (Lupin) announced that it has received final approval for its Rosuvastatin Calcium Tablets 5 mg, 10 mg, 20 mg and 40 mg from the United States Food and Drug Administration (FDA) to market a…
[Lupin receives FDA approval for generic Dovonex Scalp Solution - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-dovonex-scalp-solution/): Mumbai: Pharma Major Lupin announced that it has received final approval for its Calcipotriene Topical Solution, 0.005% (Scalp Solution) from the United States Food and Drug Administration (FDA) to market a generic version of Dovonex Scalp Solution, 0.005% of…
[Lupin receives FDA approval for generic Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-drospirenone-ethinyl-estradiol/): Mumbai, Baltimore: Pharma major Lupin announced that it has received final approval for its Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, from the United States Food and Drug Administration…
[Lupin Receives FDA Approval for Generic Evoxac® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-evoxac-capsules/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Cevimeline Hydrochloride Capsules, 30 mg from the United States Food and Drug Administration (FDA) to market a generic version of Daiichi Sankyo Inc’s…
[Lupin receives FDA approval for generic Gabapentin Tablets USP, 600 mg and 800 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-gabapentin-tablets-usp-600-mg-and-800-mg/): Mumbai, Baltimore: Pharma major Lupin announced that it has received final approval for its Gabapentin Tablets USP, 600 mg and 800 mg from the United States Food and Drug Administration (FDA) to market a generic version of Pfizer Inc.’s…
[Lupin receives FDA approval for generic Flagyl® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-flagyl-tablets/): Mumbai: Pharma Major Lupin announced that it has received final approval for its Metronidazole Tablets USP, 250 mg and 500 mg from the United States Food and Drug Administration (FDA) to market a generic version of G.D. Searle LLC’s…
[Lupin Receives FDA Approval for Generic Epivir® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-epivir-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for generic Hydroxychloroquine Sulfate Tablets USP, 200 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-hydroxychloroquine-sulfate-tablets-usp-200-mg/): Mumbai, Baltimore: Pharma major Lupin announced that it has received final approval for its Hydroxychloroquine Sulfate Tablets USP, 200 mg from the United States Food and Drug Administration (FDA) to market a generic version of Concordia Pharmaceuticals, Inc.’s Plaquenil…
[Lupin receives FDA approval for generic Hydrocortisone Butyrate Lotion, 0.1% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-hydrocortisone-butyrate-lotion-0-1/): Mumbai, Baltimore: Pharma major Lupin announced that it has received final approval for its Hydrocortisone Butyrate Lotion, 0.1% from the United States Food and Drug Administration (FDA) to market a generic version of PreCision Dermatology, Inc.’s (PreCision) Locoid Lotion,…
[Lupin Receives FDA Approval for Generic Generess® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-generes-tablets/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced that it has received final approval for its KaitlibTM Fe Tablets (Norethindrone and Ethinyl Estradiol Chewable Tablets, 0.8 mg/0.025 mg and Ferrous Fumarate Chewable Tablets, 75 mg) from the United States…
[Lupin receives FDA approval for generic Kapvay® Extended-Release Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-kapvay-extended-release-tablets/): Mumbai: Pharma Major Lupin announced that it has received final approval for its Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg from the United States Food and Drug Administration (FDA) to market a generic version of Concordia Pharmaceuticals Inc.’s Kapvay® Extended-Release…
[Lupin Receives FDA Approval for Generic Klor-Con® Extended-Release Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-klor-con-extended-release-tablets/): Mumbai: Pharma Major Lupin Limited announced today that its US subsidiary, Gavis Pharmaceuticals LLC., U.S.A. (collectively Lupin) has received final approval for its Potassium Chloride Extended-Release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the…
[Lupin Receives FDA Approval for Generic Generess® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-generess-tablets/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) has received final approval for its FyavolvTM Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/0.0025 mg and 1 mg/0.005 mg) from the United States Food and Drug Administration (FDA) to…
[Lupin receives FDA approval for Generic KEPPRA® Oral Solution 100 mg / ml - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-keppra-oral-solution-100-mg-ml/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for generic Lidex® Ointment - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-lidex-ointment/): Mumbai: Pharma Major Lupin Limited (Lupin) announced that it has received final approval for its Fluocinonide Topical Ointment USP, 0.05% from the United States Food and Drug Administration (FDA) to market a generic version of County Line Pharmaceuticals, LLC’s…
[Lupin receives FDA approval for Generic Lexapro® Tablets e® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-lexapro-tablets-e-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for generic Lodosyn® tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-lodosyn-tablets/): Mumbai: Pharma Major Lupin announced that it has received final approval for its Carbidopa Tablets, 25 mg from the United States Food and Drug Administration (FDA) to market a generic version of Aton Pharma, Inc.’s Lodosyn® Tablets, 25 mg….
[Lupin Receives FDA Approval for Generic Paxil CR® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-paxil-cr-tablets/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Paroxetine Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg from the United States Food and Drug Administration (FDA) to market…
[Lupin Receives FDA Approval for Generic Nuvigil® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-nuvigil-tablets/): The filing is from Lupin’s Goa manufacturing facility Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary Lupin Pharmaceuticals, Inc. (LPI) has received final approval for its Armodafinil Tablets 50 mg, 150 mg, 200…
[Lupin Receives FDA Approval for Generic Ortho-Cyclen® 28 Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-ortho-cyclen-28-tablets/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for Norgestimate and Ethinyl Estradiol Tablets USP, 0.25 mg/0.035 mg from the United States Food and Drug Administration (FDA) to market a generic version of…
[Lupin Receives FDA Approval for Generic Loestrin®24 Fe Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-loestrin24-fe-tablets/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Blisovi 24 Fe Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) from the…
[Lupin Receives FDA Approval for Generic Mycobutin® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-mycobutin-capsules-2/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives FDA Approval for Generic Monodox® Capsules and Cipro® for Oral Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-monodox-capsules-and-cipro-for-oral-suspension/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives FDA Approval for Generic Namenda XR® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-namenda-xr-capsules/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Memantine Hydrochloride Extended-Release Capsules, 7 mg, 14 mg, 21 mg, and 28 mg from the United States Food and Drug Administration (FDA)…
[Lupin receives FDA approval for generic Nitrofurantoin Capsules USP (Macrocrystals), 50 mg and 100 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-nitrofurantoin-capsules-usp/): Mumbai, Baltimore: Pharma major Lupin announced that it has received final approval for its Nitrofurantoin Capsules USP (Macrocrystals), 50 mg and 100 mg from the United States Food and Drug Administration (FDA) to market a generic version of Alvogen…
[Lupin Receives FDA Approval for Generic Norco® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-norco-tablets/): Mumbai: Pharma Major Lupin Limited announced today that Lupin Somerset (also known as Novel Laboratories, Inc.) has received final approval for its Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg from…
[Lupin Receives FDA Approval for Generic Mycobutin® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-mycobutin-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives FDA Approval for Generic Percocet® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-percocet-tablets/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Oxycodone and Acetaminophen Tablets USP, 2.5 mg/325 mg, 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg from the United States Food…
[Lupin receives FDA approval for generic Potassium Chloride Oral Solution USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-potassium-chloride-oral-solution-usp/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10%) and 40 mEq/15 mL (20%) from the United States Food and Drug Administration (FDA) to market a…
[Lupin receives FDA Approval for Generic Prilosec® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-prilosec-capsules/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Omeprazole Delayed-Release capsules 40 mg from the United States Food and Drugs Administration (FDA) to market a generic version of AstraZeneca Pharmaceuticals LP…
[Lupin receives FDA Approval for Generic Ranexa® Extended-release Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-ranexa-extended-release-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for generic Roxicodone® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-roxicodone-tablets/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Oxycodone Hydrochloride Tablets USP, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg from the United States Food and Drug Administration…
[Lupin Receives FDA Approval for Generic Rifadin® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-rifadin-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives FDA Approval for Generic Suprep® Bowel Prep Kit - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-suprep-bowel-prep-kit/): Lupin is eligible for 180 days of generic drug exclusivity Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate Oral Solution, 17.5 g/3.13 g/1.6…
[Lupin receives FDA approval for generic Safyral Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-safyral-tablets/): Mumbai: Pharma Major Lupin announced that it has received final approval for its Tydemy (Drospirenone, Ethinyl Estradiol, and Levomefolate Calcium Tablets, 3 mg/0.03 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg) from the United States Food and Drug Administration…
[Lupin receives FDA Approval for Generic SOLODYN® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-solodyn-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for generic Seroquel XR® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-seroquel-xr-tablets/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Quetiapine Fumarate Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg from the United States Food and Drug Administration…
[Lupin receives FDA approval for generic Tamiflu® for Oral Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-tamiflu-for-oral-suspension/): Mumbai, Baltimore: Pharma major Lupin announced that it has received final approval for its Oseltamivir Phosphate for Oral Suspension from the United States Food and Drug Administration (FDA) to market the generic version of Hoffman-La Roche, Inc.’s Tamiflu for…
[Lupin receives FDA approval for generic Tamiflu Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-tamiflu-capsules/): Mumbai: Pharma Major Lupin announced that it has received final approval for its Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) from the United States Food and Drug Administration (FDA) to market a…
[Lupin receives FDA approval for generic Temovate Cream, 0.05% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-temovate-cream-0-05/): Mumbai: Pharma major Lupin announced that it has received final approval for its Clobetasol Propionate Cream USP, 0.05% from the United States Food and Drug Administration (FDA) to market a generic version of Fougera Pharmaceuticals Inc.’s Temovate Cream, 0.05%….
[Lupin receives FDA approval for generic Temovate Ointment, 0.05% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-temovate-ointment-0-05/): Mumbai, Baltimore: Pharma major Lupin announced that it has received final approval for its Clobetasol Propionate Ointment USP, 0.05% from the United States Food and Drug Administration (FDA) to market a generic version of Fougera Pharmaceuticals Inc.’s Temovate Ointment, 0.05%….
[Lupin Receives FDA Approval for Generic TOBI® Inhalation Solution - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-tobi-inhalation-solution/): Lupin’s first generic approval in the Inhalation space Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Tobramycin Inhalation Solution USP, 300 mg/5 ml from the United States Food and Drug…
[Lupin Receives FDA Approval for Generic Topicort® LP Emollient Cream, 0.05% and Topicort® Cream, 0.25% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-topicort-lp-emollient-cream-0-05-and-topicort-cream-0-25/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Desoximetasone Cream USP, 0.05% and Desoximetasone Cream USP, 0.25% from the United States Food and Drug Administration (FDA) to market a generic equivalent…
[Lupin Receives FDA Approval for Generic Topicort® Ointment, 0.05% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-topicort-ointment-0-05/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Desoximetasone Ointment USP, 0.05% from the United States Food & Drug Administration (FDA) to market a generic version of Taro Pharms North’s…
[Lupin receives FDA approval for generic Topicort Topical Spray, 0.25% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-topicort-topical-spray-0-25/): Mumbai, Baltimore: Pharma major Lupin announced that it has received final approval for its Desoximetasone Topical Spray, 0.25%, 30 ml, 50 ml, and 100 ml from the United States Food and Drug Administration (FDA) to market a generic version…
[Lupin receives FDA approval for generic Triamcinolone Acetonide Ointment USP, 0.1% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-triamcinolone-acetonide-ointment-usp-0-1/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Triamcinolone Acetonide Ointment USP, 0.1% from the United States Food and Drug Administration (FDA) to market a generic version of Mylan Pharmaceuticals, Inc.’s (Mylan) Triamcinolone Acetonide…
[Lupin Receives FDA Approval for Generic Trizivir® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-trizivir-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives FDA Approval for Generic Vancocin® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-vancocin-capsules/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Vancomycin Hydrochloride Capsules, 125 mg and 250 mg from the United States Food and Drugs Administration (FDA) to market a generic version…
[Lupin receives FDA approval for generic Vibra-Tabs® Tablet - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-vibra-tabs-tablet/): Mumbai: Pharma Major Lupin announced that it has received final approval for its Doxycycline Hyclate Tablet USP, 100 mg from the United States Food and Drug Administration (FDA) to market a generic version of Pfizer Inc.’s Vibra-Tabs®, 100 mg….
[Lupin receives FDA approval for generic Wellbutrin XL® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-wellbutrin-xl-tablets/): The filing is from Lupin’s Goa manufacturing facility Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Bupropion Hydrochloride Extended-Release tablets USP (XL), 150 mg and 300 mg from the United…
[Lupin receives FDA approval for generic Xenazine® Tablets, 12.5 mg and 25 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-xenazine-tablets-12-5-mg-and-25-mg/): Mumbai, Baltimore: Pharma major Lupin announced that it has received final approval for its Tetrabenazine Tablets, 12.5 mg and 25 mg from the United States Food and Drug Administration (FDA) to market a generic version of Valeant Pharmaceuticals North…
[Lupin Receives FDA Approval for Generic Zyvox® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-zyvox-tablets/): Mumbai: Pharma Major Lupin Limited announced today that its US subsidiary, Gavis Pharmaceuticals LLC., U.S.A. (collectively Lupin) has received final approval for its Linezolid® Tablets, 600 mg from the United States Food and Drug Administration (FDA) to market a…
[Lupin Receives FDA Approval for Hydrocodone Bitartrate and Acetaminophen Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-hydrocodone-bitartrate-and-acetaminophen-tablets/): Mumbai: Pharma Major Lupin Limited announced today that its US subsidiary, Gavis Pharmaceuticals LLC., U.S.A. (collectively Lupin) has received final approval for its Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5mg/300 mg, 7.5 mg/300 mg & 10 mg/300 mg from…
[Lupin receives FDA approval for Imipramine Pamoate Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-imipramine-pamoate-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives FDA Approval for its New Drug Application for Antara® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-its-new-drug-application-for-antara-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for its Oral Contraceptive Kurvelo® Tablets; The Generic of Nordette® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-its-oral-contraceptive-kurvelo-tablets-the-generic-of-nordette-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for its Oral Contraceptive Pirmella™ 7/7/7 and Pirmella™ 1/35 Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-its-oral-contraceptive-pirmella-7-7-7-and-pirmella-1-35-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for its Oral Contraceptive VyfemlaTM Tablets Generic of Ovcon® 35 Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-its-oral-contraceptive-vyfemlatm-tablets-generic-of-ovcon-35-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for KCl for Oral Solution 20 mEq - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-kcl-for-oral-solution-20-meq/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Potassium Chloride for Oral Solution USP, 20 mEq from the United States Food and Drug Administration (FDA) to market a generic version of Pharma Research Software…
[Lupin receives FDA approval for Lamotrigine tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-lamotrigine-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for Levothyroxine Sodium Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-levothyroxine-sodium-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg,…
[Lupin receives FDA approval for Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg & 120 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-lurasidone-hydrochloride-tablets/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg & 120 mg from the United States Food and Drug Administration (FDA) to market a…
[Lupin receives FDA approval for Methylprednisolone Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-methylprednisolone-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Methylprednisolone Tablets USP, 2 mg, 4 mg, 8 mg, 16 mg and 32 mg, from the United States Food and Drug Administration (FDA) to market a…
[Lupin Receives FDA Approval for New Drug Application for SUPRAX® Oral Suspension, 500 mg/5mL - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-new-drug-application-for-suprax-oral-suspension-500-mg-5ml/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for Nikita™ (Pitavastatin) Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-nikita-pitavastatin-tablets/): Mumbai: Pharma Major Lupin Limited (Lupin) announced that it has received a 505 (b) (2) NDA approval for its NikitaTM (Pitavastatin) Tablets 1 mg, 2 mg and 4 mg from the United States Food and Drug Administration (FDA). Lupin’s…
[Lupin Receives FDA Approval for Potassium Chloride Extended Release Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-potassium-chloride-extended-release-capsules-2/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) has received final approval for its Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq from the United States Food and Drug Administration (FDA) to market a generic version of…
[Lupin receives FDA approval for Sildenafil Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-sildenafil-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg from the United States Food and Drug Administration (FDA) to market a generic version…
[Lupin Receives FDA Approval for Potassium Chloride Extended-Release Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-potassium-chloride-extended-release-capsules/): Mumbai: Pharma Major Lupin Limited announced today that its US subsidiary, Gavis Pharmaceuticals LLC., U.S.A. (collectively Lupin) has received final approval for its Potassium Chloride Extended-Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the…
[Lupin receives FDA approval for SUPRAX® (Cefixime) Capsules, 400 mg NDA Approval to add to growing SUPRAX® Franchise ® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-suprax-cefixime-capsules-400-mg-nda-approval-to-add-to-growing-suprax-franchise/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for Tadalafil Tablets USP, 20 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-tadalafil-tablets-usp-20-mg/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Tadalafil Tablets USP, 20 mg from the United States Food and Drug Administration (FDA) to market a generic version of Eli Lilly and Company’s Adcirca Tablets,…
[Lupin receives FDA approval for Testosterone Gel - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-testosterone-gel/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie,…
[Lupin receives FDA approval for Tadalafil Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-tadalafil-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg, from the United States Food and Drug Administration (FDA) to market a…
[Lupin Receives FDA Approval for Triamcinolone Acetonide Cream - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-triamcinolone-acetonide-cream/): Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% from the United States Food and Drug Administration (FDA) to market a generic equivalent of…
[Lupin Receives FDA Approvals for Generic Loestrin® Fe 1/20 and Loestrin®1.5/30 Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approvals-for-generic-loestrin-fe-1-20-and-loestrin1-5-30-tablets/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received final approvals for its Blisovi® Fe 1/20 Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) and Blisovi®…
[Lupin Receives FDA Approvals for Generic Vfend® Tablets 50mg, 200mg & Vfend® Oral Suspension, 40 mg/mL - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-approvals-for-generic-vfend-tablets-50mg-200mg-vfend-oral-suspension-40-mg-ml/): Mumbai, Baltimore: Pharma Major Lupin Limited announced today that its US subsidiary, Gavis Pharmaceuticals LLC., (collectively Lupin) has received final approvals for its Voriconazole® Tablets, 50 mg & 200 mg and Voriconazole® Oral Suspension, 40 mg/mL from the United…
[Lupin Receives Final Approval to Market Generic Ultram® ER - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-final-approval-to-market-generic-ultram-er/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA tentative approval for Eszopiclone tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-fda-tentative-approval-for-eszopiclone-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives final approval for Quinapril Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-final-approval-for-quinapril-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives Final FDA Approval for Generic LoSeasonique® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-final-fda-approval-for-generic-loseasonique-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives Final FDA Approval for Trandolapril - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-final-fda-approval-for-trandolapril/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives Health Canada Approval for Biosimilar Pegfilgrastim - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-health-canada-approval-for-biosimilar-pegfilgrastim/): Mumbai, Quebec, August 23, 2024: Global pharma major Lupin Limited (Lupin) today announced that ithas received approval from Health Canada for its biosimilar Pegfilgrastim. This product will be marketed under the brand name Armlupeg® and manufactured at Lupin’s Biotech…
[Lupin Receives Health Canada Approval for Rymti® (biosimilar Etanercept) - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-health-canada-approval-for-rymti-biosimilar-etanercept/): Rymti® is Lupin’s biosimilar etanercept approved for all indications of the reference product Enbrel® Rymti® is available as an injectable easy-to-use pre-filled pen and a pre-filled syringe Mumbai, Canada, September 13, 2022: Global pharma major Lupin Limited (Lupin) announced…
[Lupin Receives Health Canada Approval for Propranolol Hydrochloride ER Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-health-canada-approval-for-propranolol-hydrochloride-er-capsules/): Mumbai, Canada: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg from Health Canada. Lupin is the first generic company to…
[Lupin receives IND approvals for anti-TB and anti-psoriasis molecules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-ind-approvals-for-anti-tb-and-anti-psoriasis-molecules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives International Sustainability Rating System (ISRS) Certification, 8th Edition - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-international-sustainability-rating-system-isrs-certification-8th-edition/): Mumbai: Pharma major Lupin Limited (Lupin) announced today that the Company has received certification for International Sustainability Rating System (ISRS), 8th edition, from DNV GL, a global service provider for managing risk and helping customers to safely and…
[Lupin Receives International Sustainability Rating Standard (ISRS) Certification First Pharmaceutical Company globally to adopt ISRS, 8th Edition standard - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-international-sustainability-rating-standard-isrs-certification-first-pharmaceutical-company-globally-to-adopt-isrs-8th-edition-standard/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives sANDA approval from U.S. FDA for Levothyroxine Sodium Tablets USP to be considered AB rated to Reference Listed Drug, UNITHROID® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-sanda-approval-from-u-s-fda-for-levothyroxine-sodium-tablets-usp-to-be-considered-ab-rated-to-reference-listed-drug-unithroid/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its sANDA for Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg,…
[Lupin receives INDA approval for psoriasis oral treatment April 22, 2004 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-inda-approval-for-psoriasis-oral-treatment-april-22-2004/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives sANDA approval from US FDA for Levothyroxine Sodium Tablets USP AB rating to Reference Listed Drug, LEVOXYL® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-sanda-approval-from-us-fda-for-levothyroxine-sodium-tablets-usp-ab-rating-to-reference-listed-drug-levoxyllupin-receives-approval-for-droxidopa-capsules-2/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its sANDA for Levothyroxine Sodium Tablets USP from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of LEVOXYL® 25…
[Lupin Receives Tentative Approval for Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 mL - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-arformoterol-tartrate-inhalation-solution-15-mcg-base-2-ml/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received tentative approval for its Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 mL, Unit-dose Vials, from the United States Food and Drug Administration (U.S. FDA) to market…
[Lupin Receives Tentative Approval for Empagliflozin and Linagliptin Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-empagliflozin-and-linagliptin-tablets/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received tentative approval for its Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg, from the United States Food and Drug Administration (U.S. FDA) to market…
[Lupin Receives Tentative Approval for Efinaconazole Topical Solution - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-efinaconazole-topical-solution/): Mumbai, Baltimore: Lupin Limited (NSE: Lupin), global pharmaceutical company, announced today that it has received tentative approval for its Efinaconazole Topical Solution, 10%, from the United States Food and Drug Administration, to market a generic equivalent of Jublia® Topical…
[Lupin Receives Tentative Approval for Empagliflozin and Metformin Hydrochloride ER Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-empagliflozin-and-metformin-hydrochloride-er-tablets/): Mumbai, Baltimore: Lupin Limited (Lupin), global pharmaceutical company, announced today that it has received tentative approval for its Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, from…
[Lupin Receives Tentative Approval for Empagliflozin Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-empagliflozin-tablets/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received tentative approval for its Empagliflozin Tablets, 10 mg and 25 mg, from the United States Food and Drug Administration (U.S. FDA) to market a generic version of…
[Lupin receives Tentative Approval for Generic Cymbalta® Delayed-release Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-cymbalta-delayed-release-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives Tentative Approval for Generic Benicar® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-benicar-tablets/): Lupin’s 150th ANDA approval Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received tentative approval for its Olmesartan Medoximil Tablets, 5 mg, 20 mg and 40 mg from the United States Food and Drug Administration…
[Lupin Receives Tentative Approval for Generic Epzicom® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-epzicom-tablets/): The filing is from Lupin’s Goa manufacturing facility Mumbai, Baltimore: Pharma Major Lupin Limited(Lupin) announced today that it has received tentative approval for its Abacavir Sulfate and Lamivudine Tablets, 600 mg/300 mg from the United States Food and…
[Lupin Receives Tentative Approval for Generic Giazo® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-giazo-tablets/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received tentative approval for its Balasalazide Disodium Tablets, 1.1 gm from the United States Food and Drug Administration (FDA) to market a generic version of Salix Pharmaceuticals…
[Lupin receives Tentative Approval for Generic Glumetza® Extended-Release Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-glumetza-extended-release-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives Tentative Approval for Generic Lexiva® Tablets, 700 mg from US FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-lexiva-tablets-700-mg-from-us-fda/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has received tentative approval from the United States Food and Drug Administration (FDA) to market a generic equivalent of ViiV Healthcare’s (ViiV) Lexiva®…
[Lupin Receives Tentative Approval for Generic Paxil CR® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-paxil-cr-tablets/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received tentative approval for its Paroxetine Extended-Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg from the United States Food and Drug Administration (FDA) to market…
[Lupin Receives Tentative Approval for Generic Livalo® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-livalo-tablets/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received tentative approval for its Pitavastatin Tablets, 1 mg, 2 mg, and 4 mg from the United States Food and Drug Administration (FDA) to market a generic…
[Lupin Receives Tentative Approval for Generic Rapaflo® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-rapaflo-capsules/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received tentative approval for its Silodosin Capsules, 4 mg and 8 mg from the United States Food and Drug Administration (FDA) to market a generic version of Allergan Sales,…
[Lupin Receives Tentative Approval for Generic Prezista® Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-prezista-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives Tentative Approval for Generic Zithromax® Oral Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-zithromax-oral-suspension/): Mumbai: Pharma Major Lupin Limited announced today that its US subsidiary, Gavis Pharmaceuticals LLC., U.S.A. (collectively Lupin) has received tentative approval for its Azithromycin for oral suspension USP, 300 mg (100 mg/5 mL) and 1200 mg (200 mg/5 mL)…
[Lupin Receives Tentative Approval for Generic Zorvolex® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-zorvolex-capsules/): Mumbai, Baltimore: Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (collectively Lupin) has received tentative approval for its Diclofenac Capsules USP, 18 mg and 35 mg from the United States Food and Drug Administration…
[Lupin Receives Tentative Approval from U.S. FDA for Amifampridine Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-amifampridine-tablets/): Mumbai, Naples, March 17, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Amifampridine Tablets, 10…
[Lupin Receives Tentative Approval from U.S. FDA for Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-abacavir-dolutegravir-and-lamivudine-tablets-for-oral-suspension/): Mumbai, Naples, December 06, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Abacavir, Dolutegravir and…
[Lupin Receives Tentative Approval from U.S. FDA for Apalutamide Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-apalutamide-tablets/): Mumbai, Baltimore, October 13, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Apalutamide Tablets, 60…
[Lupin Receives Tentative Approval from U.S. FDA for Brexpiprazole Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-brexpiprazole-tablets/): Mumbai, Baltimore, October 6, 2021: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) Brexpiprazole Tablets, 0.25 mg,…
[Lupin Receives Tentative Approval from U.S. FDA for Azilsartan Medoxomil Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-azilsartan-medoxomil-tablets/): Mumbai, Baltimore, December 24, 2021: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) Azilsartan Medoxomil Tablets, 40…
[Lupin Receives Tentative Approval from U.S. FDA for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-bictegravir-emtricitabine-and-tenofovir-alafenamide-tablets/): Mumbai, Naples, September 24, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Bictegravir, Emtricitabine, and…
[Lupin Receives Tentative Approval from U.S. FDA for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-brimonidine-tartrate-ophthalmic-solution-0-025-otc/): Mumbai, Naples, August 14, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Brimonidine Tartrate Ophthalmic…
[Lupin Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution/): Mumbai, Baltimore, October 12, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Calcium, Magnesium, Potassium,…
[Lupin Receives Tentative Approval from U.S. FDA for Canagliflozin and Metformin Hydrochloride Extended-Release Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-canagliflozin-and-metformin-hydrochloride-extended-release-tablets/): Mumbai, Baltimore, November 07, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Canagliflozin and Metformin…
[Lupin Receives Tentative Approval from U.S. FDA for Canagliflozin Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-canagliflozin-tablets/): Mumbai, Baltimore, November 23, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Canagliflozin Tablets, 100…
[Lupin Receives Tentative Approval from U.S. FDA for Dapagliflozin and Saxagliptin Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-dapagliflozin-and-saxagliptin-tablets/): Mumbai, Baltimore, January 04, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Saxagliptin…
[Lupin Receives Tentative Approval from U.S. FDA for Dapagliflozin Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-dapagliflozin-tablets/): Mumbai, Baltimore, November 21, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA)for its Abbreviated New Drug Application for Dapagliflozin Tablets, 5 mg,…
[Lupin Receives Tentative Approval from U.S. FDA for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-darunavir-cobicistat-emtricitabine-and-tenofovir-alafenamide-tablets/): Mumbai, Naples, February 3, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Darunavir, Cobicistat,…
[Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-dolutegravir-and-rilpivirine-tablets/): Mumbai, Baltimore, January 16, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Dolutegravir and Rilpivirine Tablets,…
[Lupin Receives Tentative Approval from U.S. FDA for Dasatinib Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-dasatinib-tablets/): Mumbai, Baltimore, August 29, 2022: Global pharma major Lupin Limited (Lupin) in partnership with Pharmascience Inc. today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application…
[Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-dolutegravir-emtricitabine-and-tenofovir-alafenamide-detaf-tablets/): Mumbai, Baltimore, January 31, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) under the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) for…
[Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-dolutegravir-lamivudine-and-tenofovir-alafenamide-tablets-2/): Mumbai, Baltimore, July 21, 2023:Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) under the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) for…
[Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir Tablets for Oral Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-dolutegravir-tablets-for-oral-suspension/): Mumbai, Baltimore, July 04, 2023: Global pharma major Lupin Limited (Lupin)today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA), Dolutegravir Tablets for Oral…
[Lupin Receives Tentative Approval from U.S. FDA for Doxycycline Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-doxycycline-capsules/): Mumbai, Baltimore, November 08, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Doxycycline Capsules, 40 mg,…
[Lupin Receives Tentative Approval from U.S. FDA for Drospirenone Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-drospirenone-tablets/): Mumbai, Baltimore, November 04, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Drospirenone Tablets, 4 mg,…
[Lupin Receives Tentative Approval from U.S. FDA for Empagliflozin, Linagliptin and Metformin Hydrochloride Extended-Release Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-empagliflozin-linagliptin-and-metformin-hydrochloride-extended-release-tablets/): Mumbai, Naples, July 09, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA)for its Abbreviated New Drug Application for Empagliflozin, Linagliptin and Metformin…
[Lupin Receives Tentative Approval from U.S. FDA for Ivacaftor Oral Granules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-ivacaftor-oral-granules/): Mumbai, Naples, January 9, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Ivacaftor Oral Granules,…
[Lupin Receives Tentative Approval from U.S. FDA for Ivacaftor Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-ivacaftor-tablets/): Mumbai, Baltimore, June 08, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) Ivacaftor Tablets, 150 mg,…
[Lupin Receives Tentative Approval from U.S. FDA for Letermovir Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-letermovir-tablets/): Mumbai, Naples, June 03, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received a tentative approval from the United States Food and Drug Administration (U.S. FDA)for its Abbreviated New Drug Application for Letermovir Tablets, 240…
[Lupin Receives Tentative Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-loteprednol-etabonate-ophthalmic-gel/): Mumbai, Naples, January 9, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic…
[Lupin Receives Tentative Approval from U.S. FDA for Migalastat Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-migalastat-capsules/): Mumbai, Naples, April 01, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Migalastat Capsules, 123…
[Lupin Receives Tentative Approval from U.S. FDA for Obeticholic Acid Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-obeticholic-acid-tablets/): Mumbai, Baltimore, March 23, 2023: Global pharma major Lupin Limited (Lupin)today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA), Obeticholic Acid Tablets, 5…
[Lupin Receives Tentative Approval from U.S. FDA for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-olopatadine-hydrochloride-ophthalmic-solution-usp-0-7-otc/): Mumbai, Naples, June 27, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received a tentative approval from the United States Food and Drug Administration (U.S. FDA)for its Abbreviated New Drug Application for Olopatadine Hydrochloride Ophthalmic…
[Lupin Receives Tentative Approval from U.S. FDA for Oxcarbazepine ER Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-oxcarbazepine-er-tablets/): Mumbai, Naples, June 7, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Oxcarbazepine Extended-Release…
[Lupin Receives Tentative Approval from U.S. FDA for Raltegravir Tablets, USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-raltegravir-tablets-usp/): Mumbai, Naples, November 8, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Raltegravir Tablets USP,…
[Lupin Receives Tentative Approval from U.S. FDA for Rivaroxaban Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-rivaroxaban-tablets-usp/): Mumbai, Baltimore, January 23, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Rivaroxaban Tablets USP,…
[Lupin Receives Tentative Approval from U.S. FDA for Sitagliptin and Metformin Hydrochloride Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-sitagliptin-and-metformin-hydrochloride-tablets/): Mumbai, Naples, November 28, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Sitagliptin and Metformin…
[Lupin Receives Tentative Approval from U.S. FDA for Selexipag for Injection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-selexipag-for-injection/): Mumbai, Baltimore, November 02, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Selexipag for Injection,…
[Lupin Receives Tentative Approval from U.S. FDA for Sitagliptin Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-sitagliptin-tablets/): Mumbai, Baltimore, December 15, 2023: Global pharma major Lupin Limited (Lupin)today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA), Sitagliptin Tablets USP, 25…
[Lupin Receives Tentative Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-sodium-sulfate-magnesium-sulfate-and-potassium-chloride-tablets/): Mumbai, Naples, July 16, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Sodium Sulfate, Magnesium…
[Lupin Receives Tentative Approval from U.S. FDA for Tenofovir Alafenamide Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-tenofovir-alafenamide-tablets/): Mumbai, Baltimore, April 18, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) Tenofovir Alafenamide Tablets, 25…
[Lupin Receives Tentative Approval from U.S. FDA for Tolvaptan Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-tolvaptan-tablets/): Mumbai, Baltimore, October 05, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Tolvaptan Tablets, 15…
[Lupin Receives Tentative Approval from U.S. FDA for Valbenazine Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-valbenazine-capsules/): Mumbai, Baltimore, March 27, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA), Valbenazine Capsules, 40…
[Lupin receives tentative FDA approval for generic Locoid® Lotion - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-fda-approval-for-generic-locoid-lotion/): Mumbai, Baltimore: Pharma major Lupin announced that it has received tentative approval for its Hydrocortisone Butyrate Lotion, 0.1% from the United States Food and Drug Administration (FDA) to market a generic version of Precision Dermatology, Inc.’s Locoid® Lotion, 0.1%….
[Lupin receives tentative FDA approval for generic AndroGel®, 1.62% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-fda-approval-for-generic-androgel-1-62/): Mumbai, Baltimore: Pharma major Lupin announced that it has received tentative approval for its Testosterone Gel, 1.62% (20.25 mg/1.25 gm actuation) from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie Inc.’s AndroGel®,…
[Lupin receives tentative FDA approval for generic Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-fda-approval-for-generic-lurasidone-hydrochloride-tablets/): Mumbai, Baltimore: Pharma major Lupin announced that it has received tentative approval for its Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg from the United States Food and Drug Administration (FDA) to market…
[Lupin receives tentative FDA approval for generic Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-fda-approval-for-generic-tadalafil-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin announced that it has received tentative approval for its Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg from the United States Food and Drug Administration (FDA) to market a generic…
[Lupin receives tentative FDA approval for generic Nudovra (Estradiol Valerate Tablets, 3 mg and 1 mg and Estradiol Valerate and Dienogest Tablets, 2 mg/2 mg and 2 mg/3 mg) Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-fda-approval-for-generic-nudovra/): Mumbai, Baltimore: Pharma major Lupin announced that it has received tentative approval for its Nudovra (Estradiol Valerate Tablets, 3 mg and 1 mg and Estradiol Valerate and Dienogest Tablets, 2 mg/2 mg and 2 mg/3 mg) Tablets from the…
[Lupin Receives Tentative FDA Approvals for Generic Nuvigil® Tablets and Generic Oracea® Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-fda-approvals-for-generic-nuvigil-tablets-and-generic-oracea-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives Tentative U.S. FDA Approval for Brivaracetam Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-u-s-fda-approval-for-brivaracetam-tablets/): Mumbai, Baltimore, August 16, 2021: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) Brivaracetam Tablets, 10 mg,…
[Lupin Receives Tentative U.S. FDA Approval for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) Tablets under PEPFAR - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-u-s-fda-approval-for-dolutegravir-lamivudine-and-tenofovir-disoproxil-fumarate-tld-tablets-under-pepfar/): Mumbai, Baltimore, June 30, 2021: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) under the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) for…
[Lupin receives tentative US FDA approval for Dimethyl Fumarate Delayed Release Capsules, 120 mg and 240 mgn - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-us-fda-approval-for-dimethyl-fumarate-delayed-release-capsules-120-mg-and-240-mgn/): Mumbai, Baltimore: Pharma major Lupin announced that it has received tentative approval for its Dimethyl Fumarate Delayed Release Capsules, 120 mg and 240 mg from the United States Food and Drug Administration (FDA) to market a generic version of…
[Lupin receives tentative U.S. FDA approval for Mirabegron ER Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-us-fda-approval-for-mirabegron-er-tablets/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received tentative approval for its Mirabegron Extended Release (ER) Tablets, 25 mg and 50 mg, from the United States Food and Drug Administration (FDA), to market a generic…
[Lupin receives tentative U.S. FDA approval for Fosaprepitant for Injection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-u-s-fda-approval-for-fosaprepitant-for-injection/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received tentative approval for its Fosaprepitant for Injection, 150 mg Single-Dose Vial, from the United States Food and Drug Administration (FDA) to market a generic version of Emend…
[Lupin receives tentative US FDA approval for Tadalafil Tablets USP, 20 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-us-fda-approval-for-tadalafil-tablets-usp-20-mg/): Mumbai, Baltimore: Pharma major Lupin announced that it has received tentative approval for its Tadalafil Tablets USP, 20 mg from the United States Food and Drug Administration (FDA) to market a generic version of Eli Lilly and Company’s (Lilly)…
[Lupin receives tentative US FDA Approval for Ziprasidone - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-tentative-us-fda-approval-for-ziprasidone/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives U.S. FDA approval for Divalproex Sodium ER Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-divalproex-sodium-er-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Divalproex Sodium Extended-Release (ER) Tablets USP,250 mg and 500 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent…
[Lupin Receives the 2014 ASTD BEST Award for Learning & Development - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-the-2014-astd-best-award-for-learning-development/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives U.S. FDA approval for Ethacrynic Acid Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-ethacrynic-acid-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Ethacrynic Acid Tablets USP, 25 mg, from the United States Food and Drug Administration (U.S. FDA). Lupin’s Ethacrynic Acid Tablets USP, 25 mg, is…
[Lupin receives U.S. FDA approval for Extended Phenytoin Sodium Capsules USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-extended-phenytoin-sodium-capsules-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Extended Phenytoin Sodium Capsules USP, 100 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Dilantin®…
[Lupin receives U.S. FDA approval for Fosaprepitant for Injection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-fosaprepitant-for-injection/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Fosaprepitant for Injection, 150 mg Single-Dose Vial, from the United States Food and Drug Administration (U.S. FDA). Lupin’s Fosaprepitant for Injection, 150 mg Single-Dose…
[Lupin receives U.S. FDA approval for Hydrocortisone Valerate Cream - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-hydrocortisone-valerate-cream/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Hydrocortisone Valerate Cream USP, 0.2% from the United States Food and Drug Administration (U.S. FDA). Lupin’s Hydrocortisone Valerate Cream USP, 0.2%, is the generic…
[Lupin Receives U.S. FDA Approval for Sacubitril and Valsartan Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-sacubitril-and-valsartan-tablets/): Mumbai, Naples, January 24, 2025:Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S.FDA) for its Abbreviated new Drug Application (ANDA), Sacubitril and Valsartan Tablets, 24 mg/26…
[Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi’s Long-Acting Injectable Platform - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-risperidone-long-acting-injectable-with-180-day-cgt-exclusivity-the-first-product-from-its-nanomis-long-acting-injectable-platform/): Mumbai, Naples, September 3, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Risperidone for extended-release…
[Lupin Receives U.S. FDA Approval for Sevelamer Hydrochloride Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-sevelamer-hydrochloride-tablets/): Mumbai, Baltimore, June 17, 2021: Global pharma major Lupin Limited (Lupin) today announced that it has received approval for its Sevelamer Hydrochloride Tablets, 400 mg and 800 mg from the United States Food and Drug Administration to market a…
[Lupin receives US FDA approval for Amlodipine / Benazepril capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-amlodipine-benazepril-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives US FDA Approval for Amlodipine - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-amlodipine/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives US FDA Approval for Cefadroxil Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-cefadroxil-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives US FDA approval for Cefprozil Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-cefprozil-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives U.S. FDA approval for Cinacalcet Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-cinacalcet-tablets/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Cinacalcet Tablets, 30 mg, 60 mg, and 90 mg from the United States Food and Drug Administration (U.S. FDA). Lupin’s Cinacalcet Tablets, 30 mg,…
[Lupin receives US FDA approval for Clobazam Tablets, 10 mg and 20 mg - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-clobazam-tablets-10-mg-and-20-mg/): Mumbai, Baltimore: Pharma major Lupin announced that it has received approval for its Clobazam Tablets, 10 mg and 20 mg from the United States Food and Drug Administration (FDA) to market a generic version of Lundbeck Pharmaceuticals, LLC’s Onfi…
[Lupin receives US FDA Approval for Novel Formulation of Suprax® Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-novel-formulation-of-suprax-suspension-2/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives US FDA approval for Perindopril Erbumine Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-perindopril-erbumine-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives US FDA Approval for Novel Formulation of Suprax® Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-novel-formulation-of-suprax-suspension/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives US FDA approval for Sertraline - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-sertraline-2/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives US FDA Approval for Generic Lumigan® Ophthalmic Solution 0.03%. - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-generic-lumigan-ophthalmic-solution-0-03/): Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Bimatoprost Ophthalmic Solution, 0.03% from the United States Food and Drugs Administration (FDA) to market a generic version of Allergan Inc.’s Lumigan®…
[Lupin receives US FDA approval for Sertraline - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-sertraline/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Receives US FDA Approval for Simvastatin Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-simvastatin-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives US FDA approval for Zileuton Extended-Release Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-zileuton-extended-release-tablets/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Zileuton Extended-Release Tablets, 600 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Zyflo CR®…
[Lupin Receives US FDA Approvals for Liraglutide and Glucagon Injectable Products - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approvals-for-liraglutide-and-glucagon-injectable-products/): Mumbai, Naples, July 24, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Applications for Liraglutide Injection Single-Patient-Use Prefilled Pens…
[Lupin receives USFDA approval for cefotaxime sterile vials for injection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-cefotaxime-sterile-vials-for-injection/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives US FDA tentative approval for Memantine HCl tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-us-fda-tentative-approval-for-memantine-hcl-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives USFDA approval for Cefixime Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-cefixime-suspension/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives USFDA approval for Cefixime Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-cefixime-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives USFDA approval for ceftriaxone sterile vials for injection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-ceftriaxone-sterile-vials-for-injection/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives USFDA approval for cefuroxime axetil tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-cefuroxime-axetil-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives USFDA approval for Cephalexin Oral Suspension - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-cephalexin-oral-suspension/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives USFDA approval for Cephalexin Capsules - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-cephalexin-capsules/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives USFDA approval for Divalproex Sodium Delayed-Release Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-divalproex-sodium-delayed-release-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives USFDA approval for Escitalopram Oxalate Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-escitalopram-oxalate-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives USFDA approval for Levetiracetam Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-levetiracetam-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives USFDA Approval for Topiramate Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-topiramate-tablets/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Sales and Operating Profit up 22% - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-sales-and-operating-profit-up-22/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Resumes Sales of Generic Fortamet® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-resumes-sales-of-generic-fortamet/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Secures a Place in the Prestigious S&P Global Sustainability Yearbook 2025 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-secures-a-place-in-the-prestigious-sp-global-sustainability-yearbook-2025/): Mumbai, February 27, 2025: Global pharma major Lupin Limited (Lupin) proudly announces its inclusion in prestigious S&P Global Sustainability Yearbook 2025, for the second consecutive year. This recognition highlights Lupin’s exceptional performance and dedication to sustainability. Lupin has been…
[Lupin sells Intellectual Property on Perindopril to Servier - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-sells-intellectual-property-on-perindopril-to-servier-2/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Settles Ongoing Litigation with Medicis over Generic Versions of SOLODYN® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-settles-ongoing-litigation-with-medicis-over-generic-versions-of-solodyn/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin signs an agreement with CSIR-NCL and DST for the development of a continuous manufacturing process for biosimilar monoclonal antibody therapeutic (mAb) - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-signs-an-agreement-with-csir-ncl-and-dst-for-the-development-of-a-continuous-manufacturing-process-for-biosimilar-monoclonal-antibody-therapeutic-mab/): Pune: Pharma major Lupin today announced the signing of an agreement with CSIR-National Chemical Laboratory (CSIR-NCL, Pune) and Department of Science and Technology, (DST, Delhi) for conducting research on a continuous purification process development of a biosimilar monoclonal antibody…
[Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-signs-distribution-agreement-with-medis-for-orphan-drug-namuscla/): Agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms innon-dystrophic myotonic disorders in Central and Eastern European territories Mumbai, Zug, February 09,2022:Global pharma major, Lupin Limited (Lupin) announced today that it hasentered into a distribution…
[Lupin Signs Distribution Agreement in Key EU Territories for Orphan Drug NaMuscla® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-signs-distribution-agreement-in-key-eu-territories-for-orphan-drug-namuscla/): Enables expanded patient access of rare disease medicine to treat myotonia symptoms in non-dystrophic myotonic disorders in three key territories Mumbai, India | Zug, Switzerland:Pharma major Lupin Limited (Lupin) is pleased to announce that it has entered into distribution…
[Lupin Signs Distribution Agreement with Celnova for Orphan Drug NaMuscla® - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-signs-distribution-agreement-with-celnova-for-orphan-drug-namuscla/): Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia Mumbai, Zug, Sept 27, 2024: Global pharma major, Lupin Limited (Lupin) announced today that its subsidiary Lupin Atlantis Holdings SA…
[Lupin Signs Agreement to Acquire Two Inhalation Brands from Sunovion - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-signs-agreement-to-acquire-two-inhalation-brands-from-sunovion/): Mumbai, Naples, October 20, 2022: Global pharmaceutical major Lupin Limited (Lupin) today announced signing of an agreement to acquire all rights to two inhalation medicines, Brovana® (arformoterol tartrate) Inhalation Solution and Xopenex HFA® (levalbuterol tartrate) Inhalation Aerosol, from Sunovion…
[Lupin Signs Exclusive Distribution Pact with ForDoz Pharma for 2 Complex Injectable Assets Under Development - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-signs-exclusive-distribution-pact-with-fordoz-pharma-for-2-complex-injectable-assets-under-development/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced today that its U.S. based wholly-owned subsidiary Lupin Inc. has entered into an agreement with ForDoz Pharma Corp (ForDoz) for granting Lupin the exclusive rights to market and distribute 2 complex injectable…
[Lupin Signs First Partnership Agreement with Foncoo for China - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-signs-first-partnership-agreement-with-foncoo-for-china/): Mumbai, Shanghai, January 19, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has entered into a partnership with Shenzhen Foncoo Pharmaceutical Co. Ltd (Foncoo). This is Lupin’s first partnership arrangement in China and reinforces Lupin’s commitment…
[Lupin sells Intellectual Property on Perindopril to Servier - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-sells-intellectual-property-on-perindopril-to-servier/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Settles all Ongoing Litigation with Sunovion over Generic of LUNESTA® (eszopiclone) - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-settles-all-ongoing-litigation-with-sunovion-over-generic-of-lunesta-eszopiclone/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Signs MoU with the Government of Rajasthan to strengthen Healthcare system - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-signs-mou-with-the-government-of-rajasthan-to-strengthen-healthcare-system/): Collaboration to strengthen healthcare system, reduce prevalence and improve health outcomes for patients diagnosed with Cardiovascular and COPD/Asthma disease in Alwar Jaipur, November 21, 2022: Lupin Human Welfare and Research Foundation (LHWRF), the Corporate Social Responsibility (CSR) arm of…
[Lupin signs on Mary Kom for its Women’s Cardiovascular Health Awareness Initiative, Shakti - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-signs-on-mary-kom-for-its-womens-cardiovascular-health-awareness-initiative-shakti/): The initiative brings internationally eminent cardiologists to increase awareness of health screening tests amongst pre-menopausal women Mumbai, India, March 07, 2022: Global pharma major Lupin Limited (Lupin), announced today that it has signed on six-time world boxing champion, Mary…
[Lupin Signs MoU with Government of Maharashtra to Combat Rising Prevalence of Cardiovascular Diseases and COPD - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-signs-mou-with-government-of-maharashtra-to-combat-rising-prevalence-of-cardiovascular-diseases-and-copd/): Collaboration to enhance healthcare services, ensure timely diagnosis, and improve accessibility of healthcare services Mumbai, June 20, 2023:Lupin Human Welfare and Research Foundation (LHWRF), the Corporate Social Responsibility (CSR) arm of Lupin Limited, announced today that it has signed…
[Lupin Strengthens its Board; Appoints Three Independent Directors - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-strengthens-its-board-appoints-three-independent-directors/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin submits Marketing Authorization Application for Etanercept Biosimilar in Europe - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-submits-marketing-authorization-application-for-etanercept-biosimilar-in-europe/): Mumbai: Pharma major Lupin announced today that its Marketing Authorization Application (MAA) for a biosimilar of Etanercept has been accepted for review by the European Medicines Agency (EMA). The indications targeted for approval are Rheumatoid Arthritis (RA), Psoriatic Arthritis,…
[Lupin Teams up with Mary Kom to Raise Awareness Amongst Women on Cardiovascular Disease - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-teams-up-with-mary-kom-to-raise-awareness-amongst-women-on-cardiovascular-disease/): Mumbai, India, March 09, 2022: On the occasion of International Women’s Day, global pharma major Lupin Limited (Lupin) hosted an informative Facebook Live session as a part of their Shakti campaign designed to empower women in their fight against…
[LUPIN signs strategic agreement with FARMANGUINHOS, Brazil - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-signs-strategic-agreement-with-farmanguinhos-brazil/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Signs Promotional Agreement with Exeltis on SOLOSEC® expanding access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-signs-promotional-agreement-with-exeltis-on-solosec-secnidazole-expanding-access-for-adult-women-suffering-with-bacterial-vaginosis-and-adults-with-trichomoniasis/): Mumbai Baltimore, January 27, 2022: Lupin Pharmaceuticals Inc., (Lupin) and Exeltis USA Inc. announced a promotional agreement for Exeltis to promote SOLOSEC® along with Exeltis’ existing line of Women’s Health products, further enhancing value to OBGYNs and their patients. …
[Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-strengthens-its-global-specialty-ophthalmology-business-with-acquisition-of-visufarma-from-gho-capital/): Mumbai, London, Rome, Zug, September 29, 2025: Global pharma major Lupin Limited (Lupin), today announced its wholly owned subsidiary, Nanomi B.V. (‘Nanomi’), has signed a definitive agreement for the acquisition of VISUfarma B.V. (VISUfarma), a portfolio company of global…
[Lupin submits New Drug Application for Etanercept biosimilar in Japan - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-submits-new-drug-application-for-etanercept-biosimilar-in-japan/): Mumbai: Pharma major Lupin announced that YL Biologics (YLB) – its JV with Yoshindo and Kyowa (Lupin’s Subsidiary) in Japan has submitted a New Drug Application (NDA) for Marketing Authorization to the Pharmaceuticals and Medical Devices Agency (PMDA) for…
[Lupin ties up with leading Institutes for PhD Program - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-ties-up-with-leading-institutes-for-phd-program/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin to acquire 51% stake in Dafra - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-to-acquire-51-stake-in-dafra/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin to donate Yen 10 mn. for Japan’s earthquake victims - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-to-donate-yen-10-mn-for-japans-earthquake-victims/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin to Market new Inhaler under the brand name Loftair® in India - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-to-market-new-inhaler-under-the-brand-name-loftair-in-india/): Mumbai: Pharma Major Lupin Limited (Lupin) and Novartis Healthcare Private Limited (NHPL) have entered into a co-marketing agreement to promote Novartis’s Indacaterol / Glycopyrronium 110mcg/50mcg inhaler, a treatment for chronic obstructive pulmonary disease (COPD) under the brand name of…
[Lupin to focus on the development of inhalers with near-zero global warming potential propellants - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-to-focus-on-the-development-of-inhalers-with-near-zero-global-warming-potential-propellants/): Lupin’s R&D teams are working on products with a near-zero global warming potential propellant Mumbai, Germany, France, Spain, October 28, 2024: Global pharma major Lupin Limited (Lupin) today announced its focus on formulating respiratory inhalers by incorporating a propellant…
[Lupin to Reorganise Sale Structure for Suprax - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-to-reorganise-sale-structure-for-suprax/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin triples Research spend - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-triples-research-spend/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin to set up new Lovastatin plant A move to consolidate presence in lifestyle drugs - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-to-set-up-new-lovastatin-plant-a-move-to-consolidate-presence-in-lifestyle-drugs/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin To Set Up New Formulations Manufacturing Facility In MIHAN - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-to-set-up-new-formulations-manufacturing-facility-in-mihan/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin unveils herbal products - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-unveils-herbal-products/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-unveils-strategic-partnership-program-to-expand-reach-of-its-long-acting-injectable-platform/): Mumbai, Naples, October 09, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of a strategic partnership program aimed at expanding the reach of PrecisionSphere™ – the long-acting injectable (LAI) platform developed by its subsidiary, Nanomi B.V….
[Lupin Wins Award for Operational Excellence in Manufacturing at India Pharma Awards 2019 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-wins-award-for-operational-excellence-in-manufacturing-at-india-pharma-awards-2019/): New Delhi: Pharma major Lupin Limited won the prestigious award for ‘Operational Excellence in Manufacturing’ at the India Pharma Awards 2019. The jury panel which comprised senior leaders and veterans from the industry, chose Lupin as the recipient…
[Lupin Wins Five INDIASTAR 2020 Awards for Excellence in Packaging - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-wins-five-indiastar-2020-awards-for-excellence-in-packaging/): Mumbai: Pharma major Lupin Limited (Lupin) announced that it has won five ‘INDIASTAR 2020’ awards under the category ‘Excellence in packaging, innovative design and development’ for its derma products – Novegrow, Lupiaqua cream, Novilite cream, Noviglo face wash and…
[Lupin wins India Packaging Award for ‘Corcal Bone & Beauty’ - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-wins-india-packaging-award-for-corcal-bone-beauty/): Mumbai: Pharma major Lupin Limited (Lupin) announced today that it has won the India Packaging Award 2019 for its Consumer Healthcare brand ‘Corcal Bone & Beauty’, a calcium supplement specially for women. Corcal is the latest launch by the…
[Lupin wins India Pharma Leader Award at India Pharma 2020 and India Medical Device 2020 Conference - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-wins-india-pharma-leader-award-at-india-pharma-2020-and-india-medical-device-2020-conference/): Mumbai: Pharma major Lupin Limited (Lupin) won the coveted India Pharma Leader Award at the India Pharma 2020 and India Medical Device 2020 conference. This was the 5th edition of the event organized by FICCI in collaboration with…
[Lupin wins Packaging Award for its patient awareness initiative ‘Lupin Sahayak’ - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-wins-packaging-award-for-its-patient-awareness-initiative-lupin-sahayak/): Mumbai: Pharma major Lupin Limited (Lupin) announced today that it has won the India Packaging Award 2019 for its patient awareness initiative ‘Lupin Sahayak’ and its special packaging for Telista. Telista is Lupin’s brand of Telmisartan and combinations that…
[Lupin wins Ramipril product patent challenge at Federal Circuit - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-wins-ramipril-product-patent-challenge-at-federal-circuit/): Read the latest press releases and corporate communications from Lupin Limited.
[LupinLife Launches Be One, Ayurvedic Energy Supplement - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupinlife-launches-be-one-ayurvedic-energy-supplement/): Be One is a natural, non-addictive and steroid-free daily health supplement for men Mumbai, India: LupinLife, consumer healthcare business of global pharma major, Lupin Limited, today announced the launch of a new ayurvedic energy supplement for men, Be One….
[LupinLife Partners with Uttarakhand Police to Promote Hand Hygiene at Kumbh Mela 2021 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupinlife-partners-with-uttarakhand-police-to-promote-hand-hygiene-at-kumbh-mela-2021-2/): Mumbai, India, March 24, 2021: LupinLife, consumer healthcare business of global pharma major Lupin Limited, today announced its association with the Uttarakhand Police for Kumbh Mela 2021. During the Kumbh, LupinLife will provide five lakh LupiSafe hand sanitizers to policemen and…
[LupinLife signs Hrithik Roshan as the brand ambassador for Be One, Ayurvedic Energy Supplement - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupinlife-signs-hrithik-roshan-as-the-brand-ambassador-for-be-one-ayurvedic-energy-supplement/): Mumbai, India, October 22, 2021: LupinLife, the consumer healthcare business of global pharma major Lupin Limited (Lupin), announced today that it has roped in Bollywood megastar and fitness icon Hrithik Roshan as the brand ambassador for the recently launched…
[LupinLife Collaborates With Payal Singhal and Mithali Raj at Lakmé Fashion Week 2020 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupinlife-collaborates-with-payal-singhal-and-mithali-raj-at-lakme-fashion-week-2020/): Corcal Bone & Beauty celebrates #Beautifullystrong initiative Mumbai: Corcal Bone & Beauty calcium supplement from LupinLife (Consumer healthcare business of pharma major Lupin) returns to Lakmé Fashion Week at the Summer/Resort 2020 edition. In its 2nd edition, LupinLife collaborated…
[LupinLife’s Be One wins the best packaging design, graphics and brand value add award at the India Packaging Awards 2021 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupinlifes-be-one-wins-the-best-packaging-design-graphics-and-brand-value-add-award-at-the-india-packaging-awards-2021/): Mumbai, India, November 08, 2021: LupinLife, the consumer healthcare business of global pharma major Lupin Limited (Lupin), won the Best Packaging Design – Graphics and Brand Value Add Award at the India Packaging Awards for its daily health supplement…
[LupinLife’s Corcal Bone & Beauty to launch at Lakme Fashion Week with an initiative to bring #Beautifullystrong real women to the ramp - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupinlifes-corcal-bone-beauty-to-launch-at-lakme-fashion-week/): Mumbai: LupinLife’s Corcal Bone & Beauty announces a collaboration with Lakme Fashion Week to celebrate #beautifullystrong women across India at the upcoming Lakme Fashion Week Summer/Resort 2019 edition. Marking its launch in India, the Corcal Bone & Beauty show will…
[Lupin’s Alliance Partner Caplin Receives U.S. FDA Approval for Rocuronium Bromide Injection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-alliance-partner-caplin-receives-u-s-fda-approval-for-rocuronium-bromide-injection/): Mumbai, Baltimore, March 20, 2023: Global pharma major Lupin Limited (Lupin) today announced that its alliance partner Caplin Steriles Limited (Caplin) has received final approval from the United States Food and Drug Administration (U.S.FDA) for its Abbreviated new Drug…
[LupinLife’s LupiSafe Announces Association with Chennai Super Kings as Official Hygiene Partner – Digital - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupinlifes-lupisafe-announces-association-with-chennai-super-kings/): Mumbai, India: LupinLife’s ‘LupiSafe Hand Sanitizer’ announced today its association as the official Hygiene Partner – Digital for the three-time IPL champions Chennai Super Kings (CSK) in the 13th edition of the Indian Premier League (IPL 2020). LupiSafe, a LupinLife…
[Lupin’s Ankleshwar Facility Wins Par Excellence Award at 33rd National Convention on Quality Concept - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-ankleshwar-facility-wins-par-excellence-award-at-33rd-national-convention-on-quality-concept/): Mumbai: Pharma major Lupin Limited (Lupin) won the Par Excellence Award at the 33rd National Convention on Quality Concept (NCQC), organised by the Quality Circle Forum of India (QCFI). The event was held at IIT BHU — Varanasi…
[Lupin’s Alliance Partner Caplin Receives U.S. FDA Approval for Thiamine Hydrochloride Injection USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-alliance-partner-caplin-receives-u-s-fda-approval-for-thiamine-hydrochloride-injection-usp/): Mumbai, Baltimore, March 20, 2023: Global pharma major Lupin Limited (Lupin) today announced that its alliance partner Caplin Steriles Limited (Caplin) has received final approval from the United States Food and Drug Administration (U.S.FDA) for its Abbreviated new Drug…
[Lupin’s Aptivate Champion Run for Kids Receives Overwhelming Support - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-aptivate-champion-run-for-kids-receives-overwhelming-support/): Mumbai, India, February 14, 2023: Lupin Life, the Consumer Healthcare division of Lupin, hosted the first-ever Aptivate Champion Run for Kids on February 12, 2023, at the MMRDA Grounds, Bandra Kurla Complex, Mumbai, to support the cause of promoting…
[Lupin’s Alliance Partner Concord Receives Approval for Mycophenolic Acid Delayed-Release Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-alliance-partner-concord-receives-approval-for-mycophenolic-acid-delayed-release-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) in alliance with Concord Biotech Limited (Concord)announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and…
[Lupin’s alliance partner Natco receives FDA approval for generic Fosrenol Chewable Tablets - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-alliance-partner-natco-receives-fda-approval-for-generic-fosrenol-chewable-tablets/): Mumbai: Pharma major Lupin Limited (Lupin) and Natco announced the final ANDA approval of Lanthanum Carbonate Chewable Tablets 500 mg (base), 750 mg (base), and 1000 mg (base) from the United States Food and Drug Administration (FDA). The product,…
[Lupin’s Alliance Partner ForDoz Receives U.S. FDA Approval for Doxorubicin Hydrochloride Liposome Injection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-alliance-partner-fordoz-receives-u-s-fda-approval-for-doxorubicin-hydrochloride-liposome-injection/): Mumbai, Naples, July 19, 2024: Global pharma major Lupin Limited (Lupin) today announced that its alliance partner, ForDoz Pharma Corporation, USA (ForDoz) has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New…
[Lupin’s Alliance Partner Concord Receives U.S. FDA Approval for Mycophenolate Mofetil Tablets USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-alliance-partner-concord-receives-u-s-fda-approval-for-mycophenolate-mofetil-tablets-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) in alliance with Concord Biotech Limited (Concord) announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for Mycophenolate Mofetil Tablets USP, 500 mg, to market a…
[Lupin’s Alliance Partner Concord Receives U.S. FDA Approval for Tacrolimus Capsules USP - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-alliance-partner-concord-receives-u-s-fda-approval-for-tacrolimus-capsules-usp/): Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) in alliance with Concord Biotech Limited (Concord) announced today that it has received approval from the United States Food and Drug Administration (U.S. FDA) for Tacrolimus Capsules USP, 0.5 mg, 1 mg,…
[Lupin’s Ankleshwar Facility Wins Frost & Sullivan’s India Manufacturing Excellence Awards 2019 - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-ankleshwar-facility-wins-frost-sullivans-india-manufacturing-excellence-awards-2019/): Mumbai: Pharma major Lupin Limited announced that its Ankleshwar facility has been awarded “Future Ready Factory of the Year | Pharmaceutical Sector, Large Business,” by Frost & Sullivan’s India Manufacturing Excellence Awards (IMEA) 2019. The 2019 evaluation was…
[Lupin’s Ankleshwar Facility Wins Gold Award from American Society for Quality - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-ankleshwar-facility-wins-gold-award-from-american-society-for-quality-2/): Mumbai: Pharma major Lupin Limited (Lupin) won the gold award at the 9th Annual Conference on Quality Management, organised by the American Society for Quality (ASQ) at Ahmedabad on 22 November, 2019. The nomination case study submitted for…
[Lupin’s Aurangabad facility inspection concluded by US FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-aurangabad-facility-inspection-concluded-by-us-fda/): Mumbai: Pharma major Lupin Limited (Lupin) announced today the completion of a PAI inspection (Prior Approval Inspection) carried out by the US FDA at its Aurangabad manufacturing facility with one 483 observation. The observation was procedural in nature and…
[Lupin’s Aurangabad facility receives EIR from the U.S. FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-aurangabad-facility-receives-eir-from-the-us-fda/): Mumbai: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the U.S. FDA for its Aurangabad facility. The facility was inspected by the U.S. FDA between May 6, 2019 and May 15,…
[Lupin’s Brazilian Subsidiary, MedQuimica Acquires Rights to Nine Brands from Bausch Health - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-brazilian-subsidiary-medquimica-acquires-rights-to-nine-brands-from-bausch-health/): Mumbai, Sao Paulo, November 28, 2022: Global pharma major, Lupin Limited (Lupin) announced today that its wholly owned subsidiary in Brazil, MedQuímica Indústria Farmacêutica (MedQuímica), has signed a definitive agreement to acquire all rights to nine medicines from BL…
[Lupin’s Aurangabad Facility Receives EIR from U.S. FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-aurangabad-facility-receives-eir-from-u-s-fda/): Mumbai, India: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the U.S. FDA for its Aurangabad, India facility. The inspection for the facility was carried out by the U.S. FDA between…
[Lupin’s ESG Score Rises to 76 in S&P Global ESG Ratings - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-esg-score-rises-to-76-in-sp-global-esg-ratings/): Improvement across all ESG Metrics Mumbai, November 22, 2024: Global pharma major Lupin Limited (Lupin) today announced its S&P Global ESG scores have moved up to 76 from 69 last year, well above the industry average of 30…
[Lupin’s Goa facility completes successful UK MHRA inspection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-goa-facility-completes-successful-uk-mhra-inspection/): Mumbai: Pharma major Lupin Limited (Lupin) announced the successful completion of the inspection by the UK MHRA at its Goa facility in March, 2018. There were no critical or major observations in the inspection. Responding to the positive outcome,…
[Lupin’s Goa facility inspection concluded by US FDA without any observations - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-goa-facility-inspection-concluded-by-us-fda-without-any-observations/): Mumbai: Pharma major Lupin Limited (Lupin) announced today the successful completion of a PAI inspection (Prior Approval Inspection) carried out by the US FDA at its Goa manufacturing facility without any observations. The inspection which started on Monday, July…
[Lupin’s Goa facility gets approval from UK MHRA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-goa-facility-gets-approval-from-uk-mhra/): Mumbai: Pharma major Lupin announced that it has received approval from UK MHRA (United Kingdom’s Medicines and Healthcare products Regulatory Agency) for its Goa facility. The unit was inspected by UK MHRA in March 2018 and there were no critical…
[Lupin’s Goa Non Cephalosporin Oral Dosage Facility Inspected By USFDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-goa-non-cephalosporin-oral-dosage-facility-inspected-by-usfda/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin’s Goa Manufacturing Plant Receives EIR from US FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-goa-manufacturing-plant-receives-eir-from-us-fda/): FDA changes inspection classification of facility to Voluntary Action Indicated Mumbai, December 14, 2021:Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US…
[Lupin’s Humrahi Diabetes Support Program Expands to Include Heart Health - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-humrahi-diabetes-support-program-expands-to-include-heart-health/): Mumbai, November 18, 2024: Global pharma major Lupin Limited (Lupin) announced the re-launch of Humrahi at the Research Society for the Study of Diabetes in India (RSSDI) conference in New Delhi. Humrahi is now enhanced with comprehensive support for…
[Lupin’s Inhalation Research Center, Florida receives EIR from U.S. FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-inhalation-research-center-florida-receives-eir-from-u-s-fda/): Coral Springs, Florida, Mumbai, India: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the U.S. FDA for its Inhalation Research Center located at Coral Springs, Florida. The facility was inspected…
[Lupin’s Joint Airways Initiative surpasses 10,000 Patients - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-joint-airways-initiative-surpasses-10000-patients/): India’s first Digital Asthma Educator Platform Provides one-on-one training session to educate patients on inhalation technique Mumbai, September 28, 2023: Global pharma major Lupin Limited (Lupin) announced today that it’s digital asthma educator platform, Joint Airways Initiative (JAI), has…
[Lupin’s Nagpur Facility Receives EIR from U.S. FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-nagpur-facility-receives-eir-from-u-s-fda/): Mumbai, India: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) after closure of the U.S. FDA inspection of its Nagpur, India facility. The inspection for the facility was carried out by…
[Lupin’s Nagpur facility receives EIR from US FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-nagpur-facility-receives-eir-from-us-fda/): Mumbai: Pharma major Lupin today announced the receipt of the Establishment Inspection report (EIR) post the completion of a Pre-Approval Inspection (PAI) for its Phenytoin Sodium Extended Release 100 mg capsules, carried out by the US FDA at its…
[Lupin’s Mandideep facility gets approval from EDQM - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-mandideep-facility-gets-approval-from-edqm/): Mumbai: Pharma major Lupin announced that it has received EDQM Attestation of Inspection from EDQM (European Directorate for the Quality of Medicines) for its Mandideep facility. The unit was inspected by EDQM during March 2018. The inspection was focused…
[Lupin’s Nagpur facility inspection by US FDA concluded with no observation - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-nagpur-facility-inspection-by-us-fda-concluded-with-no-observation/): Mumbai: Pharma major Lupin announced today the successful completion of an inspection carried out by the US FDA at its Nagpur, Maharashtra, India facility. The inspection concluded without any observation. This inspection was a product specific pre-approval inspection. Lupin’s…
[Lupin’s Nagpur facility receives EIR from the U.S. FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-nagpur-facility-receives-eir-from-the-u-s-fda/): Mumbai: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the U.S. FDA for its Nagpur facility. The facility was inspected by the U.S. FDA between August 5, 2019 and August 8,…
[Lupin’s Mandideep Unit II Facility Receives EIR from U.S. FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-mandideep-unit-ii-facility-receives-eir-from-u-s-fda/): Mumbai, India: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) after closure of the U.S. FDA inspection of its Mandideep Unit II facility, classifying the inspection as Voluntary Action Indicated. The…
[Lupin’s Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-mandideep-unit-2-facility-completes-u-s-fda-inspection-with-no-observations/): Mumbai, India, August 12, 2023: Global pharma major Lupin Limited (Lupin) today announced that its Unit-2 manufacturing facility located in Mandideep, India, has successfully completed a GMP inspection by the United States Food and Drug Administration (U.S. FDA). The inspection…
[Lupin’s Nagpur facility receives Establishment Inspection Report (EIR) from US FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-nagpur-facility-receives-establishment-inspection-report-eir-from-us-fda/): Mumbai: Pharma major Lupin Limited (Lupin) announced that it has received the Establishment Inspection Report (EIR) from US FDA for the successful inspection of its Nagpur facility. The inspection was conducted in May 2018. Commenting on the development, Nilesh…
[Lupin’s Nagpur facility US FDA inspection concluded with no observations - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-nagpur-facility-us-fda-inspection-concluded-with-no-observations/): Mumbai: Pharma major Lupin announced today the successful completion of an inspection carried out by the US FDA at its Nagpur facility. The inspection concluded without any observations. Lupin’s Nagpur facility is the company’s latest facility and manufactures oral…
[Lupin’s Nagpur facility wins ENR Global Best Project Award - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-nagpur-facility-wins-enr-global-best-project-award/): Mumbai: Pharma major Lupin Limited (Lupin) announced that it has won the Engineering News-Record’s (ENR) Global Best Project Award of Merit in the Manufacturing category. The award was given to Lupin’s Oral Solid Dosage (OSD) and Injectable Pharmaceutical Manufacturing…
[Lupin’s Pithampur facility inspection concluded by US FDA without any observations - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-pithampur-facility-inspection-concluded-by-us-fda-without-any-observations/): Mumbai: Pharma major Lupin Limited (Lupin) announced today the successful completion of a GMP inspection as well as a PAI inspection (Prior Approval Inspection) carried out by the US FDA at its Pithampur manufacturing facility – Unit 1 without…
[Lupin’s Pithampur Facilities Complete Successful UK MHRA Inspection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-pithampur-facilities-complete-successful-uk-mhra-inspection/): Mumbai, India: Pharma major Lupin Limited (Lupin) today announced the successful close out of the inspection carried out by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory agency of the United Kingdom (UK), at its three manufacturing units…
[Lupin’s Pithampur Unit-3 (Indore) receives EIR from US FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-pithampur-unit-3-indore-receives-eir-from-us-fda/): Mumbai: Pharma major Lupin today announced the receipt of the Establishment Inspection Report (EIR) for its Pithampur (Unit 3) facility. The inspection at the site was conducted between June 12, 2017 and June 16, 2017. This was a Pre-approval…
[Lupin’s Pithampur Unit cleared by Health Canada - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-pithampur-unit-cleared-by-health-canada/): Mumbai: Pharma major Lupin Limited (Lupin) announced the successful facility review carried out by Health Canada for its Pithampur Unit 2 (Indore) manufacturing facility. Following the review, Health Canada has maintained the compliant rating for Unit 2 at Pithampur…
[Lupin’s Pune Biotech facility receives EU GMP clearance - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-pune-biotech-facility-receives-eu-gmp-clearance/): Mumbai: Pharma major Lupin Limited (Lupin) announced today that it has received the ‘European Good Manufacturing Practice’ (EU GMP) certificate for its Mammalian Facility in Pune where Etanercept Biosimilar is intended to be manufactured. This GMP certification further confirms…
[Lupin’s Pithampur facilities complete successful MHRA inspection - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-pithampur-facilities-complete-successful-mhra-inspection/): Mumbai: Pharma major Lupin Limited (Lupin) today announced the successful completion of the inspection carried out by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory agency of the United Kingdom (UK) at its three manufacturing units…
[Lupin’s Pithampur Unit-1 facility receives EIR from U.S. FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-pithampur-unit-1-facility-receives-eir-from-u-s-fda/): Mumbai, India: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Pithampur Unit-1, India facility. The inspection for the facility…
[Lupin’s Pithampur Unit-3 (Indore) Inspected by US FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-pithampur-unit-3-indore-inspected-by-us-fda/): Mumbai: Pharma major Lupin announced today the completion of a US FDA inspection carried out at its Pithampur Unit-3 (Indore) facility. The inspection was a GMP inspection for the facility and also a Pre-Approval Inspection (PAI) for the company’s…
[Lupin’s Pithampur Unit-3 (Indore) receives EIR from U.S. FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-pithampur-unit-3-indore-receives-eir-from-u-s-fda/): Mumbai: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) for its Pithampur (Unit-3) facility. The inspection was conducted between October 8, 2018 to October 18, 2018. Lupin’s Pithampur Unit-3 is involved in…
[Lupin’s Pithampur Unit 1 facility receives Establishment Investigation report (EIR) from US FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-pithampur-unit-1-facility-receives-establishment-investigation-report-eir-from-us-fda/): Mumbai: Pharma major Lupin Limited (Lupin) announced that it has received the Establishment Investigation Report (EIR) from US FDA for the successful inspection of its Pithampur, Unit 1. The inspection was conducted in July 2017. Commenting on the development,…
[Lupin’s Quarter II, FY2017 – Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-quarter-ii-fy2017-results/): Sales up 31.9%, EBITDA up 46.5% and Net profits up 57.8% Mumbai: Pharma Major Lupin Limited reported its performance for the second quarter ending September 30th, 2016. These results were taken on record by the Board of Directors at…
[Lupin’s R&D Facility in Pune Awarded LEED Platinum Certification - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-rd-facility-in-pune-awarded-leed-platinum-certification/): Amongst the first to be recognized for this distinguished milestone Reaffirms Lupin’s commitment to sustainable resource management Mumbai, December 05, 2024: Global pharma major Lupin Limited (Lupin) today announced that its R&D facility at Lupin Research Park, Pune…
[Lupin’s Somerset Manufacturing Plant Receives EIR from US FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-somerset-manufacturing-plant-receives-eir-from-us-fda/): FDA changes inspection classification of Somerset facility to Voluntary Action Indicated Somerset, NJ, Mumbai, July 07, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from United States Food and…
[Lupin’s Tarapur facility receives EIR from US FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-tarapur-facility-receives-eir-from-us-fda/): Mumbai: Pharma major Lupin announced the receipt of the Establishment Inspection Report (EIR) on the completion of an inspection by the US FDA (United States Food & Drug Administration) at its facility in Tarapur, Maharashtra. The inspection conducted between…
[Lupin’s US Subsidiary and Chester Valley Pharmaceuticals decide to end promotion agreement - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-us-subsidiary-and-chester-valley-pharmaceuticals-decide-to-end-promotion-agreement/): Read the latest press releases and corporate communications from Lupin Limited.
[Mr. Edward R. Roberts joins Lupin Board - Lupin | Press Release](https://www.lupin.com/media/press-releases/mr-edward-r-roberts-joins-lupin-board/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin’s Vizag API Facility Receives EIR from U.S. FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-vizag-api-facility-receives-eir-from-u-s-fda/): Mumbai, India: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) after closure of the inspection for its Vizag (Vishakhapatnam), India facility. The inspection…
[Lupin’s Softovac in The Economic Times ‘Promising Brands of 2018’ - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-softovac-in-the-economic-times-promising-brands-of-2018/): Mumbai: Lupin’s Softovac has been recognized by The Economic Times in their list of “Promising Brands of 2018”. The Economic Times ‘Promising Brands of 2018’ recognizes brands that have challenged the status quo by affecting change and remaining relevant…
[Lupin’s Tarapur API Manufacturing Facility Inspected by US FDA - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-tarapur-api-manufacturing-facility-inspected-by-us-fda/): Mumbai: Pharma major Lupin announced today the completion of a cGMP inspection carried out by the US FDA at its Tarapur facility. The inspection closed with one observation, a procedural deficiency. The inspection at the site was conducted between…
[Lupin’s subsidiary in South Africa announces Commercial Agreement with Creso Pharma for hemp oil based cannaQIX - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupins-subsidiary-in-south-africa-announces-commercial-agreement-with-creso-pharma-for-hemp-oil-based-cannaqix/): Mumbai, South Africa: Pharma major Lupin Limited (Lupin) announced that its subsidiary in South Africa, ‘Pharma Dynamics’ has signed a Commercial Agreement with Creso Pharma (Creso) for the hemp oil based cannaQIX®. Creso affords Pharma Dynamics sole distribution rights…
[Mr. K.B.S. Anand and Dr. Punita Kumar-Sinha Join Lupin Board as Independent Directors - Lupin | Press Release](https://www.lupin.com/media/press-releases/mr-k-b-s-anand-and-dr-punita-kumar-sinha-join-lupin-board-as-independent-directors/): Mumbai, India: Pharma major Lupin Limited (Lupin) announced today the appointment of Mr. K.B.S. Anand and Dr. Punita Kumar-Sinha as Independent Directors. Mr. K.B.S. Anand most recently served as Managing Director and Chief Executive Officer at Asian Paints, India’s…
[Nanomi Receives CMO Award for Life Science Leadership in Drug Delivery - Lupin | Press Release](https://www.lupin.com/media/press-releases/nanomi-receives-cmo-award-for-life-science-leadership-in-drug-delivery/): Mumbai, Oldenzaal, March 21, 2025: Nanomi B.V., a Dutch subsidiary of the global pharma major Lupin Limited, today announced that it has won the prestigious CMO Award for Life Science Leadership in Drug Delivery, during the Drug, Chemical and…
[MSD and Lupin announce Strategic Partnership to Co-market MSD’s 23-valent Pneumococcal polysaccharide vaccine (PPV) for Indian market - Lupin | Press Release](https://www.lupin.com/media/press-releases/msd-and-lupin-announce-strategic-partnership-to-co-market-msds-23-valent-pneumococcal-polysaccharide-vaccine-ppv-for-indian-market/): Read the latest press releases and corporate communications from Lupin Limited.
[NHI Drug Price Listing for Bipresso® Extended Release Tablets for the Improvement of Depressive Symptoms Associated with Bipolar Disorder Announced - Lupin | Press Release](https://www.lupin.com/media/press-releases/nhi-drug-price-listing-for-bipresso-extended-release-tablets-for-the-improvement-of-depressive-symptoms-associated-with-bipolar-disorder-announced/): Mumbai: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co., Ltd. (headquarters: Yodogawa-ku, Osaka; President and Representative Director: Ray Tsunoda; hereinafter Kyowa) announced the listing of the NHI (National Health Insurance) drug price…
[Notice of 3QFY20 Earnings call - Lupin | Press Release](https://www.lupin.com/media/press-releases/notice-of-3qfy20-earnings-call/): Read the latest press releases and corporate communications from Lupin Limited.
[Notice of Q2 FY2020 Board Meeting - Lupin | Press Release](https://www.lupin.com/media/press-releases/notice-of-q2-fy2020-board-meeting/): Read the latest press releases and corporate communications from Lupin Limited.
[Notice of Q3 FY2021 Board Meeting - Lupin | Press Release](https://www.lupin.com/media/press-releases/notice-of-q3-fy2021-board-meeting/): Read the latest press releases and corporate communications from Lupin Limited.
[Notice of Q4 FY2020 Board Meeting - Lupin | Press Release](https://www.lupin.com/media/press-releases/notice-of-q4-fy2020-board-meeting/): Read the latest press releases and corporate communications from Lupin Limited.
[Notice to the shareholders - Lupin | Press Release](https://www.lupin.com/media/press-releases/notice-to-the-shareholders-2/): Read the latest press releases and corporate communications from Lupin Limited.
[Notice of Q3 FY2020 Board Meeting - Lupin | Press Release](https://www.lupin.com/media/press-releases/notice-of-q3-fy2020-board-meeting/): Read the latest press releases and corporate communications from Lupin Limited.
[Notice to the shareholders - Lupin | Press Release](https://www.lupin.com/media/press-releases/notice-to-the-shareholders/): Read the latest press releases and corporate communications from Lupin Limited.
[Lupin receives FDA approval for generic Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1mg/gram - Lupin | Press Release](https://www.lupin.com/media/press-releases/press-release-alupin-receives-fda-approval-for-generic-nystatin-and-triamcinolone-acetonide-cream-usp/): Mumbai, Baltimore: Pharma major Lupin announced that it has received final approval for its Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1mg/gram, from the United States Food and Drug Administration (FDA) to market a generic version of…
[Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders - Lupin | Press Release](https://www.lupin.com/media/press-releases/orphan-drug-namuscla-receives-european-commission-approval-for-the-treatment-of-myotonia/): Zug, Mumbai: Lupin is pleased to announce that the European Commission (EC) has approved NaMuscla® (mexiletine) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. Non-dystrophic myotonic disorders are a group of rare, inherited neuromuscular…
[Punita Lal Joins Lupin Board as Additional Director - Lupin | Press Release](https://www.lupin.com/media/press-releases/punita-lal-joins-lupin-board-as-additional-director/): Mumbai, Naples, May 15, 2025: Global pharma major Lupin Limited (Lupin) announced the appointment of Punita Lal as an Additional Director (Non-Executive, Independent) to its Board of Directors. Punita has a distinguished career spanning over 35 years in…
[Quarter I, FY2019 – Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/quarter-i-fy2019-results/): Mumbai: Pharma Major Lupin Limited reported its financial performance for the first quarter ending June 30th, 2018. These results were taken on record by the Board of Directors at a meeting held in Mumbai today. Key Financial &…
[Quarter I, FY2018 – Results - Lupin | Press Release](https://www.lupin.com/media/press-releases/quarter-i-fy2018-results/): Mumbai: Pharma Major Lupin Limited reported its financial performance for the first quarter ending June 30th, 2017. These results were taken on record by the Board of Directors at a meeting held in Mumbai today. Key Financial & Performance…
[Quarter I Results, FY 2014-15 - Lupin | Press Release](https://www.lupin.com/media/press-releases/quarter-i-results-fy-2014-15/): Read the latest press releases and corporate communications from Lupin Limited.
[Quarter IV and Annual Results, FY 2014-15 FY 2014-15 Net Sales up 13.6%, EBITDA up 23.7%, Net profit up 30.9% - Lupin | Press Release](https://www.lupin.com/media/press-releases/quarter-iv-and-annual-results/): Mumbai: Pharma Major Lupin Limited reported its performance for the fourth quarter and the financial year ending 31st March, 2015. These audited results were taken on record by the Board of Directors at a meeting in Mumbai today. Net…
[Quarter IV and Annual Results, FY2017 - Lupin | Press Release](https://www.lupin.com/media/press-releases/quarter-iv-and-annual-results-fy2017/): Proposed Dividend 375% Sales up 24.4%, EBITDA up 18.8% and Net profits up 13.1% Mumbai: Pharma Major Lupin Limited reported its financial performance for the fourth quarter and fiscal year ending March 31st, 2017. These audited results were taken…
[Quarter IV & Annual Results, FY 2013-14 – Record Sales and Profits - Lupin | Press Release](https://www.lupin.com/media/press-releases/quarter-iv-annual-results-fy-2013-14-record-sales-and-profits/): Read the latest press releases and corporate communications from Lupin Limited.
[Rajan Dutta joins Lupin as President, HRD - Lupin | Press Release](https://www.lupin.com/media/press-releases/rajan-dutta-joins-lupin-as-president-hrd/): Read the latest press releases and corporate communications from Lupin Limited.
[Record Sales and Profits – Quarter III Results, FY 2012-13 - Lupin | Press Release](https://www.lupin.com/media/press-releases/record-sales-and-profits-quarter-iii-results-fy-2012-13/): Read the latest press releases and corporate communications from Lupin Limited.
[Quarter II Results, FY 2014-15 - Lupin | Press Release](https://www.lupin.com/media/press-releases/quarter-ii-results-fy-2014-15/): Read the latest press releases and corporate communications from Lupin Limited.
[Record Sales and Profits - Lupin | Press Release](https://www.lupin.com/media/press-releases/record-sales-and-profits/): Read the latest press releases and corporate communications from Lupin Limited.
[Record Sales & Profits Net Sales up 44%, PBT up 67%, PAT up 33% Quarter I Results, FY 2012-13 - Lupin | Press Release](https://www.lupin.com/media/press-releases/record-sales-profits-net-sales-up-44-pbt-up-67-pat-up-33-quarter-i-results-fy-2012-13/): Read the latest press releases and corporate communications from Lupin Limited.
[Record Sales & Profits Quarter II Results, FY 2012-13 Net Sales up 29%, EBITDA up 28%, PBT up 27%, PAT up 9% - Lupin | Press Release](https://www.lupin.com/media/press-releases/record-sales-profits-quarter-ii-results-fy-2012-13-net-sales-up-29-ebitda-up-28-pbt-up-27-pat-up-9/): Read the latest press releases and corporate communications from Lupin Limited.
[Robust Growth, Record Profits Net Profit Up 24%, Q2 FY 2011-12 - Lupin | Press Release](https://www.lupin.com/media/press-releases/robust-growth-record-profits-net-profit-up-24-q2-fy-2011-12/): Read the latest press releases and corporate communications from Lupin Limited.
[Sanofi Aventis & Multicare Ink Strategic Agreement in the Philippines - Lupin | Press Release](https://www.lupin.com/media/press-releases/sanofi-aventis-multicare-ink-strategic-agreement-in-the-philippines/): Read the latest press releases and corporate communications from Lupin Limited.
[Strong Growth, Record Profits Quarter III Results, FY 2013-14 Net Sales up 21%; EBITDA up 28%; Net profit up 42% Declares Interim Dividend of 150 % - Lupin | Press Release](https://www.lupin.com/media/press-releases/strong-growth-record-profits-quarter-iii-results-fy-2013-14-net-sales-up-21-ebitda-up-28-net-profit-up-42-declares-interim-dividend-of-150/): Read the latest press releases and corporate communications from Lupin Limited.
[Strong Growth, Robust Operating Performance - Lupin | Press Release](https://www.lupin.com/media/press-releases/strong-growth-robust-operating-performance/): Read the latest press releases and corporate communications from Lupin Limited.
[Statement on media reports linking SARS outbreak with demand for Lupin’s ribavirin - Lupin | Press Release](https://www.lupin.com/media/press-releases/statement-on-media-reports-linking-sars-outbreak-with-demand-for-lupins-ribavirin/): Read the latest press releases and corporate communications from Lupin Limited.
[Record Sales & Profits – A New High Quarter IV & Annual Results – FY2016 Q4 FY2016 Net Sales up 34.0%, EBITDA up 72.7%, Net profit up 47.5% Proposed Dividend 375% - Lupin | Press Release](https://www.lupin.com/media/press-releases/record-sales-profits-a-new-high-quarter-iv-annual-results/): Mumbai: Pharma Major Lupin Limited reported its performance for the fourth quarter and the financial year ending 31st March, 2016. These audited results were taken on record by the Board of Directors at a meeting in Mumbai today. Key…
[Record Sales & Profits – Quarter I FY2017 - Lupin | Press Release](https://www.lupin.com/media/press-releases/record-sales-profits-quarter-i-fy2017/): Net Sales up 40.0%, EBITDA up 54.4% and Net profits up 55.1% Mumbai: Pharma Major Lupin Limited reported its performance for the first quarter ending June 30th, 2016. These results were taken on record by the Board of Directors…
[Strong Margins, Robust Profitability Quarter I Results, FY 2013-14 EBITDA up 44%, Net profit up 43% - Lupin | Press Release](https://www.lupin.com/media/press-releases/strong-margins-robust-profitability-quarter-i-results-fy-2013-14-ebitda-up-44-net-profit-up-43/): Read the latest press releases and corporate communications from Lupin Limited.
[Strong Margins, Robust Profits Quarter III Results, FY 2014-15 Net Sales up 5%, EBITDA up 20%, Net Profit up 26% - Lupin | Press Release](https://www.lupin.com/media/press-releases/strong-margins-robust-profits-quarter-iii-results-fy-2014-15/): Mumbai: Pharmaceutical Major, Lupin Limited (Lupin) reported its performance for the third quarter ending 31st December, 2014. These unaudited results were taken on record by the Board of Directors at a meeting in Mumbai today. Key financial & performance…
[Survey Data Reveals the Need for Improved Communication Between Patients and Healthcare Providers About Bacterial Vaginosis (BV), the Most Common Gynecologic Infection in the U.S. - Lupin | Press Release](https://www.lupin.com/media/press-releases/survey-data-reveals-the-need-for-improved-communication-between-patients-and-healthcare-providers/): Mumbai, Baltimore: According to an online survey, although healthcare providers (HCPs) report sharing crucial information on bacterial vaginosis (BV) with patients, the associated risks of the condition remain a mystery to many women, indicating a significant disconnect.1 With BV…
[TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB - Lupin | Press Release](https://www.lupin.com/media/press-releases/tb-alliance-and-lupin-announce-commercial-partnership-for-new-therapy-for-highly-drug-resistant-tb/): Mumbai, New York, September 06, 2021: Non-profit drug developer, TB Alliance has granted global pharma major Lupin Limited (Lupin), a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen. Lupin intends to commercialize…
[Two Citigroup representatives join Lupin’s board - Lupin | Press Release](https://www.lupin.com/media/press-releases/two-citigroup-representatives-join-lupins-board/): I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
[Two Citigroup representatives join Lupin’s board - Lupin | Press Release](https://www.lupin.com/media/press-releases/two-citigroup-representatives-join-lupins-board-2/): Read the latest press releases and corporate communications from Lupin Limited.
[The ₹40-crore AI payoff: How Lupin is building a data-first, AI-ready pharma enterprise - Lupin | Press Release](https://www.lupin.com/media/press-releases/the-40-crore-ai-payoff-how-lupin-is-building-a-data-first-ai-ready-pharma-enterprise/): Pharma giant Lupin started its digital transformation journey in 2021. Four years later, AI is now embedded across the company’s $2.5 billion global operations. From the company’s labs to shop floors to its supply chains, it’s strategically woven…
[U.S. FDA completes inspection of Lupin’s Aurangabad facility with Zero observation - Lupin | Press Release](https://www.lupin.com/media/press-releases/u-s-fda-completes-inspection-of-lupins-aurangabad-facility-with-zero-observation/): Mumbai: Pharma major Lupin Limited (Lupin) announced today the successful completion of an inspection carried out by the U.S. FDA at its Aurangabad, India facility. The inspection was carried out between February 10, 2020 and February 14, 2020. The…
[Type 2 Diabetes: Boehringer Ingelheim India and Lupin Announce Strategic Co-marketing Agreement - Lupin | Press Release](https://www.lupin.com/media/press-releases/type-2-diabetes-boehringer-ingelheim-india-and-lupin-announce-strategic-co-marketing-agreement/): Lupin to market Empagliflozin under the brand name Gibtulio® in India Mumbai: Boehringer Ingelheim and pharma major Lupin Limited (Lupin) today announced another strategic alliance to co-market Empagliflozin, a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor in India. Boehringer…
[U.S. FDA completes inspection of Lupin’s Aurangabad facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/u-s-fda-completes-inspection-of-lupins-aurangabad-facility/): Mumbai: Pharma major Lupin Limited (Lupin) announced the completion of the United States Food and Drug Administration (U.S. FDA) inspection carried out at its Aurangabad manufacturing facility. The inspection was carried out from May 6 to May 15, 2019….
[U.S. FDA Completes Inspection of Lupin’s Dabhasa Facility with No Observations - Lupin | Press Release](https://www.lupin.com/media/press-releases/u-s-fda-completes-inspection-of-lupins-dabhasa-facility-with-no-observations/): Mumbai, India, April 12, 2024: Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed a GMP Inspection of its API manufacturing facility located at Dabhasa, India. The inspection…
[U.S. FDA Completes Inspection of Lupin’s Vizag Facility with No Observations - Lupin | Press Release](https://www.lupin.com/media/press-releases/u-s-fda-completes-inspection-of-lupins-vizag-facility-with-no-observations/): Mumbai, India, March 10, 2023: Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed a Pre-Approval and GMP Inspection of its API manufacturing facility located in Visakhapatnam (Vizag), India….
[US FDA Audit at Lupin’s Dabhasa Facility, 29th June – 06th July 2016 - Lupin | Press Release](https://www.lupin.com/media/press-releases/us-fda-audit-at-lupins-dabhasa-facility-29th-june-06th-july-2016/): Receives two 483s; Voluntary Action Indicated only Mumbai: Pharma Major Lupin Limited (Lupin) announced today that the US FDA inspected its Dabhasa facility from 29th June to 6th July 2016. At the end of the inspection two 483s…
[U.S. FDA Grants Mexiletine Orphan Drug Designation - Lupin | Press Release](https://www.lupin.com/media/press-releases/u-s-fda-grants-mexiletine-orphan-drug-designation/): Mumbai, India | Zug, Switzerland: Pharma major Lupin Limited (Lupin) announced today that the US Food and Drug Administration (U.S. FDA) has granted Orphan Drug Designation (ODD) to mexiletine hydrochloride for the treatment of myotonic disorders. Myotonic disorders are a…
[US FDA clears Lupin’s Mandideep Facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/us-fda-clears-lupins-mandideep-facility/): Read the latest press releases and corporate communications from Lupin Limited.
[U.S. FDA completes inspection of Lupin’s Goa facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/us-fda-completes-inspection-of-lupins-goa-facility/): Mumbai: Pharma major Lupin announced the completion of the United States Food and Drug Administration (U.S. FDA) inspection at its Goa manufacturing facility. The inspection was carried out between January 28 to February 8, 2019. The inspection at the…
[US FDA completes inspection of Lupin’s Mandideep location - Lupin | Press Release](https://www.lupin.com/media/press-releases/us-fda-completes-inspection-of-lupins-mandideep-location/): Mumbai: Pharma major Lupin announced today the completion of United States Food and Drug Administration (US FDA) inspections carried out at its Mandideep location. Lupin’s Mandideep location houses the company’s cardiovascular “Pril” API facilities, Cephalosporin API facilities and Cephalosporin…
[U.S. FDA completes inspection of Lupin’s Nagpur facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/us-fda-completes-inspection-of-lupins-nagpur-facility/): Mumbai: Pharma major Lupin Limited (Lupin) today announced the completion of the United States Food and Drug Administration (U.S. FDA) inspection carried out at its Nagpur oral solid manufacturing facility. The inspection was carried out between August 5, 2019…
[U.S. FDA completes inspection of Lupin’s Pithampur Unit-2 (Indore) facility - Lupin | Press Release](https://www.lupin.com/media/press-releases/us-fda-completes-inspection-of-lupins-pithampur-unit-2-indore-facility/): Mumbai: Pharma major Lupin announced today the completion of the United States Food and Drug Administration (U.S. FDA) inspection carried out at its Pithampur Unit -2 (Indore) facility. The inspection was carried out between January 14 and January 25,…
[Lupin Foundation Earns CRISIL’s Highest VO 1A Rating for Excellence in Social Responsibility - Lupin | Press Release](https://www.lupin.com/media/press-releases/lupin-foundation-earns-crisils-highest-vo-1a-rating-for-excellence-in-social-responsibility/): Mumbai, Pune, November 28, 2025: Lupin Human Welfare and Research Foundation (LHWRF), the Corporate Social Responsibility (CSR) arm of global pharma major Lupin Limited (Lupin), has been awarded the CRISIL Voluntary Organisation grading of VO 1A, the highest…

## Community

[Community Development and CSR Initiatives - Lupin](https://www.lupin.com/community/): Lupin’s community initiatives focus on rural development, sustainable livelihoods, and long-term social impact in India.

## Sitemap

[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/sitemap/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.

## Contact us

[Contact Us - Corporate and Investor Support - Lupin](https://www.lupin.com/contact-us/): Connect with Lupin. Find contact details for offices, investor support, media queries and customer assistance to get help or information quickly.

## Privacy policy

[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/privacy-policy/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.

## Product finder

[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/product-finder/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.

## Terms of service

[Lupin - Global Pharmaceutical Leader | Innovations in Healthcare](https://www.lupin.com/terms-of-service/): Lupin is a leading pharmaceutical company committed to improving lives through innovative medicines, global reach, and sustainable healthcare solutions across 100+ countries.

## Cookie policy

[Cookie Policy - Lupin](https://www.lupin.com/cookie-policy/): Read Lupin’s cookie policy to understand how cookies are used, managed, and controlled to improve website functionality and user experience.